SNPMiner Trials by Shray Alag

L858R (332) T790M (322) V600E (266) T315I (107) L861Q (92) M184V (68) V617F (58) K65R (53) G20210A (53) V600K (52) C282Y (50) V66M (49) G551D (42) P13K (39) C677T (35) A118G (29) I84V (27) V158M (26) H63D (25) V32I (24) S768I (24) I50V (23) I47V (21) K103N (21) K27M (20) Y181C (20) L33F (19) T380A (18) L76V (18) G12C (18) D842V (18) R117H (17) D816V (17) S1251N (17) S1255P (17) G178R (17) G1244E (17) S549R (17) G1349D (17) V82A (16) M41L (16) S549N (16) C3435T (16) G551S (16) Q151M (16) Q12H (15) K219Q (15) I54L (15) K70E (14) C797S (14) G719A (13) L90M (13) L74V (13) E138A (13) D67N (13) K70R (13) L89V (13) L210W (13) Y188L (13) G11778A (12) P4503A (12) L265P (12) M46I (12) I54M (12) G12D (12) E255K (12) V11I (12) R132H (12) G48V (11) V299L (11) D961H (11) T74P (11) R192G (11) T25W (10) K101E (10) G2677T (9) V106A (9) G12V (9) M184I (9) H221Y (9) V30M (9) Y253H (9) V600D (9) G1691A (8) F317L (8) F227C (8) T215Y (8) I50L (8) A1298C (8) L100I (8) I148M (7) N155H (7) F359C (7) S298P (7) G190A (7) M230I (7) C1236T (7) V600R (7) Y188C (7) G2019S (7) Q12W (6) P225H (6) Y93H (6) V108I (6) A3243G (6) G93A (6) G73S (6) P12A (6) Y115F (6) E545K (6) Q148H (6) Y537S (6) E542K (6) I10A (6) M230L (6) H1047R (6) N40D (6) D299G (6) N236T (6) D30N (6) M235T (6) T315A (6) D538G (6) T87Q (5) I47A (5) L74I (5) E92Q (5) N680S (5) A455E (5) M204V (5) D1152H (5) L755S (5) G13D (5) G190S (5) N363S (5) A181V (5) V179L (5) L24I (5) N88S (5) A2143G (5) T399I (5) M36I (5) F53L (5) R263K (5) R132C (5) V777L (5) T1405N (4) D579G (4) G719C (4) N370S (4) R117C (4) Q16W (4) L98H (4) A98G (4) K20M (4) E138G (4) E138K (4) L31M (4) E157Q (4) L10F (4) Q80K (4) C31G (4) G1202R (4) Q252H (4) L206W (4) P140K (4) C19P (4) I54V (4) K76T (4) Y537C (4) I1314L (4) S945L (4) Y402H (4) P1446A (4) V179D (4) N88D (4) A6986G (4) A1166C (4) G970R (4) Y181I (4) R352Q (4) G2385R (4) S310F (4) P67L (4) R1070W (4) G140A (4) E23K (4) S463P (4) T14484C (3) G719S (3) R206H (3) S1400A (3) S1400I (3) A71V (3) C134W (3) R24W (3) C481S (3) T24H (3) V122I (3) T47D (3) A636P (3) S977F (3) G118R (3) G3460A (3) N312S (3) D988Y (3) L444P (3) V659E (3) V769L (3) A147T (3) E10A (3) Q24W (3) L861R (3) R678Q (3) Q27E (3) E17K (3) Q148R (3) A1555G (3) S49G (3) Y537N (3) R16G (3) I10E (3) V158F (3) G21210A (3) K55R (3) V205C (3) Y181V (3) A2142G (3) R506Q (3) E298D (3) L211A (3) R172K (3) V843I (3) Y143R (3) R572Y (3) G143E (3) G1321A (3) V842I (3) H295R (3) G140S (3) T60A (3) P23H (3) F11N (2) S1009A (2) H275Y (2) T733I (2) F1074L (2) I1307K (2) Q36W (2) G250E (2) S77Y (2) E28A (2) E28C (2) E28D (2) T66A (2) S1400C (2) S1400E (2) S1400D (2) L833F (2) D1790G (2) S1400G (2) S1400F (2) R334W (2) L8585R (2) I105V (2) N375S (2) V560G (2) A194T (2) T20S (2) T69D (2) T69S (2) Y93C (2) E138R (2) E138Q (2) F359V (2) R776H (2) Q422H (2) D110H (2) D110E (2) R753Q (2) R404C (2) C283Y (2) L31F (2) S252W (2) L460D (2) L33I (2) R140W (2) R140L (2) R140Q (2) V106I (2) V106M (2) E709K (2) V697L (2) P50I (2) P535H (2) P51S (2) G1314A (2) S492R (2) G308A (2) V191T (2) G71R (2) T215F (2) E56K (2) A2063G (2) D769H (2) L248V (2) E280A (2) Q21D (2) E504K (2) Q141K (2) R496H (2) S100P (2) T128N (2) L536R (2) L536Q (2) L536P (2) A143T (2) T97A (2) G3556C (2) K751Q (2) T4396G (2) V151L (2) G170R (2) A581G (2) L536H (2) G12R (2) L180M (2) W153Q (2) G193E (2) V173L (2) F876L (2) R479H (2) L82M (2) Q28D (2) G190E (2) R347H (2) K601E (2) G16R (2) R831C (2) G5271C (2) V75I (2) G681A (2) A270S (2) L63P (2) L869R (2) P236L (2) R831H (2) T13D (2) H1047L (2) C3670T (2) V34L (2) E255V (2) G469A (2) V57I (2) L144F (2) M233I (2) C825T (2) C8092A (2) G776C (2) G776V (2) F121Y (2) R172S (2) R172W (2) R172M (2) Q192R (2) R172G (2) E380Q (2) F166L (2) A200V (2) Y121F (2) G145R (2) K101P (2) R61C (2) V600M (2) F31I (2) K540E (2) K103H (2) R132V (2) D1270N (2) R1628P (2) R132S (2) V534E (2) R132G (2) R132L (2) V207I (2) K238N (2) G4655A (2) S112A (2) I169T (2) I84A (2) Y129S (1) G1388A (1) S77F (1) R20A (1) V140A (1) C686A (1) I1768V (1) E25K (1) K652E (1) C420R (1) S9304A (1) R337H (1) C421A (1) V189I (1) K304E (1) A7445G (1) D19H (1) L304P (1) Y454S (1) A133S (1) M9T (1) P596L (1) E318D (1) C1156Y (1) N171K (1) A7445C (1) V82F (1) G47A (1) R447H (1) G47E (1) V82L (1) R776C (1) A92T (1) E27Q (1) F1052V (1) P27A (1) A289T (1) L523S (1) H54Y (1) T1095C (1) S428F (1) R400C (1) D313Y (1) Q12M (1) R139C (1) A393T (1) W719R (1) T862I (1) T66K (1) T66I (1) G49A (1) R48G (1) H58C (1) D203E (1) I104F (1) K656E (1) T40S (1) D312N (1) L747P (1) G276T (1) L747S (1) R200W (1) I1171N (1) Q14D (1) S1400K (1) R115G (1) F17L (1) A71T (1) S339F (1) A71L (1) I431V (1) F317V (1) F317S (1) G20201A (1) F317C (1) G2545R (1) C377T (1) P243R (1) S9346A (1) R25L (1) L528M (1) Q222R (1) I22M (1) I107M (1) C1858T (1) L859R (1) G2032R (1) A859S (1) G389D (1) V148I (1) K65E (1) V148G (1) C242T (1) G389R (1) H369P (1) A98S (1) G2500A (1) I349V (1) I107V (1) V561D (1) C481R (1) L833V (1) P200T (1) G1051A (1) Y93F (1) Y414C (1) Y1248H (1) K65N (1) L74M (1) P4502C (1) Y1248C (1) Y1248D (1) F227R (1) V89L (1) T164I (1) H1124D (1) C94A (1) G1628A (1) A2215D (1) E200K (1) F227L (1) I305F (1) N682S (1) T1010I (1) I655V (1) R885H (1) G7444A (1) R776G (1) E354Q (1) A21443C (1) M351T (1) R620W (1) A54T (1) D594G (1) F311L (1) T49A (1) F116Y (1) H870R (1) G205S (1) E355G (1) R535H (1) I767M (1) L55M (1) E571K (1) L55R (1) M2540A (1) E92K (1) G238A (1) L838P (1) E6V (1) L814P (1) K509I (1) V21I (1) G699A (1) V167F (1) D949V (1) L33P (1) M66V (1) D61804R (1) R849W (1) V762A (1) D816H (1) V108M (1) V326L (1) V411L (1) L10D (1) L58H (1) E158K (1) N334K (1) A1067T (1) S1800A (1) G894T (1) G202A (1) C282T (1) I191V (1) G435A (1) K1060T (1) A10H (1) R272G (1) V654A (1) V106T (1) C1091T (1) I638F (1) P317R (1) V433M (1) S230R (1) N550H (1) R4E (1) P1058A (1) M244V (1) N550K (1) E709Q (1) G304A (1) T124A (1) S253N (1) M680I (1) G1316A (1) M552V (1) M552I (1) R182H (1) D835V (1) A871E (1) D835Y (1) A677G (1) C1950G (1) H1505R (1) A893S (1) L597Q (1) S2808A (1) N55H (1) K28M (1) D89E (1) A38G (1) L485W (1) M9346A (1) L159F (1) A437G (1) R92Q (1) V29C (1) L38V (1) G135C (1) A677V (1) C34T (1) G93R (1) R270H (1) V321A (1) C10D (1) G308V (1) R122W (1) D614G (1) H2507Q (1) D20W (1) G309A (1) G721A (1) G309E (1) I90P (1) C59R (1) C416R (1) G71A (1) Q61R (1) Q61L (1) H835L (1) R498L (1) V941L (1) Q62E (1) R389G (1) D769N (1) G156A (1) E1784K (1) G98T (1) Q65E (1) T92A (1) S239D (1) C656G (1) R451C (1) G73C (1) G5665T (1) R72P (1) F64L (1) L248R (1) M204I (1) R149S (1) A105G (1) M28L (1) D769Y (1) V769M (1) R75T (1) E193K (1) T890M (1) P250R (1) P58A (1) L532S (1) S147G (1) S1235R (1) K660E (1) T454A (1) R76K (1) L1213V (1) V742I (1) V1238I (1) R74W (1) T102C (1) K3048A (1) T93M (1) D961S (1) G1269A (1) R277W (1) P187S (1) Q20W (1) A561P (1) V740A (1) T783I (1) T674I (1) T783A (1) S8814A (1) V90I (1) C325G (1) Q188R (1) R30H (1) C785T (1) S100A (1) R496L (1) G174S (1) L798F (1) V765A (1) P11A (1) C18S (1) L798H (1) G1049R (1) V765M (1) S366T (1) R230C (1) G1376T (1) H396R (1) H396P (1) S65D (1) T1191I (1) A277G (1) L755A (1) H131R (1) T878A (1) T854A (1) P253R (1) C1494T (1) L755P (1) P120H (1) E525K (1) C102T (1) Y1253D (1) G196A (1) A145T (1) K70N (1) L861G (1) H43R (1) I76V (1) C344T (1) F1174V (1) R677W (1) S9313A (1) I112T (1) G10V (1) R10C (1) F1174L (1) R10A (1) K860I (1) R34P (1) F1174C (1) R108K (1) I112M (1) V151I (1) I332E (1) S1369A (1) R32Q (1) N409S (1) C563T (1) Q24H (1) I113T (1) D761Y (1) N291S (1) Y114C (1) V151A (1) G34A (1) G1069R (1) R896C (1) S567L (1) A827G (1) G12S (1) I54T (1) D565H (1) Y113H (1) P367L (1) R102G (1) R368H (1) M3002A (1) P125A (1) V282M (1) M1040E (1) E545G (1) E545A (1) G398A (1) E545D (1) G12A (1) L409P (1) S1787N (1) S784P (1) L841V (1) R14C (1) V943A (1) S9333A (1) Q148K (1) Q148E (1) M1043I (1) Y220C (1) T416P (1) A3669G (1) R38H (1) T961C (1) V1110L (1) T961G (1) L84F (1) S108N (1) C365Y (1) A719G (1) D237E (1) G37R (1) D104N (1) S653C (1) S786I (1) V834I (1) Y376C (1) G3514C (1) G594A (1) G1947A (1) G190C (1) V834L (1) Q546R (1) F522C (1) Q546L (1) Q546K (1) P699S (1) F2004L (1) D101H (1) T393C (1) A1330T (1) R988C (1) H48Q (1) T174M (1) A62V (1) G595R (1) A62T (1) L84V (1) M165I (1) V222A (1) P479L (1) G908R (1) Y318F (1) V75M (1) D101Y (1) I10F (1) D90V (1) H1112L (1) G269S (1) R3500Q (1) V30A (1) S282R (1) D919G (1) I665V (1) H1112Y (1) D90A (1) C385A (1) M95L (1) G1170S (1) V244M (1) G17T (1) S26E (1) N251K (1) W574C (1) G464V (1) C807T (1) V77I (1) Y449D (1) C168H (1) D4064A (1) M50I (1) Q215S (1) F106C (1) K56M (1) G465R (1) G598V (1) S769N (1) E586K (1) T1482I (1) L1196M (1) E148Q (1) T12W (1) S720P (1) Y641S (1) S768R (1) F129L (1) Y641N (1) C938A (1) C165V (1) R19C (1) C383R (1) Y641H (1) C805S (1) Y641F (1) W64R (1) Y641C (1) H1047Y (1) M1268T (1) A736V (1) C61G (1) P1009S (1) V481F (1) S1612C (1) Q546E (1) L718P (1) V179F (1) G106R (1) M1002A (1) P300D (1) S131F (1) N63L (1) W21C (1) L144S (1) M1149T (1) H558R (1) S373C (1) A69S (1) V1180L (1) V774A (1) T377M (1) V689M (1) V774M (1) D164V (1) L387M (1) R199W (1) N86S (1) M694V (1) N86Y (1) G11053T (1) R175H (1) T17M (1) Y86N (1) A2144G (1) A2059G (1) N345K (1) D50W (1) I180V (1) A864V (1) L24E (1) V118I (1) G212S (1) I843S (1) N1303K (1) R1623Q (1) A1033V (1) L1198F (1) N1325S (1) Q812R (1) V773M (1) G212A (1) A997T (1) S241T (1) E167K (1) G1764A (1) G80A (1) E62D (1) E274Q (1) M34T (1) G401S (1) A2142C (1) G1631D (1) G211A (1) D76Y (1) D76N (1) E384G (1) V249I (1) M1106C (1) L234I (1) L101I (1) A2143C (1) K806E (1) A687V (1) A119S (1) P1028S (1) A313G (1) D824V (1) S9C (1) C182A (1) S9G (1) S153F (1) S1900E (1) S1900D (1) S1900C (1) R1644H (1) S1900A (1) R702W (1) T1456G (1) T1565C (1) E1021K (1) K15210D (1) G779C (1) G82S (1) G779F (1) G840A (1) V18M (1) A27L (1) L28M (1) T351I (1) K121Q (1) L28P (1) H180Q (1) G779S (1) M11T (1) M11Q (1) P549S (1) N215S (1) G60D (1) R352W (1) G623R (1) G84E (1) E161K (1) G951A (1) C23S (1) E184K (1) V1206L (1) Y842C (1) V736A (1) L432V (1) E89Q (1) R135W (1) Y253F (1) G843D (1) D820Y (1) F77L (1) S311C (1) D10W (1) Y143H (1) G86R (1) Y143C (1) R112H (1) Y143A (1) A227G (1) K101Q (1) R463C (1) G85E (1) L236P (1) A310V (1) T798M (1) S310Y (1) R222C (1) A4917G (1) T798I (1) E44D (1) L302P (1) Q30R (1) L786V (1) R287Q (1) P286R (1) D36Y (1) R263Q (1) T599I (1) K103M (1) S680N (1) K1270A (1) R88Q (1) T224M (1) P46L (1) N700D (1) A5147S (1) E21G (1) Y822D (1) Q260A (1) Y188H (1) R131H (1) R1070Q (1) C316N (1) T81C (1) T1304M (1) I167V (1) I82A (1) D13H (1) Q54H (1) Q30H (1) L239R (1) Y823D (1) T117S (1) I84T (1) A222V (1) L106V (1) K432Q (1) G163S (1) I1370K (1) G163E (1) K650E (1) E757A (1) R399Q (1) G41S (1) C1895T (1) P392L (1) T334G (1) H274Y (1) R399G (1)

SNPMiner SNPMiner Trials (Home Page)


Report for Mutation V617F

Developed by Shray Alag, 2020-2021.
SNP Clinical Trial Gene

There are 58 clinical trials

Clinical Trials


1 Genomic Screening for Hereditary Erythrocytosis and Related Diseases

Unexplained polycythemias are rare diseases, and therefore, the collection of data inherent to these diseases will not only improve their characterisation, but also allow stratification according to the risks and the course of the disease. The objective of this project is to constitute a database on the disease which will allow us to better understand it and in due course improve its management. The GENRED project thus bears uniquely on the collection of information, which will be gathered throughout the usual management of patients for this type of disease.

NCT03263364
Conditions
  1. Hereditary Erythrocytosis/Idiopathic Erythrocytosis
MeSH:Polycythemia
HPO:Polycythemia

The required tests are: complete blood counts - Blood electrolytes - Arterial and venous gazes - Serum erythropoietin dosage - Liver function tests - JAK2 mutations (both V617F and exon 12) - Bone marrow aspirate and/or biopsy and/or endogenous BFU-E culture - Abdominal ultrasound - Lung function tests Inclusion Criteria: The characteristics of the patients included in the database will be described in terms of numbers and percentages for qualitative variables and in terms of means and standard deviations or medians and interquartile intervals for quantitative variables. --- V617F ---

The required tests are: complete blood counts - Blood electrolytes - Arterial and venous gazes - Serum erythropoietin dosage - Liver function tests - JAK2 mutations (both V617F and exon 12) - Bone marrow aspirate and/or biopsy and/or endogenous BFU-E culture - Abdominal ultrasound - Lung function tests Hereditary Erythrocytosis/Idiopathic Erythrocytosis Polycythemia null --- V617F ---

Primary Outcomes

Measure: Germline mutations that cause Hereditary Erythrocytosis/Idiopathic Erythrocytosis

Time: at baseline

2 Phase II Trial of Oral Panobinostat (LBH589), a Novel Deacetylase Inhibitor (DACi) in Patients With Primary Myelofibrosis (PMF), Post Essential Thrombocythemia (ET) Myelofibrosis and Post- Polycythemia Vera (PV) Myelofibrosis

This study will assess the safety and efficacy of Panobinostat as a single agent in the treatment of Primary Myelofibrosis, Post-Polycythemia Vera and Post-Essential Thrombocythemia. There will be two cohorts - patients with JAK2 mutation and patients without JAK2 mutation.

NCT00931762
Conditions
  1. Primary Myelofibrosis
  2. Post-Polycythemia Vera
  3. Post-Essential Thrombocytopenia
Interventions
  1. Drug: Panobinostat
MeSH:Polycythemia Vera Primary Myelofibrosis Thrombocytopenia Polycythemia
HPO:Polycythemia Thrombocytopenia

To compare the response to panobinostat in patients with the JAK2 V617F mutation to those without the JAK2 V617F mutation. --- V617F ---

To compare the response to panobinostat in patients with the JAK2 V617F mutation to those without the JAK2 V617F mutation. --- V617F --- --- V617F ---

(The presence of a JAK2 V617F mutation is not required for study entry) 2. Patients must meet the following laboratory criteria: - Patients can be either JAK2 V617F mutated or wild type - Serum potassium, magnesium, phosphorous, sodium, total calcium (corrected for serum albumin) or ionized calcium within normal limits (WNL) for the institution Note: Potassium, magnesium, phosphorous, sodium, and/or calcium supplements maybe given to correct values that are < LLN. --- V617F ---

(The presence of a JAK2 V617F mutation is not required for study entry) 2. Patients must meet the following laboratory criteria: - Patients can be either JAK2 V617F mutated or wild type - Serum potassium, magnesium, phosphorous, sodium, total calcium (corrected for serum albumin) or ionized calcium within normal limits (WNL) for the institution Note: Potassium, magnesium, phosphorous, sodium, and/or calcium supplements maybe given to correct values that are < LLN. --- V617F --- --- V617F ---

Primary Outcomes

Measure: To evaluate the overall response (CR, PR, and clinical improvement) to oral panobinostat as a single agent at 40 mg daily every Monday, Wednesday and Friday in patients with myelofibrosis.

Time: Upon enrollment of 13 participants into each cohort of the study and at the end of the study.

Secondary Outcomes

Measure: To compare the response to panobinostat in patients with the JAK2 V617F mutation to those without the JAK2 V617F mutation

Time: Upon enrollment of 13 participants into the study and at the end of the study

Measure: To evaluate the symptomatic improvement of myelofibrosis patients treated with panobinostat using the Myelofibrosis Symptom Assessment Form (MF-SAF) at baseline and after 2 and 4 months of treatment

Time: Upon enrollment of 13 participants in each cohort and at the end of the study

Measure: To evaluate the symptomatic improvement of myelofibrosis patients treated with panobinostat using the Myelofibrosis Symptom Assessment Form (MF-SAF) at baseline and after 2 and 4 months of treatment

Time: throughout the study

Measure: To assess compliance to panobinostat treatment as assessed by monthly capsule counts

Time: at the end of the study

3 Molecular Study of Factors Involved in JAK-STAT Signalling Pathway in Familial Myeloproliferative Disorders

The main goal of the study is to progress in our understanding of the molecular basis of myeloproliferative disorders of the bone marrow (polycythemia vera, essential thrombocythemia, primary myelofibrosis). The study will focus on the genes encoding factors implicated in the JAK-STAT pathway which has an essential role in these diseases

NCT00873574
Conditions
  1. Myeloproliferative Disorders
Interventions
  1. Biological: Blood samples and buccal swabs
MeSH:Myeloproliferative Disorders Disease
HPO:Myeloproliferative disorder

The recent identification of a recurrent activating tyrosine kinase mutation V617F in the JAK2 gene provides a breakthrough in the understanding of the molecular mechanisms of these diseases. --- V617F ---

The investigators have shown actually that the mutation V617F is a somatic one which is variably expressed among patients in the same family.Other somatic mutations and inherited factors, still unknown, may explain these discrepancies. --- V617F ---

JAK-STAT pathway has an essential role in non-CML MPD as was shown by the functional consequences of the V617F JAK2 mutation. --- V617F ---

Primary Outcomes

Measure: Allelic frequency comparison between the 2 cohorts

Time: At the inclusion visit

Secondary Outcomes

Measure: Undescribed gene mutations.

Time: At the inclusion visit

4 The Prognostic Value of PGF and sFlt1 Variations Induced by the First Low-molecular-weight-heparin Injections in Women With Obstetrical Antiphospholipids Antibody Syndrome Starting a New Pregnancy and Following Treatment in Accordance With International Recommendations

The primary objective of this study is to evaluate plasmatic concentrations of free PGF and sFlt1 for blood samples taken before a first low-molecular-weight-heparin injection and also for blood samples taken on the 4th day of injections (the latter correspond to the first systematic control of platelet counts) in women who have an obstetric antiphospholipid antibody syndrome and who are initiating a new pregnancy with recommended treatment. Our goal is to test the prognostic value of these data on the occurrence of: - pregnancy loss categorized as embryonic loss (before 10 weeks gestation), fetal death (before 20 weeks gestation), stillbirths (from 20 weeks gestation to delivery), and neonatal death defined before reaching 28 days of age. - ischemic placental pathology (pre-eclampsia, retro-placental hematoma, birth of a small-for-gestational-age infant)

NCT02855047
Conditions
  1. Antiphospholipid Syndrome
MeSH:Antiphospholipid Syndrome Syndrome

- Women in the APS subgroup: persistently positive for LA, and/or aCL and/or aBeta2GP1 - Women initiating a new pregnancy during the 18 month observational period after obstetric APS diagnosis Exclusion Criteria: - Any history of thrombotic events or any treatment given during previous pregnancies that might have modified the natural course of the condition - Women whose pregnancy losses could be explained by infectious, metabolic, anatomic or hormonal factors, or associated with paternal or maternal chromosomal causes - Seropositivity for HIV, hepatitis B or C - Women with antithrombin, protein C, or protein S deficiency, and women with abnormal fibrinogen or with the JAK2 V617F mutation were further excluded. --- V617F ---

Primary Outcomes

Description: The primary endpoint was a composite outcome that included any of the following events occurring after 19 completed weeks during the observed pregnancy: preeclampsia, abruptio placenta, or fetal growth restriction (< 10th percentile), summarized as the so-called placenta-mediated complications PMCs.

Measure: Presence/absence of at least one of the following: preeclampsia, abruptio placenta, or fetal growth restriction (< 10th percentile)

Time: 19 weeks gestation

5 Ruxolitinib in Combination With High Dose Therapy and Autologous Stem Cell Transplantation for Myelofibrosis

To determine the safety of the approach of giving RUXOLITINIB before and after an autologous stem cell transplant, as measured by graft failure or death.

NCT02469974
Conditions
  1. Myelofibrosis
  2. MF
Interventions
  1. Drug: RUXOLITINIB / INC 424
  2. Drug: Filgrastim
  3. Drug: Busulfan
MeSH:Primary Myelofibrosis

Changes in Jak 2 V617F allele burden when present will be measured by quantitative RT-PCR. --- V617F ---

Primary Outcomes

Description: Safety of this approach as measured by graft failure or death

Measure: Safety of combining ruxolitinib with autologous HSCT measured by graft failure or death

Time: 2 years

Secondary Outcomes

Description: Total CD34+ cell dose will be calculated based on results of flow cytometric analysis and patient's weight.

Measure: CD34 cells

Time: 4 years

Measure: The regimen related mortality (RRM)

Time: day 100

Measure: The regimen related mortality (RRM)

Time: day 365

Measure: Rate of engraftment/graft failure

Time: 4 years

Measure: Time of engraftment for neutrophils and platelets

Time: 4 years

Measure: The incidence of serious infectious complications

Time: up to 1 year post transplant

Description: The myelofibrosis score will be assessed as per the European Consensus Grading published by Thiele Grading Description at 365 days as compared to 180 days

Measure: Changes in marrow fibrosis score

Time: at 180 and 365 days post-transplant

Description: Changes in FISH abnormalities when present will be measured by cytogenetics.

Measure: Change in FISH allele

Time: at 365 days post-transplant

Description: Changes in Jak 2 V617F allele burden when present will be measured by quantitative RT-PCR

Measure: Change in JAK allele

Time: at 365 days post-transplant

Description: Overall efficacy will be rated on a scale as complete remission, partial remission, clinical improvement, or stable disease

Measure: Rate of response

Time: at 6 months post-transplant

Description: Overall efficacy will be rated on a scale as complete remission, partial remission, clinical improvement, or stable disease

Measure: Rate of response

Time: at 1 year post-transplant

6 A Phase II Study of MK-0683 in Patients With Polycythaemia Vera and Essential Thrombocythaemia.

The aim of the present study is to evaluate the efficacy and safety of MK-0683 in the treatment of PV and ET. This agent has most recently been shown to be a potent inhibitor of the autonomous proliferation of haematopoietic cells of PV and ET patients carrying the JAK2 V617F mutation. Accordingly, it may be anticipated that MK-0683 - by decreasing the JAK2 allele burden - may influence clonal myeloproliferation and in vivo granulocyte, platelet and endothelial activation , which are considered to be major determinants of morbidity and mortality ( thrombosis, bleeding, extramedullary haematopoiesis , myelofibrosis ) in these disorders. The effects of MK-0683 at the molecular level will be studied by global/ focused gene expression profiling, epigenome profiling and proteomics.

NCT00866762
Conditions
  1. Polycythemia Vera
  2. Essential Thrombocythemia
Interventions
  1. Drug: HDAC inhibitor (MK-0683)
MeSH:Polycythemia Vera Polycythemia Thrombocytosis Thrombocythemia, Essential
HPO:Polycythemia Thrombocytosis

This agent has most recently been shown to be a potent inhibitor of the autonomous proliferation of haematopoietic cells of PV and ET patients carrying the JAK2 V617F mutation. --- V617F ---

Primary Outcomes

Measure: To evaluate the efficacy of study drug (MK-0683) in the treatment of patients with PV and ET.

Time: one year

Secondary Outcomes

Measure: To study changes in bone marrow morphology before and after treatment with study drug.

Time: one year

7 Randomized Trial of Pegylated Interferon Alfa-2a Versus Hydroxyurea Therapy in the Treatment of High Risk Polycythemia Vera (PV) and High Risk Essential Thrombocythemia (ET)

This research is looking at two conditions, Essential Thrombocythemia (ET) and Polycythemia Vera (PV). ET causes people to produce too many blood cells called platelets and PV causes too many platelets and red blood cells to be made. Platelets are particles which circulate in the blood stream and normally prevent bleeding and bruising. Having too many platelets in the blood increases the risk of developing blood clots, which can result in life threatening events like heart attacks and strokes. When the number of red blood cells is increased in PV this will slow the speed of blood flow in the body and increases the risk of developing blood clots. The purpose of this study is to look at the effectiveness of giving participants who have been diagnosed with ET or PV one of two different study regimens over time. The study subject will be followed for their condition for about 5 years. The subject will be randomized into one of two study regimens, either Pegylated Interferon Alfa-2a (PEGASYS) or Aspirin and Hydroxyurea (also called Hydroxycarbamide). The subject must be newly diagnosed or already receiving treatment for either PV or ET. Each of the study drugs used in this study is already being used to treat subjects with ET or PV currently, but the investigators are unsure which study drug is better.

NCT01259856
Conditions
  1. High Risk Polycythemia Vera
  2. High Risk Essential Thrombocythemia
Interventions
  1. Drug: PEGASYS
  2. Drug: Hydroxyurea
  3. Drug: Aspirin
MeSH:Polycythemia Vera Polycythemia Thrombocytosis Thrombocythemia, Essential
HPO:Polycythemia Thrombocytosis

The impact of PEGASYS on JAK2 will be measured by the allele burden; hematopoietic cell clonality will be measured by whether patients with clonal disease return to polyclonal; bone marrow histopathology will be measured by going from abnormal to normal; cytogenetic abnormalities will be measured by seeing if the cytogenetics go from abnormal to normal.To compare the impact of therapy on JAK2-V617F (JAK2), CALR, hematopoietic cell clonality in platelets and granulocytes in females, bone marrow histopathology, and cytogenetic abnormalities.. Number of Participants With Progression of Disease or Death. --- V617F ---

Primary Outcomes

Description: Number of participants with Complete Remission after 12 months of therapy assessed by hematologic response rates two strata of patients with high risk polycythemia vera (PV) or high risk essential thrombocythemia (ET). Complete remission means no evidence of disease.

Measure: Number of Participants With Complete Remission (CR)

Time: 12 months

Description: Number of participants with Partial Remission after 12 months of therapy assessed by hematologic response rates two strata of patients with high risk polycythemia vera (PV) or high risk essential thrombocythemia (ET). Partial Remission means decrease in the size of a tumor, or in the extent of cancer in the body, in response to treatment.

Measure: Number of Participants With Partial Remission (PR)

Time: 12 months

Secondary Outcomes

Description: Number of Participants with Grade 3 and Grade 4 Hematological and Non-hematological Events using the Common Terminology Criteria for Adverse Events (CTCAE) 4.0 to assess the toxicity, safety and tolerability of therapy (Pegylated Interferon Alfa-2a vs. Hydroxyurea).

Measure: Number of Participants With Grade 3 and Grade 4 Hematological and Non-hematological Events

Time: 4 years

Description: Change in the Total Symptom Score which assessed improvement in disease symptoms measured by the change in TSS from the Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF) instrument being used in this study from baseline to 12 months. This 19 item instrument includes the previously validated 9 item brief fatigue inventory (BFI), symptoms related to splenomegaly, inactivity, cough, night sweats, pruritus, bone pains, fevers, weight loss, and an overall quality of life assessment. Each item is scored from 0-10 with full scale from 0-190, with higher scores mean worse symptoms.

Measure: Change in the Total Symptom Score (TSS)

Time: baseline and 12 months

Description: To compare the impact of therapy (Pegylated Interferon Alfa-2a vs. Hydroxyurea) on key biomarkers of the disease(s) by measuring the JAK2 allele burden.

Measure: JAK2 Allele Burden

Time: 4 years

Description: The impact of PEGASYS on JAK2 will be measured by the allele burden; hematopoietic cell clonality will be measured by whether patients with clonal disease return to polyclonal; bone marrow histopathology will be measured by going from abnormal to normal; cytogenetic abnormalities will be measured by seeing if the cytogenetics go from abnormal to normal.To compare the impact of therapy on JAK2-V617F (JAK2), CALR, hematopoietic cell clonality in platelets and granulocytes in females, bone marrow histopathology, and cytogenetic abnormalities.

Measure: Allele Burden

Time: 4 years

Description: Survival and incidence of development of myelodysplastic syndrome, myelofibrosis, or leukemic transformation after therapy To estimate survival and incidence of development of myelodysplastic syndrome, myelofibrosis, or leukemic transformation after therapy (Pegylated Interferon Alfa-2a vs. Hydroxyurea) by capturing the rate of progression to a more advanced myeloid malignancy.

Measure: Number of Participants With Progression of Disease or Death

Time: 4 years

Measure: Number of Participants With Major Cardiovascular Events After Therapy

Time: 4 years

8 Single Arm Salvage Therapy With Pegylated Interferon Alfa-2a for Patients With High Risk Polycythemia Vera or High Risk Essential Thrombocythemia Who Are Either Hydroxyurea Resistant or Intolerant or Have Had Abdominal Vein Thrombosis

The aim of this research is to look at two conditions, Essential Thrombocythemia (ET) and Polycythemia Vera (PV). ET causes people to produce too many blood cells called platelets and PV causes too many platelets and red blood cells to be made. Platelets are particles which circulate in the blood stream and normally prevent bleeding and bruising. Having too many platelets in the blood increases the risk of developing blood clots, which can result in life threatening events like heart attacks and strokes. When the number of red blood cells is increased in PV this will slow the speed of blood flow in the body and increases the risk of developing blood clots. It is important for patients with ET or PV who are at risk of blood clots to receive drugs which will minimize the risks of developing these blood clots but at the moment the investigators are not sure which drugs will best control the disorder. The purpose of this study is to look at the effectiveness of giving patients who have been diagnosed with ET and PV a study drug regimen using Aspirin and PEGASYS (also known as Pegylated interferon alfa-2a, instead of the standard treatment drug called Hydroxyurea (or hydroxycarbamide or Hydroxyurea), for whom this drug may not be suitable. The drug may not be suitable either because it is not adequately controlling the number of blood cells or some specific side effects occur.

NCT01259817
Conditions
  1. High Risk Polycythemia Vera
  2. High Risk Essential Thrombocythemia
Interventions
  1. Drug: PEGASYS
  2. Drug: Aspirin
MeSH:Polycythemia Vera Polycythemia Thrombocytosis Thrombocythemia, Essential
HPO:Polycythemia Thrombocytosis

To measure the impact of Pegylated Interferon Alfa-2a on JAK2-V617F, CALR, hematopoietic cell clonality in platelets and granulocytes in females, bone marrow histopathology, and cytogenetic abnormalities.. --- V617F ---

For these patients the following additional inclusion/exclusion criteria apply: - > 3 months since onset of SVT - SVT treated with oral anticoagulants but no aspirin - Liver enzymes not > 2 times the normal value - Absence of encephalopathy, refractory or infected ascites, esophageal varicose of grade > 1 at time of trial entry - Bone marrow biopsy confirmed diagnosis of PV or ET - JAK2-V617F mutations present - These patients may have a normal blood count at trial entry - Age over 18 years (no upper age limit) - Able and willing to comply with study criteria - Signed and informed consent to participant in this study - Willing to participate in associated correlative science biomarker study - Serum creatinine < 1.5 x upper limit of normal - AST and ALT < 2 x upper limit of normal - Total bilirubin within normal limits Exclusion Criteria: - Patients cannot have any other form of chemotherapy for their MPD (other than hydroxyurea). --- V617F ---

The point mutation in JAK2 encodes a valine to phenylalanine change at position 617 (JAK2 V617F), and confers constitutive tyrosine kinase activity. --- V617F ---

Introducing the mutation into the bone marrow of mouse models recapitulates the PV phenotype (complete with evolution to bone marrow fibrosis) and inhibitors of JAK2 attenuate the growth of cell lines bearing the mutation in vitro and in vivo, suggesting that JAK2 V617F is a pathophysiologically relevant therapeutic target. --- V617F ---

It is estimated that 95% of PV cases carry JAK2 V617F, while 50 to 60% of ET and PMF cases are JAK2 V617F+. --- V617F ---

Primary Outcomes

Measure: Evaluate the ability of Pegylated Interferon Alfa-2a to achieve Complete Response or Partial Response in patients with (1) high risk polycythemia vera or (2) high risk essential thrombocythemia or (3) splanchnic vein thrombosis

Time: 4 years

Secondary Outcomes

Measure: To evaluate the toxicity and tolerability of therapy Pegylated Interferon Alfa-2a in each of the 3 strata by recording the number of adverse events that occur during the study by using CTC 4.0 as the guide.

Time: 4 years

Measure: To measure the impact of Pegylated Interferon Alfa-2a on key biomarkers of the disease(s)by measuring the JAK2 allele burden.

Time: 4 years

Description: Improvement in disease symptoms will be measured by the Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF) instrument being used in this study.

Measure: To evaluate specific pre-defined toxicity and tolerance of Pegylated Interferon Alfa-2a through a sequential structured symptom assessment package of patient reported outcome instruments.

Time: 4 years

Description: We plan to capture the rate of disease progression to a more advanced myeloid malignancy.

Measure: To estimate survival, and incidence of development of myelodysplastic syndrome, myelofibrosis, or leukemic transformation during therapy Pegylated Interferon Alfa-2a.

Time: 4 years

Description: Capture and record the cardiovascular events that occur during the study.

Measure: Estimate the observed incidence of major cardiovascular events during therapy Pegylated Interferon Alfa-2a.

Time: 4 years

Description: The impact of PEGASYS on JAK2 will be measured by the allele burden; hematopoietic cell clonality will be measured by whether patients with clonal disease return to polyclonal; bone marrow histopathology will be measured by going from abnormal to normal; cytogenetic abnormalities will be measured by seeing if the cytogenetics go from abnormal to normal.

Measure: To measure the impact of Pegylated Interferon Alfa-2a on JAK2-V617F, CALR, hematopoietic cell clonality in platelets and granulocytes in females, bone marrow histopathology, and cytogenetic abnormalities.

Time: 4 years

9 Phase 1/2 Study of an EZH2 Inhibitor (Tazemetostat) in Combination With Dual BRAF/MEK Inhibition in Patients With BRAF- Mutated Metastatic Melanoma Who Progressed on Prior BRAF/MEK Inhibitor Therapy

This phase I/II trial investigates the best dose and side effects of tazemetostat and how well it works in combination with dabrafenib and trametinib in treating patients with melanoma that has a specific mutation in the BRAF gene (BRAFV600) and that has spread to other places in the body (metastatic). Tazemetostat, dabrafenib, and trametinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving tazemetostat with dabrafenib and trametinib may help treat patients with BRAFV600 mutated melanoma.

NCT04557956
Conditions
  1. Clinical Stage IV Cutaneous Melanoma AJCC v8
  2. Metastatic Malignant Neoplasm in the Central Nervous System
  3. Metastatic Melanoma
  4. Pathologic Stage IV Cutaneous Melanoma AJCC v8
Interventions
  1. Drug: Dabrafenib Mesylate
  2. Drug: Tazemetostat Hydrobromide
  3. Drug: Trametinib Dimethyl Sulfoxide
MeSH:Melanoma Neoplasms Skin Neoplasms
HPO:Cutaneous melanoma Melanoma Neoplasm Neoplasm of the skin

JAK2 V617F) observed in cytogenetic testing and DNA sequencing - History of T-lymphoblastic lymphoma (T-LBL)/T-cell acute lymphoblastic leukemia (T-ALL) - Patients with history of RAS mutation-positive tumors are not eligible regardless of interval from the current study. --- V617F ---

Primary Outcomes

Description: Data analysis will be descriptive in nature, and will be determined using the standard 3+3 algorithm. Toxicities by grade, number of cycles administered, and response to treatment will be listed for each dose level.

Measure: Recommended phase 2 dose (R2PD) (Phase 1)

Time: Up to 3 years

Description: Median PFS in each arm will be assessed using Kaplan-Meier product limit methods and the randomized arms will be compared using log-rank test (at 0.15 one-sided significance level) when 36 PFS events are observed.

Measure: Median progression-free survival (PFS) in Arm 1 and 2 (Phase 2)

Time: At 6 and 12 months

Secondary Outcomes

Description: Assessed by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1, and 95% confidence intervals will be calculated.

Measure: Overall response rates (complete response [CR], partial response [PR])

Time: Up to 3 years

Description: Will be estimated in each arm using Kaplan-Meier product limit methods, and its 95% confidence interval will be calculated.

Measure: Overall survival

Time: Up to 3 years

Description: Toxicity evaluation will be descriptive, and standard toxicity definitions and criteria will be used as outlined in the National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0. The number and percentage of subjects experiencing each type of adverse event will be tabulated by severity. If appropriate, confidence intervals will be used to characterize the precision of the estimate. A complete listing of adverse events will also be tabulated, and will provide details including severity, relationship to treatment, onset, duration, and outcome. Laboratory data measured on a continuous scale will be characterized by summary statistics (mean and standard deviation).

Measure: Incidence of adverse events

Time: Up to 3 years

10 Efficacy and Safety of Dabigatran in Patients With Cirrhosis and Portal Vein Thrombosis-A Randomized Placebo Controlled Trial

A randomized controlled trial to study the efficacy and safety of Dabigatran in Cirrhotic patients who develop PVT.In this study the patients who meet the inclusion criteria will be randomized to either receive Dabigatran or placebo [multivitamin tablet]. Blood samples will be taken &Imaging will be done accordingly to notice progression or recanalization of PVT.The patients are followed up every 2 months up to 18 month .Then statistical analysis will be done to find whether the Dabigatran is efficacious in cirrhotic patients for recanalization of PVT.

NCT04433481
Conditions
  1. Liver Cirrhosis
  2. Portal Vein Thrombosis
Interventions
  1. Drug: Dabigatran
  2. Other: Placebo
MeSH:Liver Cirrhosis Thrombosis Venous Thrombosis Fibrosis
HPO:Cirrhosis Deep venous thrombosis Hepatic fibrosis Venous thrombosis

All included patients will be evaluated with - 1. Etiology of cirrhosis 2. Upper GI endoscopy 3. Haemogram (including reticulocyte count) 4. Coagulogram- PT/INR,APTT,TEG 5. Prothrombotic profile- protein c/protein-s/AT-III/Factor V Leiden mutation/ MTHFR C677T/PROTHROMBIN G20210A/ JAK2 V617F MUTATION / Anticardiolipin Ab. 6. Liver function tests, Renal function tests 7. Alpha fetoprotein/PIVKA II 8. USG abdomen with Doppler study 9. CECT-TP or CEMRI-TP to R/O HCC or angiography when PVT diagnosis doubtful. --- C677T --- --- G20210A --- --- V617F ---

Primary Outcomes

Measure: Number of participants with complete recanalization of thrombus in both groups.

Time: 1 year

Secondary Outcomes

Measure: Number of participants with partial recanalization of thrombus in both groups.

Time: 1 Year

Measure: Number of participants with improvements in Child-Turcotte-Pugh (CTP) in both groups.

Time: 6 months

Measure: Number of participants with improvements in Child-Turcotte-Pugh (CTP) in both groups.

Time: 1 year

Description: MELD score ranges from 6 to 40.

Measure: Improvements in Model for End Stage Liver Disease (MELD) Score in both groups

Time: 6 months

Description: MELD score ranges from 6 to 40.

Measure: Improvements in Model for End Stage Liver Disease (MELD) Score in both groups

Time: 1 Year

Measure: Number of participants with prevention of secondary decompensation in both groups

Time: 1 Year

Measure: Adverse Events in both groups

Time: 1 year

Measure: To study the changes in coagulation parameters by ROTEM(Rotational Thrombo Elastometry) analysis which includes CFT(clot formation time).

Time: 6 Months

Measure: To study the changes in coagulation parameters by ROTEM(Rotational Thrombo Elastometry) analysis which includes CFT(clot formation time).

Time: 12 Months

Measure: Number of participants with reduction in clinical complications in patients with PVT in both groups

Time: 3 Months

Measure: Number of participants with reduction in clinical complications in patients with PVT in both groups

Time: 6 Months

Measure: Number of participants with reduction in clinical complications in patients with PVT in both groups

Time: 12 Months

Measure: To study the number of participants developing reoccurrence of PVT after treatment with Dabigatran for 12 months by Ultrasound Doppler of splenoportal venous system.

Time: 12 months

11 Molecular Disease Profile of Haematological Malignancies. A Prospective Registry Study by the Rete Ematologica Lombarda (REL) Clinical Network

In this prospective multicentric study, the University of Pavia together with the Fondazione IRCCS Policlinico San Matteo, Pavia and the IRCCS Fondazione Maugeri, Pavia, Italy will provide a systematic analysis of gene mutations in hematological malignancies by using NGS techniques. Patients with a conclusive diagnosis of haematological malignancies according to WHO criteria referred to the Rete Ematologica Lombarda clinical network (REL, www.rel-lombardia.net) will be enrolled. The investigators will analyse genomic DNA extracted from hematopoietic cells at different time points of patient disease. The study contemplates the use of molecular platforms (Next Generation Sequencing, NGS) aimed at the identification of recurrent mutations in myeloid and lymphoid neoplasms, respectively. Screening of gene mutations by NGS will be prospectively implemented in the context of REL clinical network. Patient samples will be analyzed at diagnosis and sequentially during the course of the disease at specific timepoints. The researchers will analyze the correlations between somatic mutations, specific clinical phenotypes (according to the WHO classification) and disease evolution. This will allow to: 1) identify new recurrent genetic mutations involved in the molecular pathogenesis of hematological malignancies; 2) define the role of mutated genes, distinguishing between genes which induce a clonal proliferation of hematopoietic stem cells, and genes which determine the clinical phenotype of the disease; 3) identify mutations which are responsible for disease evolution; 4) define the diagnostic/prognostic role of the identified mutations, and update the current disease classifications and prognostic scores by including molecular parameters. A systematic biobanking of biological material will be provided.

NCT02459743
Conditions
  1. Hematological Malignancies
MeSH:Neoplasms Hematologic Neoplasms
HPO:Hematological neoplasm Leukemia Neoplasm

In 2005 the University of Pavia described the diagnostic and prognostic significance of the JAK2 V617F mutation in myeloproliferative neoplasms (MPN): this mutation was included into the WHO classification of MPN and innovative anti-JAK2 drugs were developed. --- V617F ---

Primary Outcomes

Measure: Cumulative incidence of gene mutations in principal clone and subclones in each hematological malignancy

Time: 3 years

Secondary Outcomes

Measure: Genotype-phenotype correlations between clinical characteristics and mutational status

Time: 3 years

Measure: Overall survival and disease-free survival according to clinical and biological risk factors at diagnosis and during disease evolution

Time: 3 years

12 Efficacy of Heat-shock Protein (HSP) Inhibitors in Myeloproliferative Syndromes (MPS): Fundamental Observational in Vitro Study Using Samples From a Collection

Heat-shock proteins (HSP) have been very highly conserved throughout the evolution of species and are characterized by their chaperone function, thanks to their ability to prevent aggregation and to promote the renaturation/break down of damaged proteins. Among other targets, they also chaperone JAK2, a key step that is deregulated in signalling in myeloproliferative syndromes (MPS) because of the JAK2V617F mutation. These HSP also have a potent cytoprotective action through their multiples inhibiting effects on apoptotic processes. Little is known about levels of HSP expression, in particular for HSP70 and HSP27, in MPS cells. However, in vitro studies of different cell models have shown the interest of HSP90 inhibitors in slowing cell proliferation in MPS. These results have been confirmed in animal models with results in terms of blood counts and overall survival. In addition, it seems that the V617F mutated form of JAK2 is more sensitive than the wild-type to HSP90 inhibitors. Finally, inhibitors of HSP90 remain efficacious with regard to the inhibition of cell growth, even in cases of resistance to JAK2 inhibitors. Nonetheless, HSP90 inhibitors are known to stimulate the expression of other HSP, notably HSP27 and HSP70, which are, through their properties, tumorigenic and could lead to an escape phenomenon. Thus the combined use of several HSP inhibitors could be beneficial, and eventually present synergistic effects on the inhibition of tumour processes.

NCT02873832
Conditions
  1. Myeloproliferative Syndrome
Interventions
  1. Biological: Blood sample
  2. Other: Flow cytometry
  3. Other: western blot
MeSH:Myeloproliferative Disorders Syndrome
HPO:Myeloproliferative disorder

In addition, it seems that the V617F mutated form of JAK2 is more sensitive than the wild-type to HSP90 inhibitors. --- V617F ---

Primary Outcomes

Description: Level of protein expression using flow cytometry and western blot

Measure: Comparing the level of expression of HSP (HSP90, HSP70, HSP27) between cells from a collection of samples of patients with myeloproliferative disease and healthy controls .

Time: through study completion, an average of 1 year

Secondary Outcomes

Measure: Cell death after in vitro treatment with different HSP inhibitors

Time: through study completion, an average of 1 year

13 A Phase 2, Prospective, Randomized, Multicenter, Double-blind, Active-control, Parallel-group Study to Determine the Safety of and to Select a Treatment Regimen of CC-4047 (Pomalidomide) Either as Single-agent or in Combination With Prednisone to Study Further in Subjects With Myelofibrosis With Myeloid Metaplasia

The purpose of this study is to determine the safety of and to select a treatment regimen of pomalidomide (CC-4047) either as single-agent or in combination with prednisone to study further in patients with myelofibrosis with myeloid metaplasia (MMM).

NCT00463385
Conditions
  1. Myelofibrosis With Myeloid Metaplasia
  2. Myeloid Metaplasia
  3. Myelofibrosis
Interventions
  1. Drug: Pomalidomide
  2. Drug: Prednisone
  3. Drug: Placebo to pomalidomide
  4. Drug: Placebo to prednisone
MeSH:Primary Myelofibrosis Metaplasia

Percentage of participants who achieved a clinical response, presented by participants with positive and negative janus kinase 2 (JAK2) V617F mutation results at Baseline.. Number of Participants With Adverse Events (AEs). --- V617F ---

Primary Outcomes

Description: A clinical responder was defined as either: A baseline red blood cell (RBC)-transfusion-dependent participant with a ≥ 56 consecutive day RBC transfusion-free period after the first dose of study drug, or A baseline RBC-transfusion-independent participant with an increase in hemoglobin of 2.0 g/dL or more from baseline for ≥ 56 consecutive days in the absence of RBC transfusions, or A participant with either a ≥ 50% reduction in palpable splenomegaly of a spleen that was ≥ 10 cm at baseline or a spleen that was palpable at > 5 cm and became not palpable. Participants who discontinued the study early without achieving clinical response were counted as non-responders.

Measure: Percentage of Participants With a Clinical Response Within the First 6 Cycles of Treatment

Time: Up to 168 days

Secondary Outcomes

Description: A clinical responder was defined as either: A baseline red blood cell (RBC)-transfusion-dependent participant with a ≥ 56 consecutive day RBC transfusion-free period after the first dose of study drug, or A baseline RBC-transfusion-independent participant with an increase in hemoglobin of 2.0 g/dL or more from baseline for ≥ 56 consecutive days in the absence of RBC transfusions, or A participant with either a ≥ 50% reduction in palpable splenomegaly of a spleen that was ≥ 10 cm at baseline or a spleen that was palpable at > 5 cm and became not palpable. Participants who discontinued the study early without achieving clinical response were counted as non-responders.

Measure: Percentage of Participants With a Clinical Response Within the First 12 Cycles of Treatment

Time: Up to 336 days

Description: The time to the first clinical response achieved within 168 days after the first study drug dosing date was calculated for participants who achieved a clinical response as: Start date of the first clinical response - the first study drug date +1. A clinical responder was defined as either: A baseline red blood cell (RBC)-transfusion-dependent participant with a ≥ 56 consecutive day RBC transfusion-free period after the first dose of study drug, or A baseline RBC-transfusion-independent participant with an increase in hemoglobin of 2.0 g/dL or more from baseline for ≥ 56 consecutive days in the absence of RBC transfusions, or A participant with either a ≥ 50% reduction in palpable splenomegaly of a spleen that was ≥ 10 cm at baseline or a spleen that was palpable at > 5 cm and became not palpable.

Measure: Time to the First Clinical Response

Time: Up to 168 days

Description: For RBC-transfusion-dependent patients, duration of response was calculated as the last day of response - first day of response +1, where the last day of response was the date of the first RBC-transfusion administrated at or more than 56 days after the response started. For patients who did not receive a subsequent transfusion after the response started, the end date of response was censored at the day of last hemoglobin assessment. For RBC-transfusion-independent patients, the duration of response was calculated as the last day of response - first day of response +1, where the last day of response was the earlier of the date of a hemoglobin increase of < 2.0 g/dL and the date of a RBC transfusion at ≥ 56 days after the response started. For patients whose hemoglobin measurements were always ≥ 2.0 g/dL and never received a RBC transfusion after response started, the end date of the response was censored at the date of last hemoglobin measurement. Kaplan-Meier methodology was used.

Measure: Duration of First Clinical Response

Time: Up to 40 months

Description: The FACT-An comprises the four subscales of the 27-item FACT-General Scale (FACT-G), Physical Well-being, Social/Family Well-being, Emotion Well-being, Functional Well-Being, and the Additional Concerns Anemia subscale. Questions are rated on a scale from 0 to 4, where higher scores indicate more impact on quality of life. Physical Well-being consists of 7 questions, the subscale score ranges from 0-28; Social/Family Well-being consists of 7 questions, the subscale score ranges from 0-28; Emotion Well-being consists of 6 questions, the subscale score ranges from 0-24; Functional Well-Being consists of 7 questions, the subscale score ranges from 0-28; Anemia subscale consists of 20 questions, the subscale score ranges from 0-80; Total FACT-An score ranges from 0-188.

Measure: Change From Baseline in Functional Assessment of Cancer Therapy-Anemia (FACT-An) Subscale and Total Scores

Time: Baseline and Cycle 6 (168 days).

Description: Change from Baseline in hemoglobin for participants with a clinical response within the first 6 cycles of treatment.

Measure: Change From Baseline in Hemoglobin Concentration for Responders

Time: Baseline, Cycle 6 (168 days)

Description: Change from Baseline in hemoglobin for participants without a clinical response within the first 6 cycles of treatment.

Measure: Change From Baseline in Hemoglobin Concentration for Non-Responders

Time: Baseline, Cycle 6 (168 days)

Description: Participants rated abdominal discomfort or pain over the previous week on a scale from zero to ten, where zero is no discomfort or pain and ten is the worst pain imaginable.

Measure: Change From Baseline in Likert Abdominal Pain Scale

Time: Baseline and Cycle 6 (168 days)

Description: Percentage of participants who achieved a clinical response, presented by participants with positive and negative janus kinase 2 (JAK2) V617F mutation results at Baseline.

Measure: Percentage of Participants With Clinical Response by Baseline JAK2 Assessment

Time: Up to 336 days

Description: A serious AE (SAE) was defined as any AE which resulted in death or was life-threatening, required or prolonged inpatient hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, or constituted an important medical event (events that may have jeopardized the patient or required intervention to prevent one of the outcomes listed above). The severity of AEs were graded according to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE, Version 3.0) or according to the following scale: Grade 1 = Mild; Grade 2 = Moderate; Grade 3 = Severe; Grade 4 = Life-threatening; Grade 5 = Death. The Investigator determined the relationship between study drug and the occurrence of an AE as "Not Related" or "Related" (since the study was double-blinded, a patient receiving only prednisone could have an AE that was judged as related to pomalidomide, and vice-versa).

Measure: Number of Participants With Adverse Events (AEs)

Time: From date of the first dose of the study drug until discontinuation or the data cut-off date (up to approximately 45 months).

14 Anticoagulation Treatment of Patients With Gastroesophageal Varices and JAK2 V617 Mutation

Myeloproliferative neoplasms (MPNs), including polycythemia vera, essential thrombocythemia, and primary myelofibrosis, may lead to gastroesophageal varices. The quality of life, morbidity, and mortality of MPN patients mainly depend on disease-related symptoms, thromboembolic and hemorrhagic complications. Previous studies have shown that JAK2 V617F has a prominent role in vascular risk and MPN-associated gastroesophageal varices. The aim of this study is to evaluate the efficacy of anticoagulation in patients with JAK2 mutation and gastroesophageal varices.

NCT04527666
Conditions
  1. Gastroesophageal Varices
  2. JAK2 Mutation
  3. Myeloproliferative Neoplasm
Interventions
  1. Drug: Anticoagulation Agents
MeSH:Esophageal and Gastric Varices Varicose Veins Myeloproliferative Disorders
HPO:Esophageal varix Gastric varix Myeloproliferative disorder Varicose veins

Previous studies have shown that JAK2 V617F has a prominent role in vascular risk and MPN-associated gastroesophageal varices. --- V617F ---

Primary Outcomes

Description: The changes of portal vein thrombosis including progression, disappear or unchanged.

Measure: Changes of portal vein thrombosis

Time: 1 year

Secondary Outcomes

Description: The occurrence of variceal bleeding including haematemesis and melena

Measure: The occurrence of variceal bleeding

Time: 1 year

Description: Overall survival rate

Measure: Overall survival

Time: 1 year

15 Characteristic of Patients With Gastroesophageal Varices and Portal Cavernoma

Myeloproliferative neoplasms (MPNs), including polycythemia vera, essential thrombocythemia, and primary myelofibrosis, may lead to gastroesophageal varices. The quality of life, morbidity, and mortality of MPN patients mainly depend on disease-related symptoms, thromboembolic and hemorrhagic complications. Previous studies have shown that JAK2 V617F has a prominent role in vascular risk and MPN-associated gastroesophageal varices. Portal vein thrombosis and portal cavernoma frequently occur in the MPN population and the management of gastroesophageal varices in these patients are sometimes technically difficult. The aim of this study is to investigate the the characteristics of patients with gastroesophageal varices and portal caver cavernoma with or without JAK2 mutation.

NCT04525768
Conditions
  1. Gastroesophageal Varices
  2. Myeloproliferative Neoplasm
  3. Portal Caver Cavernoma
  4. Portal Hypertension
Interventions
  1. Diagnostic Test: JAK2 mutation test
MeSH:Hemangioma, Cavernous Hypertension, Portal Esophageal and Gastric Varices Hypertension Varicose Veins Myeloproliferative Disorders
HPO:Cavernous hemangioma Esophageal varix Gastric varix Hypertension Myeloproliferative disorder Portal hypertension Varicose veins

Previous studies have shown that JAK2 V617F has a prominent role in vascular risk and MPN-associated gastroesophageal varices. --- V617F ---

Primary Outcomes

Description: Have a history of the occurrence of gastroesophageal variceal bleeding

Measure: History of variceal bleeding

Time: 1 day (the same time as diagnosis)

Secondary Outcomes

Description: 1-year death rate

Measure: 1-year death rate

Time: 1 year

Description: The concurrence of complications of portal hypertension (ascites, infections, variceal bleeding, et al)

Measure: Complications of portal hypertension

Time: 1 year

16 A Phase II Study of Tazemetostat (EPZ-6438) in Recurrent or Persistent Endometrioid or Clear Cell Carcinoma of the Ovary, and Recurrent or Persistent Endometrioid Endometrial Adenocarcinoma

This phase II trial studies how well tazemetostat works in treating patients with ovarian or endometrial cancer that has come back (recurrent). Chemotherapy drugs, such as tazemetostat, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.

NCT03348631
Conditions
  1. FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma
  2. FIGO Grade 2 Endometrial Endometrioid Adenocarcinoma
  3. Recurrent Endometrial Endometrioid Adenocarcinoma
  4. Recurrent Ovarian Carcinoma
  5. Recurrent Ovarian Clear Cell Adenocarcinoma
  6. Recurrent Ovarian Endometrioid Adenocarcinoma
  7. Recurrent Uterine Corpus Cancer
Interventions
  1. Other: Laboratory Biomarker Analysis
  2. Drug: Tazemetostat
MeSH:Carcinoma Adenocarcinoma Carcinoma, Endometrioid Adenocarcinoma, Clear Cell
HPO:Carcinoma

JAK2 V617F) observed in cytogenetic testing and deoxyribonucleic acid (DNA) sequencing - A prior history of T-cell lymphoblastic lymphoma (T-LBL)/T-cell acute lymphoblastic leukemia (T-ALL) - Severe, active co-morbidity per the treating investigator's discretion - Pregnant or lactating patients - Known human immunodeficiency virus (HIV) positive patients on combination antiretroviral therapy are ineligible because of the potential for pharmacokinetic interactions with tazemetostat; in addition, treatments involved in this protocol may be immunosuppressive, increasing the risk of lethal infections in this patient population - Treatment with strong inhibitors or inducers of CYP3A within 14 days of registration and during the study treatment Inclusion Criteria: - Pathologically (histologically or cytologically) proven diagnosis of recurrent or persistent ovarian endometrioid or clear cell carcinoma, OR recurrent or persistent endometrioid endometrial adenocarcinoma; patients with recurrent endometrial cancer must have mismatch repair (MMR) immunohistochemistry completed; if they are found to be mismatch repair deficient, they should be offered treatment with immune checkpoint inhibition before consideration for treatment on trial; primary ovarian tumors must be at least 50% endometrioid or clear cell morphology, or have histologically documented recurrence with at least 50% endometrioid or clear cell morphology; institutional pathology reports must be provided indicating at least 50% endometrioid or clear cell morphology for ovarian tumors (primary or recurrent lesions) - All patients must have measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) version (v) 1.1; measurable disease is defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded); each lesion must be >= 10 mm when measured by computed tomography (CT), magnetic resonance imaging (MRI) or caliper measurement by clinical exam; or >= 20 mm when measured by chest x-ray; lymph nodes must be > 15 mm in short axis when measured by CT or MRI - Patients must have had at least one, but no more than 3, prior cytotoxic regimens for management of primary disease; unlimited prior hormonal therapy, targeted therapy (including immunotherapy) or antiangiogenic therapy will be permitted - Patients must have completed prior therapy: - Chemotherapy: cytotoxic - At least 28 days since last dose of chemotherapy prior to registration. --- V617F ---

JAK2 V617F) observed in cytogenetic testing and deoxyribonucleic acid (DNA) sequencing - A prior history of T-cell lymphoblastic lymphoma (T-LBL)/T-cell acute lymphoblastic leukemia (T-ALL) - Severe, active co-morbidity per the treating investigator's discretion - Pregnant or lactating patients - Known human immunodeficiency virus (HIV) positive patients on combination antiretroviral therapy are ineligible because of the potential for pharmacokinetic interactions with tazemetostat; in addition, treatments involved in this protocol may be immunosuppressive, increasing the risk of lethal infections in this patient population - Treatment with strong inhibitors or inducers of CYP3A within 14 days of registration and during the study treatment FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma FIGO Grade 2 Endometrial Endometrioid Adenocarcinoma Recurrent Endometrial Endometrioid Adenocarcinoma Recurrent Ovarian Carcinoma Recurrent Ovarian Clear Cell Adenocarcinoma Recurrent Ovarian Endometrioid Adenocarcinoma Recurrent Uterine Corpus Cancer Carcinoma Adenocarcinoma Carcinoma, Endometrioid Adenocarcinoma, Clear Cell PRIMARY OBJECTIVE: I. To assess the clinical activity (overall response rate) of tazemetostat in patients with recurrent or persistent endometrioid or clear cell ovarian carcinoma, and patients with recurrent or persistent endometrioid endometrial adenocarcinoma. --- V617F ---

Primary Outcomes

Description: Will be defined by Response Evaluation Criteria in Solid Tumors (RECIST) version (v) 1.1.

Measure: Tumor response

Time: Up to 6 months

Secondary Outcomes

Description: Will be defined by RECIST v 1.1.

Measure: Tumor response in patients with ARID1A mutations using tumor response

Time: Up to 6 months

Description: Will be assessed according to grade of toxicity by organ or organ system.

Measure: Incidence of adverse events

Time: Up to 5 years

Description: Will be characterized by quartiles and the median of the distribution with confidence intervals. Kaplan-Meier plots will show an estimate of the survival function for these populations.

Measure: Progression-free survival

Time: From study entry to time of progression or death, whichever occurs first, assessed up to 5 years

Description: Will be characterized by quartiles and the median of the distribution with confidence intervals. Kaplan-Meier plots will show an estimate of the survival function for these populations.

Measure: Overall survival

Time: From study entry to time of death or the date of last contact, assessed up to 5 years

Other Outcomes

Description: Associations between BAF250a and ARID1A mutations may be examined with contingency table analysis (e.g. potentially including Chi-square analyses or Spearman's correlation).

Measure: ARID1A mutational status

Time: Up to 6 months

Description: Will be assessed by immunohistochemistry. Associations between BAF250a and ARID1A mutations may be examined with contingency table analysis (e.g. potentially including Chi-square analyses or Spearman's correlation).

Measure: BAF250a expression

Time: Up to 6 months

17 Assessment of the Prevalence of Major Psychiatric Disorders in a Cohort of Women With Clinical Criteria Corresponding to Pure, Abortive-form, Obstetrical, Antiphospholipid Syndrome

The primary objective of this study was to evaluate and compare the prevalence of the following psychiatric pathologies (based on the MINI5.0.0 questionnaire) among 3 groups of women (Leiden versus aP1Ab-positive versus thrombophilia-negative) with similar obstetrical histories 10 years after their initial assessment/diagnosis. - Mood disorders, including depressive episodes during the previous two weeks, recurrent depressive disorders at any point in life, dysthymia in the last two years, or any current or past manic episode; - Anxiety disorders, including current agoraphobia, current panic disorders, agoraphobia with panic disorders, current social phobia, generalized anxiety in the last 6 months, or current posttraumatic stress syndrome; - Apparent psychotic syndromes, including isolated or recurrent psychotic syndromes, past or present (clinically validated), - Current alcohol or drug problems (dependence or abuse).

NCT02833194
Conditions
  1. Antiphospholipid Syndrome
  2. Factor V Leiden Thrombophilia
MeSH:Thrombophilia Antiphospholipid Syndrome Syndrome Mental Disorders Problem Behavior
HPO:Behavioral abnormality Hypercoagulability

Exclusion Criteria: - Any history of thrombotic events or any treatment given during previous pregnancies that might have modified the natural course of the condition - Women whose pregnancy losses could be explained by infectious, metabolic, anatomic or hormonal facotrs, or associated with paternal or maternal chromosomal causes - Seropositivity for HIV, hepatitis B or C - Women with antithrombin, protein C, or protein S deficiency, and women with abnormal fibrinogen or with the JAK2 V617F mutation were further excluded. --- V617F ---

Primary Outcomes

Measure: Mini Internationl Neuropsychiatric Interview 5.0.0

Time: 10 years

18 Molecular Changes and Biomarkers in Chronic Myeloproliferative Disorders

The three main chronic myeloproliferative disorders are polycythemia vera (PV), essential thrombocythemia (ET) and idiopathic myelofibrosis (IMF). These are clonal neoplastic diseases characterized by proliferation of one or more hematopoietic lineages. Recently a mutation of the Janus Kinase 2 (JAK2) gene that leads to the substitution of phenylalanine for valine at position 617 of the JAK2 protein, JAK2 V617F, has been found in 76% to 97% of patients with PV, 29% to 57% of patients with ET and 50% of patients with IMF. This mutation confers constitutive activity on to the JAK2 protein and appears to play an important role in the pathobiology of these conditions. However, not all patients with myeloproliferative disorders have this mutation and it may not be the primary cause of these diseases. The primary goal of this prospective natural history study is to investigate the molecular basis of these diseases in groups of patients who have JAK2 V617F and in those who do not. A second goal is to identify biomarkers for PV and the other myeloproliferative disorders that are easier to measure than JAK2 V617F. Approximately, 150 patients with myeloproliferative disorders will be studied over 3 years. The studies will involve the collection of 40 mL to 50 mL of peripheral blood from each subject. The blood will be used to assess neutrophil gene and protein expression, gene polymorphisms, and plasma protein levels.

NCT00433862
Conditions
  1. Polycythemia Vera
  2. Essential Thrombocytosis
  3. Idiopathic Myelofibrosis
  4. Neutrophils
  5. Chronic Myeloproliferative Disorders
MeSH:Polycythemia Vera Primary Myelofibrosis Polycythemia Myeloproliferative Disorders Thrombocytosis Thrombocythemia, Essential Disease
HPO:Myeloproliferative disorder Polycythemia Thrombocytosis

Recently a mutation of the Janus Kinase 2 (JAK2) gene that leads to the substitution of phenylalanine for valine at position 617 of the JAK2 protein, JAK2 V617F, has been found in 76% to 97% of patients with PV, 29% to 57% of patients with ET and 50% of patients with IMF. --- V617F ---

The primary goal of this prospective natural history study is to investigate the molecular basis of these diseases in groups of patients who have JAK2 V617F and in those who do not. --- V617F ---

A second goal is to identify biomarkers for PV and the other myeloproliferative disorders that are easier to measure than JAK2 V617F. --- V617F ---


19 A Phase I Study of Single Agent Tazemetostat in Subjects With Advanced Solid Tumors and B-Cell Lymphomas With Hepatic Dysfunction

This phase I trial studies the best dose and side effects of tazemetostat in treating patients with solid tumors or B-cell lymphomas with liver dysfunction that have spread to other places in the body or cannot be removed by surgery. Tazemetostat may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.

NCT03217253
Conditions
  1. Ann Arbor Stage III B-Cell Non-Hodgkin Lymphoma
  2. Ann Arbor Stage IV B-Cell Non-Hodgkin Lymphoma
  3. Metastatic Malignant Solid Neoplasm
  4. Stage III Hepatocellular Carcinoma AJCC v7
  5. Stage IIIA Hepatocellular Carcinoma AJCC v7
  6. Stage IIIB Hepatocellular Carcinoma AJCC v7
  7. Stage IIIC Hepatocellular Carcinoma AJCC v7
  8. Stage IV Hepatocellular Carcinoma AJCC v7
  9. Stage IVA Hepatocellular Carcinoma AJCC v7
  10. Stage IVB Hepatocellular Carcinoma AJCC v7
  11. Unresectable Solid Neoplasm
Interventions
  1. Other: Laboratory Biomarker Analysis
  2. Other: Pharmacological Study
  3. Drug: Tazemetostat
MeSH:Lymphoma Carcinoma Neoplasms Lymphoma, Non-Hodgkin Carcinoma, Hepatocellular Lymphoma, B-Cell
HPO:B-cell lymphoma Carcinoma Hepatocellular carcinoma Lymphoma Neoplasm Non-Hodgkin lymphoma

JAK2 V617F) observed in cytogenetic testing and DNA sequencing - Has a prior history of T-acute lymphoblastic lymphoma (T-LBL)/T-acute lymphoblastic leukemia (ALL) Inclusion Criteria: - Patients must have histologically and/or cytologically confirmed solid tumors or B cell lymphoma that are metastatic or unresectable and for which standard treatment options do not exist; patients with hepatocellular carcinoma are eligible without pathological diagnosis if diagnosed on the basis of blood work and imaging - Patients with evaluable disease will be eligible - All patients must have completed any prior chemotherapy, targeted therapy and major surgery, >= 28 days before study entry; for daily or weekly chemotherapy without the potential for delayed toxicity, a washout period of 14 days may be acceptable, and questions related to this can be discussed with study principal investigator - Eastern Cooperative Oncology Group (ECOG) performance status =< 2 (Karnofsky >= 60%) - Life expectancy of greater than 3 months - Able to swallow and retain orally-administered medication and does not have any clinically significant gastrointestinal abnormalities that may alter absorption such as malabsorption syndrome or major resection of the stomach or bowels - All prior treatment-related toxicities must be Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 grade =< 1 (except alopecia) at the time of enrollment - Leukocytes >= 3,000/mcL - Absolute neutrophil count >= 1,500/mcL - Platelets >= 100,000/mcL - Hemoglobin >= 90 g/L (9.0 g/dL) - Creatinine within normal institutional limits OR calculated creatinine clearance >= 60 mL/min/1.73 --- V617F ---

JAK2 V617F) observed in cytogenetic testing and DNA sequencing - Has a prior history of T-acute lymphoblastic lymphoma (T-LBL)/T-acute lymphoblastic leukemia (ALL) Ann Arbor Stage III B-Cell Non-Hodgkin Lymphoma Ann Arbor Stage IV B-Cell Non-Hodgkin Lymphoma Metastatic Malignant Solid Neoplasm Stage III Hepatocellular Carcinoma AJCC v7 Stage IIIA Hepatocellular Carcinoma AJCC v7 Stage IIIB Hepatocellular Carcinoma AJCC v7 Stage IIIC Hepatocellular Carcinoma AJCC v7 Stage IV Hepatocellular Carcinoma AJCC v7 Stage IVA Hepatocellular Carcinoma AJCC v7 Stage IVB Hepatocellular Carcinoma AJCC v7 Unresectable Solid Neoplasm Lymphoma Carcinoma Neoplasms Lymphoma, Non-Hodgkin Carcinoma, Hepatocellular Lymphoma, B-Cell PRIMARY OBJECTIVES: I. To determine safety, tolerability and recommended phase 2 dose (RP2D) of tazemetostat in patients with varying degrees of hepatic dysfunction. --- V617F ---

Primary Outcomes

Description: Frequency and severity of adverse events will be tabulated using counts and proportions detailing frequently occurring, serious and severe events of interest. Adverse events will be summarized using all adverse events experienced, although a sub-analysis may be conducted including only those adverse events in which the treating physician deems possibly, probably or definitely attributable to study treatment.

Measure: Incidence of adverse events of tazemetostat in patients with varying degrees of hepatic dysfunction assessed using Common Terminology Criteria for Adverse Events version 5.0

Time: Up to 2 years

Description: RP2D will be determined.

Measure: Recommended phase 2 dose (RP2D) of tazemetostat in patients with varying degrees of hepatic dysfunction

Time: Up to 2 years

Secondary Outcomes

Description: Plasma concentrations will be measured by Q2 Solutions using a validated Liquid chromatography (LC)/mass spectrometry (MS)/MS assay. Molecular and clinical predictors of clinical outcomes will be investigated using logistic regression and Cox proportional hazards models. Potential predictors include clinical predictors and molecular correlates. Descriptive statistics and plotting of data will also be used to better understand potential relationships. Given the small sample size, and exploratory nature of these endpoints, all pharmacodynamic analyses conducted will be considered exploratory. All analyses will be considered exploratory and inference will be performed with appropriate caution.

Measure: Pharmacokinetic (PK) profiles of tazemetostat in patients with varying degrees of hepatic dysfunction

Time: Up to course 4 day 1 (day 85)

Description: Molecular and clinical predictors of clinical outcomes will be investigated using logistic regression and Cox proportional hazards models. Potential predictors include clinical predictors and molecular correlates. Descriptive statistics and plotting of data will also be used to better understand potential relationships. All analyses will be considered exploratory and inference will be performed with appropriate caution.

Measure: Antitumor activity of tazemetostat

Time: Up to 2 years

Description: Molecular and clinical predictors of clinical outcomes will be investigated using logistic regression and Cox proportional hazards models. Potential predictors include clinical predictors and molecular correlates. Descriptive statistics and plotting of data will also be used to better understand potential relationships. All analyses will be considered exploratory and inference will be performed with appropriate caution.

Measure: Antitumor activity of tazemetostat in population with tumors with aberrations in EZH2 or SWI/SNF complex pathways

Time: Up to 2 years

Description: Response will be assessed using the Response Evaluation Criteria in Solid Tumors (RECIST) criteria 1.1

Measure: Objective confirmed response

Time: Up to 2 years

Description: Response will be assessed using the RECIST criteria 1.1.

Measure: Duration of response

Time: Up to 2 years

Description: Response will be assessed using the RECIST criteria 1.1.

Measure: Best response

Time: Up to 2 years

20 A Phase I, Open-label Multi-dose Two-part Study to Characterize the Effects of a Strong CYP3A4 Inhibitor and a Strong CYP3A4 Inducer on the Steady-State Pharmacokinetics of Tazemetostat (EPZ-6438) in Subjects With Advanced Malignancies

This is a phase I, multi-center, open-label, multi-dose, two-part PK and safety study to characterize the DDI potential of oral Tazemetostat.

NCT04537715
Conditions
  1. All Malignancies
  2. Advanced Malignancies
  3. Hematologic Malignancy
  4. Solid Tumor
  5. Follicular Lymphoma (FL)
  6. Non-Hodgkin Lymphoma (NHL)
  7. Diffuse Large B-Cell Lymphoma (DLBCL)
  8. Epithelioid Sarcoma (ES)
  9. Synovial Sarcoma
  10. Renal Medullary Carcinoma
  11. Mesothelioma
  12. Rhabdoid Tumor
Interventions
  1. Drug: Tazemetostat
  2. Drug: Itraconazole
  3. Drug: Rifampin
MeSH:Lymphoma Neoplasms Sarcoma Lymphoma, Non-Hodgkin Lymphoma, Large B-Cell, Diffuse Mesothelioma Hematologic Neoplasms Sarcoma, Synovial Rhabdoid Tumor Carcinoma, Medullary
HPO:Hematological neoplasm Leukemia Lymphoma Neoplasm Non-Hodgkin lymphoma Sarcoma Soft tissue sarcoma Synovial sarcoma

Has abnormalities known to be associated with MDS (e.g., del 5q, chr 7 abn) and myeloproliferative neoplasms (MPN) (e.g., JAK2 V617F) observed in cytogenetic testing and DNA sequencing. --- V617F ---

Primary Outcomes

Description: AUC0-t: area under the plasma concentration-time curve from time 0 to the time of the last quantifiable concentration

Measure: Part 1: To evaluate the effect of CYP3A4 inhibition by itraconazole on the steady-state pharmacokinetics (PK) of Tazemetostat when administered as a single and twice daily oral dose in subjects with advanced malignancies, AUC0-t.

Time: 0 to 48 hours post-dose on Days 1 - 3. 0 to 72 hours post-dose on Days 15 - 18 and 36 - 39. 0 to 24 hours post-dose on Days 21 - 22. 0 and 2 hours post-dose on Days 25, 28, 31, and 34.

Description: AUC0-72: area under the plasma concentration-time curve from time 0 to 72 hours post dose

Measure: Part 1: To evaluate the effect of CYP3A4 inhibition by itraconazole on the steady-state pharmacokinetics (PK) of Tazemetostat when administered as a single and twice daily oral dose in subjects with advanced malignancies, AUC0-72.

Time: 0 to 48 hours post-dose on Days 1 - 3. 0 to 72 hours post-dose on Days 15 - 18 and 36 - 39. 0 to 24 hours post-dose on Days 21 - 22. 0 and 2 hours post-dose on Days 25, 28, 31, and 34.

Description: Cmax: observed maximum plasma concentration

Measure: Part 1: To evaluate the effect of CYP3A4 inhibition by itraconazole on the steady-state pharmacokinetics (PK) of Tazemetostat when administered as a single and twice daily oral dose in subjects with advanced malignancies, Cmax.

Time: 0 to 48 hours post-dose on Days 1 - 3. 0 to 72 hours post-dose on Days 15 - 18 and 36 - 39. 0 to 24 hours post-dose on Days 21 - 22. 0 and 2 hours post-dose on Days 25, 28, 31, and 34.

Description: AUC0-t: area under the plasma concentration-time curve from time 0 to the time of the last quantifiable concentration

Measure: Part 2: To evaluate the effect of CYP3A4 induction by rifampin on the steady-state PK of Tazemetostat when administered as a single and twice daily oral dose in subjects with advanced malignancies, AUC0-t.

Time: 0 to 48 hours post-dose on Days 1 - 3, 15 - 17 and 24 - 26. 0 and 2 hours post-dose on Days 19 and 21.

Description: AUC0-48: area under the plasma concentration-time curve from time 0 to 48 hours post dose

Measure: Part 2: To evaluate the effect of CYP3A4 induction by rifampin on the steady-state PK of Tazemetostat when administered as a single and twice daily oral dose in subjects with advanced malignancies, AUC0-48.

Time: 0 to 48 hours post-dose on Days 1 - 3, 15 - 17 and 24 - 26. 0 and 2 hours post-dose on Days 19 and 21.

Description: Cmax: observed maximum plasma concentration

Measure: Part 2: To evaluate the effect of CYP3A4 induction by rifampin on the steady-state PK of Tazemetostat when administered as a single and twice daily oral dose in subjects with advanced malignancies, Cmax.

Time: 0 to 48 hours post-dose on Days 1 - 3, 15 - 17 and 24 - 26. 0 and 2 hours post-dose on Days 19 and 21.

Secondary Outcomes

Description: AUC0-t: area under the plasma concentration-time curve from time 0 to the time of the last quantifiable concentration

Measure: Part 1: To evaluate the steady-state PK of Tazemetostat and its metabolites after administration alone and with itraconazole, and to evaluate the effect of itraconazole on PK of a single 400 mg oral dose of Tazemetostat, AUC0-t.

Time: 0 to 48 hours post-dose on Days 1 - 3. 0 to 72 hours post-dose on Days 15 - 18 and 36 - 39. 0 to 24 hours post-dose on Days 21 - 22. 0 and 2 hours post-dose on Days 25, 28, 31, and 34.

Description: Cmax: observed maximum plasma concentration

Measure: Part 1: To evaluate the steady-state PK of Tazemetostat and its metabolites after administration alone and with itraconazole, and to evaluate the effect of itraconazole on PK of a single 400 mg oral dose of Tazemetostat, Cmax.

Time: 0 to 48 hours post-dose on Days 1 - 3. 0 to 72 hours post-dose on Days 15 - 18 and 36 - 39. 0 to 24 hours post-dose on Days 21 - 22. 0 and 2 hours post-dose on Days 25, 28, 31, and 34.

Description: Tmax: observed time at Cmax

Measure: Part 1: To evaluate the steady-state PK of Tazemetostat and its metabolites after administration alone and with itraconazole, and to evaluate the effect of itraconazole on PK of a single 400 mg oral dose of Tazemetostat, Tmax.

Time: 0 to 48 hours post-dose on Days 1 - 3. 0 to 72 hours post-dose on Days 15 - 18 and 36 - 39. 0 to 24 hours post-dose on Days 21 - 22. 0 and 2 hours post-dose on Days 25, 28, 31, and 34.

Description: λz: terminal phase elimination rate constant

Measure: Part 1: To evaluate the steady-state PK of Tazemetostat and its metabolites after administration alone and with itraconazole, and to evaluate the effect of itraconazole on PK of a single 400 mg oral dose of Tazemetostat, λz.

Time: 0 to 48 hours post-dose on Days 1 - 3. 0 to 72 hours post-dose on Days 15 - 18 and 36 - 39. 0 to 24 hours post-dose on Days 21 - 22. 0 and 2 hours post-dose on Days 25, 28, 31, and 34.

Description: t1/2: terminal elimination half-life

Measure: Part 1: To evaluate the steady-state PK of Tazemetostat and its metabolites after administration alone and with itraconazole, and to evaluate the effect of itraconazole on PK of a single 400 mg oral dose of Tazemetostat, t1/2.

Time: 0 to 48 hours post-dose on Days 1 - 3. 0 to 72 hours post-dose on Days 15 - 18 and 36 - 39. 0 to 24 hours post-dose on Days 21 - 22. 0 and 2 hours post-dose on Days 25, 28, 31, and 34.

Description: AUC0-t: area under the plasma concentration-time curve from time 0 to the time of the last quantifiable concentration

Measure: Part 2: To evaluate the steady-state PK of Tazemetostat and its metabolites after administration alone and with rifampin, AUC0-t.

Time: 0 to 48 hours post-dose on Days 1 - 3, 15 - 17 and 24 - 26. 0 and 2 hours post-dose on Days 19 and 21.

Description: Cmax: observed maximum plasma concentration

Measure: Part 2: To evaluate the steady-state PK of Tazemetostat and its metabolites after administration alone and with rifampin, Cmax.

Time: 0 to 48 hours post-dose on Days 1 - 3, 15 - 17 and 24 - 26. 0 and 2 hours post-dose on Days 19 and 21.

Description: Tmax: observed time at Cmax

Measure: Part 2: To evaluate the steady-state PK of Tazemetostat and its metabolites after administration alone and with rifampin, Tmax.

Time: 0 to 48 hours post-dose on Days 1 - 3, 15 - 17 and 24 - 26. 0 and 2 hours post-dose on Days 19 and 21.

Description: λz: terminal phase elimination rate constant

Measure: Part 2: To evaluate the steady-state PK of Tazemetostat and its metabolites after administration alone and with rifampin, λz.

Time: 0 to 48 hours post-dose on Days 1 - 3, 15 - 17 and 24 - 26. 0 and 2 hours post-dose on Days 19 and 21.

Description: t1/2: terminal elimination half-life

Measure: Part 2: To evaluate the steady-state PK of Tazemetostat and its metabolites after administration alone and with rifampin, t1/2.

Time: 0 to 48 hours post-dose on Days 1 - 3, 15 - 17 and 24 - 26. 0 and 2 hours post-dose on Days 19 and 21.

Description: Severity of adverse events experienced by all subjects with at least 1 dose or partial dose of tazemetostat will be evaluated by the Investigator based on the CTCAE, version 5.0.

Measure: To evaluate the number of participants with treatment-emergent adverse events as assessed by CTCAE v5.0.

Time: Cycle 1, Part 1: Days 1-39 of the 39-day cycle. Cycle 1, Part 2: Days 1-26 of the 26-day cycle. Cycle 2+: Day 1 (±3 days) of every 28-day cycle. End of Study: 30 (±3) days after last dose of study drug. Annual Assessments: Yearly from Day 1 of Cycle 1.

Description: Investigators will note any new clinically significant findings (e.g., not noted at screening) or changes in intensity of conditions that occurred after the initial tazemetostat administration.

Measure: To evaluate the number of abnormalities or changes in intensity of conditions noted during the physical exam.

Time: Cycle 1, Part 1: Days 1-39 of the 39-day cycle. Cycle 1, Part 2: Days 1-26 of the 26-day cycle. Cycle 2+: Day 1 (±3 days) of every 28-day cycle. End of Study: 30 (±3) days after last dose of study drug. Annual Assessments: Yearly from Day 1 of Cycle 1.

Description: Investigators will note any clinically significant changes from baseline in systolic and diastolic blood pressure measured in units of millimeters of mercury (mmHg).

Measure: To evaluate change in blood pressure.

Time: Cycle 1, Part 1: Days 1-39 of the 39-day cycle. Cycle 1, Part 2: Days 1-26 of the 26-day cycle. Cycle 2+: Day 1 (±3 days) of every 28-day cycle. End of Study: 30 (±3) days after last dose of study drug. Annual Assessments: Yearly from Day 1 of Cycle 1.

Description: Investigators will note any clinically significant changes from baseline in heart rate measured in units of beats per minute (BPM).

Measure: To evaluate change in heart rate

Time: Cycle 1, Part 1: Days 1-39 of the 39-day cycle. Cycle 1, Part 2: Days 1-26 of the 26-day cycle. Cycle 2+: Day 1 (±3 days) of every 28-day cycle. End of Study: 30 (±3) days after last dose of study drug. Annual Assessments: Yearly from Day 1 of Cycle 1.

Description: Investigators will note any clinically significant changes from baseline in body temperature measured in degrees Fahrenheit or Celsius.

Measure: To evaluate change in body temperature.

Time: Cycle 1, Part 1: Days 1-39 of the 39-day cycle. Cycle 1, Part 2: Days 1-26 of the 26-day cycle. Cycle 2+: Day 1 (±3 days) of every 28-day cycle. End of Study: 30 (±3) days after last dose of study drug. Annual Assessments: Yearly from Day 1 of Cycle 1.

Description: Investigators will note any changes in concomitant medications from baseline in all subjects with at least 1 dose or partial dose of tazemetostat.

Measure: To evaluate changes in concomitant medications.

Time: Cycle 1, Part 1: Days 1-39 of the 39-day cycle. Cycle 1, Part 2: Days 1-26 of the 26-day cycle. Cycle 2+: Day 1 (±3 days) of every 28-day cycle. End of Study: 30 (±3) days after last dose of study drug. Annual Assessments: Yearly from Day 1 of Cycle 1.

Description: Investigators will report any clinically significant changes from baseline in the RR interval (sec) as noted by a 12 lead electrocardiogram (ECG).

Measure: To evaluate change in electrical activity of the heartbeat, RR interval.

Time: Cycle 1, Part 1: Days 1-39 of the 39-day cycle. Cycle 1, Part 2: Days 1-26 of the 26-day cycle. Cycle 2+: Day 1 (±3 days) of every 28-day cycle. End of Study: 30 (±3) days after last dose of study drug. Annual Assessments: Yearly from Day 1 of Cycle 1.

Description: Investigators will report any clinically significant changes from baseline in the PR interval (sec) as noted by a 12 lead electrocardiogram (ECG).

Measure: To evaluate change in electrical activity of the heartbeat, PR interval.

Time: Cycle 1, Part 1: Days 1-39 of the 39-day cycle. Cycle 1, Part 2: Days 1-26 of the 26-day cycle. Cycle 2+: Day 1 (±3 days) of every 28-day cycle. End of Study: 30 (±3) days after last dose of study drug. Annual Assessments: Yearly from Day 1 of Cycle 1.

Description: Investigators will report any clinically significant changes from baseline in the QRS complex (sec) as noted by a 12 lead electrocardiogram (ECG).

Measure: To evaluate change in electrical activity of the heartbeat, QRS complex.

Time: Cycle 1, Part 1: Days 1-39 of the 39-day cycle. Cycle 1, Part 2: Days 1-26 of the 26-day cycle. Cycle 2+: Day 1 (±3 days) of every 28-day cycle. End of Study: 30 (±3) days after last dose of study drug. Annual Assessments: Yearly from Day 1 of Cycle 1.

Description: Investigators will report any clinically significant changes from baseline in the QT interval (sec) as noted by a 12 lead electrocardiogram (ECG).

Measure: To evaluate change in electrical activity of the heartbeat, QT interval.

Time: Cycle 1, Part 1: Days 1-39 of the 39-day cycle. Cycle 1, Part 2: Days 1-26 of the 26-day cycle. Cycle 2+: Day 1 (±3 days) of every 28-day cycle. End of Study: 30 (±3) days after last dose of study drug. Annual Assessments: Yearly from Day 1 of Cycle 1.

Description: Investigators will note any clinically significant changes in hematological clinical laboratory values from baseline in all subjects with at least 1 dose or partial dose of tazemetostat using laboratory reference ranges.

Measure: To evaluate changes in clinical laboratory values, hematology.

Time: Cycle 1, Part 1: Days 1-39 of the 39-day cycle. Cycle 1, Part 2: Days 1-26 of the 26-day cycle. Cycle 2+: Day 1 (±3 days) of every 28-day cycle. End of Study: 30 (±3) days after last dose of study drug. Annual Assessments: Yearly from Day 1 of Cycle 1.

Description: Investigators will note any clinically significant changes in serum chemistry clinical laboratory values from baseline in all subjects with at least 1 dose or partial dose of tazemetostat using laboratory reference ranges.

Measure: To evaluate changes in clinical laboratory values, serum chemistry.

Time: Cycle 1, Part 1: Days 1-39 of the 39-day cycle. Cycle 1, Part 2: Days 1-26 of the 26-day cycle. Cycle 2+: Day 1 (±3 days) of every 28-day cycle. End of Study: 30 (±3) days after last dose of study drug. Annual Assessments: Yearly from Day 1 of Cycle 1.

Description: Investigators will note any clinically significant changes in urinalysis clinical laboratory values from baseline in all subjects with at least 1 dose or partial dose of tazemetostat using laboratory reference ranges.

Measure: To evaluate changes in clinical laboratory values, urinalysis.

Time: Cycle 1, Part 1: Days 1-39 of the 39-day cycle. Cycle 1, Part 2: Days 1-26 of the 26-day cycle. Cycle 2+: Day 1 (±3 days) of every 28-day cycle. End of Study: 30 (±3) days after last dose of study drug. Annual Assessments: Yearly from Day 1 of Cycle 1.

21 Retrospective and Prospective Multicenter Study Evaluating the Impact of Treatment With Cytoreducing Agents on the Recurrence of Thrombosis in Thrombotic Patients With a Diagnosis of Myeloproliferative Neoplasia and Normal Blood Counts - a FIM Study

Among the etiologies of thrombosis, myeloproliferative neoplasia (MPN) is quite rare but should be investigated in case of thrombosis of atypical localization (digestive or cerebral) or in the context of recurrent idiopathic thrombosis in a young subject. Thrombosis could reveal an underlying MPN through the identification of a JAK2 V617F mutation. Rarely, MPN with thrombotic complications present with normal complete blood count(CBC). In case of a MPN with a thrombotic event but without CBC abnormality, anti-thrombotic treatment is recommended. But there is no recommendation for the indication of cytoreductive therapy and the clinician's decision is often empirical. One of the major complications of for essential thrombocythemia (ET) or polycythemia vera (PV) is thrombosis and an age over 60 is a major risk factor. The treatment of thrombosis associated with TE or PV is based on recommendations the main therapeutic objective of which is to reduce the thrombotic risk. The combination of a cytoreducing agent and antithrombotic treatment is thus proposed in high-risk patients. The efficacy of this management is monitored by assessing CBC with the objective of normalization at <400 G/L of platelets for ET patients and <45% hematocrit in case of PV. The absence of abnormal CBC makes it difficult to justify cytoreduction. The benefit of such a therapy in this context has not been clinically demonstrated. If a cytoreductive therapy is initiated, no biological parameters are available to assess the response to treatment. The objective of this observational study is to evaluate the incidence of recurrence of thrombosis in patients whose thrombotic event revealed an underlying MPN with normal CBC. A comparison of groups treated or not with cytoreductive agents will be performed. Longitudinal monitoring of the patients will provide a better understanding of the nature and kinetics of hematological changes in these patients.

NCT04539678
Conditions
  1. Thrombotic Patient
  2. Thrombotic Patients
  3. Diagnosis of Myeloproliferative Neoplasia
  4. Impact of Treatment With Cytoreducing Agent
MeSH:Neoplasms
HPO:Neoplasm

Thrombosis could reveal an underlying MPN through the identification of a JAK2 V617F mutation. --- V617F ---

Primary Outcomes

Description: The diagnosis of thromboembolic events must be confirmed by imaging

Measure: Cumulative incidence of recurrence of thromboembolic events after the initial thrombosis leading to the diagnosis of MPN

Time: 24 months follow-up

Secondary Outcomes

Description: Hematological progression criteria will be based on the WHO classification

Measure: Cumulative incidence of hematological progression to essential thrombocythemia, polycythemia vera, secondary myelofibrosis or acute transformation

Time: 24 months follow-up

Description: The diagnosis of thromboembolic event must be confirmed by imaging

Measure: Cumulative incidence of recurrence of thromboembolic events according to the type and duration of anticoagulant or anti-aggregant treatment

Time: 24 months follow-up

22 An Exploratory, Observational, Multicentre Study to Investigate the Impact of the Presence of JAK2 (V617F) Mutation on Treatment Response in Patients With Essential Thrombocythaemia Treated With XAGRID® (Anagrelide Hydrochloride)

This study is hypothesis-generating to explore the impact of JAK2 (V617F) mutation status on the treatment response to anagrelide hydrochloride

NCT01352585
Conditions
  1. Essential Thrombocythemia (ET)
Interventions
  1. Drug: Anagrelide hydrochloride
MeSH:Thrombocytosis Thrombocythemia, Essential
HPO:Thrombocytosis

An Exploratory, Observational, Multicentre Study to Investigate the Impact of the Presence of JAK2 (V617F) Mutation on Treatment Response in Patients With Essential Thrombocythaemia Treated With XAGRID® (Anagrelide Hydrochloride). --- V617F ---

Exploratory Multi-centre Trial In Patients With ET Treated With XAGRID® This study is hypothesis-generating to explore the impact of JAK2 (V617F) mutation status on the treatment response to anagrelide hydrochloride Number of Patients With Platelet Count ≤600x10^9/L After 12 Months. --- V617F ---

Primary Outcomes

Description: A platelet count of ≤600x10^9/L after 12 months is considered at least a partial response.

Measure: Number of Patients With Platelet Count ≤600x10^9/L After 12 Months

Time: 1 year

Secondary Outcomes

Description: A platelet count of ≤400x10^9/L after 12 months is considered a complete response.

Measure: Number of Patients With Platelet Count ≤400x10^9/L After 12 Months

Time: 1 year

Measure: Platelet Count

Time: 1 year

Measure: Red Blood Cell (RBC) Count

Time: 1 year

Measure: White Blood Cell (WBC) Count

Time: 1 year

Measure: Differential WBC Count

Time: 1 year

Measure: Hemoglobin Concentration

Time: 1 year

Measure: Hematocrit Level

Time: 1 year

23 A Two-part Study Top Assess the Safety and Preliminary Efficacy of Givinostat in Patients With JAK2V617F Positive Polycythemia Vera

This is a two-part, multicenter, open label, non-randomized, phase Ib/II study to assess the safety and tolerability, Maximum Tolerated Dose and preliminary efficacy of Givinostat in patients with JAK2V617F positive Polycythemia Vera. Part A is the dose finding part while Part B is assessing the preliminary efficacy. Patients will be enrolled either in Part A or Part B and transition from one part to the other is not allowed. Eligible patients for this study will have a confirmed diagnosis of Polycythemia Vera according to the revised World Health Organization criteria. Only if the enrolment in Part A is slow (i.e. < 5 patients enrolled in 3 months), eligibility for this part of the study may be expanded to all patients with chronic myeloproliferative neoplasms. Study therapy will be administered in 28 day cycles (4 weeks of treatment). Disease response will be evaluated according to the European LeukemiaNet criteria after 3 and 6 cycles (i.e. at weeks 12 and 24, respectively) of treatment with Givinostat for both parts of the study. All phlebotomies performed in the first 3 weeks of treatment will not be counted to assess the clinico-haematological response. The study will last up to a maximum of 24 weeks of treatment. However, after completion of the trial, all patients achieving clinical benefit will be allowed to continue treatment with Givinostat (at the same dose and schedule) in a long-term study. Safety will be monitored at each visit throughout the entire duration of the study. Treatment will be administered on an outpatient basis and patients will be followed regularly with physical and laboratory tests, as specified in the protocol; in case of hospitalization, the treatment will be continued or interrupted according to the Investigators' decision.

NCT01901432
Conditions
  1. Polycythemia Vera
Interventions
  1. Drug: Givinostat
MeSH:Polycythemia Vera Polycythemia
HPO:Polycythemia

dose group was not available for PK analysis.. Inclusion Criteria: 1. Patients must be able to provide informed consent and be willing to sign an informed consent form; 2. Patients must have an age ≥18 years; 3. Patients must have a confirmed diagnosis of Polycythemia Vera according to the revised World Health Organization criteria; 4. Patients must have mutated Janus Kinase 2 (mutation V617F) positive disease; 5. Patients must have an active/not controlled disease defined as 1. hematocrit ≥ 45% or hematocrit <45% in need of phlebotomy, and 2. platelet count > 400 x109/L, and 3. white blood cell count > 10 x109/L; 6. Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1 in Part A, ECOG performance status ≤ 2 in Part B within 7 days of initiating study drug; 7. Female patient of childbearing potential has a negative serum or urine pregnancy test within 72 hours of the first dose of study therapy; 8. Use of an effective means of contraception for women of childbearing potential and men with partners of childbearing potential; 9. Adequate and acceptable organ function within 7 days of initiating study drug; 10. --- V617F ---

Inclusion Criteria: 1. Patients must be able to provide informed consent and be willing to sign an informed consent form; 2. Patients must have an age ≥18 years; 3. Patients must have a confirmed diagnosis of Polycythemia Vera according to the revised World Health Organization criteria; 4. Patients must have mutated Janus Kinase 2 (mutation V617F) positive disease; 5. Patients must have an active/not controlled disease defined as 1. hematocrit ≥ 45% or hematocrit <45% in need of phlebotomy, and 2. platelet count > 400 x109/L, and 3. white blood cell count > 10 x109/L; 6. Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1 in Part A, ECOG performance status ≤ 2 in Part B within 7 days of initiating study drug; 7. Female patient of childbearing potential has a negative serum or urine pregnancy test within 72 hours of the first dose of study therapy; 8. Use of an effective means of contraception for women of childbearing potential and men with partners of childbearing potential; 9. Adequate and acceptable organ function within 7 days of initiating study drug; 10. --- V617F ---

Primary Outcomes

Description: Evaluations were performed on the type, incidence and severity of TEAEs, graded according to Common Terminology Criteria for Adverse Events (CTCAE) v. 4.03, following administration of givinostat for up to 6 cycles of treatment in Part A. Grades 1 through 5 were as follows: Grade 1: Mild; Grade 2: Moderate; Grade 3: Severe or medically significant but not immediately life threatening or requiring hospitalisation; Grade 4: Life threatening consequences; Grade 5: Death related to AE. Results are reported as number of patients with TEAEs for each of the indicated categories. Definitions: drug-related TEAE / treatment-emergent serious adverse event (TESAE) corresponded to reasonable suspicion that the TEAE / TESAE was associated with the use of the study drug, according to investigator assessment; discontinuation refers to discontinuation from treatment.

Measure: Number of Patients Experiencing Treatment-emergent Adverse Events (TEAEs) in Part A of the Study

Time: 168 days (up to Cycle 6 Day 28 in Part A).

Description: The MTD of givinostat was based only on Cycle 1 DLTs. A DLT was defined as the following drug-related toxicity: Grade 4 hematological toxicity, or Grade 3 febrile neutropenia, or Grade ≥3 non-hematological toxicity (with the exception Grade 3 diarrhea without adequate supportive care lasting less than 3 days, and Grade 3 nausea or vomiting without adequate supportive care lasting less than 3 days), or Any drug-related serious AE, or Any toxicity clearly not related to disease progression or intercurrent illness requiring interruption of dosing for more than 3 days during first cycle. At end of Cycle 1, for the third patient in each DL, the safety of the 3 patients treated for 1 cycle was reviewed and it was decided if the dose should be escalated or not. Results are reported as the number of patients with DLT events for Cycle 1 in Part A.

Measure: Number of Dose Limiting Toxicities (DLTs) After 1 Cycle in Part A of the Study

Time: 28 days (up to Cycle 1 Day 28 in Part A).

Description: Evaluations were performed on the type, incidence and severity of TEAEs, graded according to CTCAE v. 4.03, following administration of givinostat at the MTD for up to 3 cycles of treatment in Part B. Grades 1 through 5 were as follows: Grade 1: Mild; Grade 2: Moderate; Grade 3: Severe or medically significant but not immediately life threatening or requiring hospitalisation; Grade 4: Life threatening consequences; Grade 5: Death related to AE. Results are reported as number of patients with TEAEs for each of the indicated categories. Definitions: drug-related TEAE / TESAE corresponded to reasonable suspicion that the TEAE / TESAE was associated with the use of the study drug, according to investigator assessment; discontinuation refers to discontinuation from treatment.

Measure: Number of Patients Experiencing TEAEs After 3 Cycles in Part B of the Study

Time: 84 days (up to Cycle 3 Day 28 in Part B).

Description: ORR, CR and PR following administration of givinostat at MTD for 3 cycles in Part B, reported as percentage of patients with a response. Response was evaluated according to the clinico-hematological European LeukemiaNet (ELN) response criteria. If Investigator's clinical response assessment (taking into account the overall medical judgment of the specific patient's case) was not in agreement with exact application of the ELN response criteria, the Investigator's assessment superseded the mathematical application of these criteria and was used for analysis. CR defined as: Hematocrit (HCT) <45% without phlebotomy, and Platelets ≤400 x10^9/litre (L), and White Blood Cell count ≤10 x10^9/L, and Normal spleen size, and No disease-related systemic symptoms (i.e. pruritus, headache, microvascular disturbances). PR defined as: Patients not fulfilling CR and HCT <45% without phlebotomy, or Response in ≥3 other criteria.

Measure: Overall Response Rate (ORR) (i.e. Complete Response [CR] and Partial Response [PR]) After 3 Cycles in Part B of the Study

Time: 84 days (up to cycle 3 Day 28 in Part B).

Secondary Outcomes

Description: ORR following administration of givinostat after 3 cycles and after 6 cycles in Part A, reported as percentage of patients with a response. Response was evaluated according to the clinico-hematological ELN response criteria. If Investigator's clinical response assessment (taking into account the overall medical judgment of the specific patient's case) was not in agreement with exact application of the ELN response criteria, the Investigator's assessment superseded the mathematical application of these criteria and was used for analysis. Analysis performed using the dataset for all Part A patients combined.

Measure: ORR After 3 Cycles and After 6 Cycles in Part A of the Study

Time: 84 and 168 days (up to Cycle 3 Day 28 and Cycle 6 Day 28 in Part A).

Description: ORR following administration of givinostat at the MTD for 6 cycles in Part B, reported as percentage of patients with a response. Response was evaluated according to the clinico-hematological ELN response criteria. If Investigator's clinical response assessment (taking into account the overall medical judgment of the specific patient's case) was not in agreement with exact application of the ELN response criteria, the Investigator's assessment superseded the mathematical application of these criteria and was used for analysis.

Measure: ORR After 6 Cycles in Part B of the Study

Time: 168 days (up to Cycle 6 Day 28 in Part B).

Description: Evaluations were performed on the type, incidence and severity of TEAEs, graded according to CTCAE v. 4.03, following administration of givinostat at the MTD for up to 6 cycles of treatment in Part B. Grades 1 through 5 were as follows: Grade 1: Mild; Grade 2: Moderate; Grade 3: Severe or medically significant but not immediately life threatening or requiring hospitalisation; Grade 4: Life threatening consequences; Grade 5: Death related to AE. Results are reported as number of patients with TEAEs for each of the indicated categories. Definitions: drug-related TEAE / TESAE corresponded to reasonable suspicion that the TEAE / TESAE was associated with the use of the study drug, according to investigator assessment; discontinuation refers to discontinuation from treatment. Results are reported as number of patients with TEAEs for each of the indicated categories.

Measure: Number of Patients Experiencing TEAEs After 6 Cycles in Part B of the Study

Time: 168 days (up to Cycle 6 Day 28 in Part B).

Description: Pharmacokinetic (PK) evaluation of givinostat and metabolites (ITF2374 and ITF2375) by assessment of Cmax following administration of givinostat for 1 cycle in Part A. PK calculations were performed by standard non-compartmental analysis. Results are reported for Cycle 1 Day 1 and Cycle 1 Day 28. Note: concentration data for ITF2374 (Cycle 1 Day 1 and Cycle 1 Day 28) and for ITF2375 (Cycle 1 Day 1) in the DL0 dose group of Part A were not available for PK analysis.

Measure: Assessment of Maximum Plasma Concentration (Cmax) of Givinostat and Metabolites (ITF2374 and ITF2375) in Part A of the Study

Time: Blood samples were collected in Part A on Cycle 1 Day 1: pre-dose and 2, 3 and 8 hours post-dose; and on Cycle 1 Day 28: pre-dose and 1, 2, 4 and 8 hours post-dose.

Description: PK evaluation of givinostat and metabolites (ITF2374 and ITF2375) by assessment of Tmax following administration of givinostat for 1 cycle in Part A. PK calculations were performed by standard non-compartmental analysis. Results are reported for Cycle 1 Day 1 and Cycle 1 Day 28. Note: concentration data for ITF2374 (Cycle 1 Day 1 and Cycle 1 Day 28) and for ITF2375 (Cycle 1 Day 1) in the DL0 dose group of Part A were not available for PK analysis.

Measure: Assessment of Time to Maximum Plasma Concentration (Tmax) of Givinostat and Metabolites (ITF2374 and ITF2375) in Part A of the Study

Time: Blood samples were collected in Part A on Cycle 1 Day 1: pre-dose and 2, 3 and 8 hours post-dose; and on Cycle 1 Day 28: pre-dose and 1, 2, 4 and 8 hours post-dose.

Description: PK evaluation of givinostat and metabolites (ITF2374 and ITF2375) by assessment of Tlast following administration of givinostat for 1 cycle in Part A. PK calculations were performed by standard non-compartmental analysis. Results are reported for Cycle 1 Day 1 and Cycle 1 Day 28. Note: concentration data for ITF2374 (Cycle 1 Day 1 and Cycle 1 Day 28) and for ITF2375 (Cycle 1 Day 1) in the DL0 dose group of Part A were not available for PK analysis.

Measure: Assessment of Time of the Last Detectable Concentration (Tlast) of Givinostat and Metabolites (ITF2374 and ITF2375) in Part A of the Study

Time: Blood samples were collected in Part A on Cycle 1 Day 1: pre-dose and 2, 3 and 8 hours post-dose; and on Cycle 1 Day 28: pre-dose and 1, 2, 4 and 8 hours post-dose.

Description: PK evaluation of givinostat and metabolites (ITF2374 and ITF2375) by assessment of AUClast following administration of givinostat for 1 cycle in Part A. PK calculations were performed by standard non-compartmental analysis and AUClast was calculated using the linear trapezoidal rule. Results are reported for Cycle 1 Day 1 and Cycle 1 Day 28. Note: concentration data for ITF2374 (Cycle 1 Day 1 and Cycle 1 Day 28) and for ITF2375 (Cycle 1 Day 1) in the DL0 dose group of Part A were not available for PK analysis.

Measure: Assessment of Area Under Plasma Concentration Versus the Time Curve up to the Last Detectable Concentration (AUClast) of Givinostat and Metabolites (ITF2374 and ITF2375) in Part A of the Study

Time: Blood samples were collected in Part A on Cycle 1 Day 1: pre-dose and 2, 3 and 8 hours post-dose; and on Cycle 1 Day 28: pre-dose and 1, 2, 4 and 8 hours post-dose.

Description: PK evaluation of givinostat and metabolites (ITF2374 and ITF2375) by assessment of AUC0-12 following administration of givinostat for 1 cycle in Part A. PK calculations were performed by standard non-compartmental analysis and AUC0-12 was calculated using the linear trapezoidal rule. Results are reported for Cycle 1 Day 1 and Cycle 1 Day 28. Note:concentration data for ITF2374 (Cycle 1 Day 1 and Cycle 1 Day 28) across all dose groups and for ITF2375 (Cycle 1 Day 1) in the DL0 dose group of Part A were not available for PK analysis.

Measure: Assessment of Area Under Plasma Concentration Versus the Time Curve in the Dosing Interval (0-12 Hours) (AUC0-12) of Givinostat and Metabolites (ITF2374 and ITF2375) in Part A of the Study

Time: Blood samples were collected in Part A on Cycle 1 Day 1: pre-dose and 2, 3 and 8 hours post-dose; and on Cycle 1 Day 28: pre-dose and 1, 2, 4 and 8 hours post-dose.

Description: PK evaluation of givinostat and metabolites (ITF2374 and ITF2375) by assessment of Cmax following administration of givinostat for 2 cycles in Part B. PK calculations were performed by standard non-compartmental analysis. Following definition of the MTD in Part A, during Part B Cycle 1, givinostat was administered at 100 mg b.i.d. and during Part B Cycle 2 was administered at 100 mg, 75 mg and 50 mg b.i.d. (since dose reductions due to TEAEs were allowed from Cycle 2 onwards, as per protocol). Results are reported for Cycle 1 Day 1 and Cycle 2 Day 28 for the doses administered during Part B. Note: PK evaluation for the givinostat 75 mg and 50 mg b.i.d. dose groups for Cycle 1 Day 1 was not applicable (since all received givinostat 100 mg b.i.d.). Additionally, concentration data for ITF2375 (Cycle 1 Day 28) in the 50 mg b.i.d. dose group was not available for PK analysis.

Measure: Assessment of Cmax of Givinostat and Metabolites (ITF2374 and ITF2375) in Part B of the Study

Time: Blood samples were collected in Part B on Cycle 1 Day 1: pre-dose and 2, 3 and 8 hours post-dose; and on Cycle 2 Day 28: pre-dose and 1, 2, 4 and 8 hours post-dose.

Description: PK evaluation of givinostat and metabolites (ITF2374 and ITF2375) by assessment of Tmax following administration of givinostat for 2 cycles in Part B. PK calculations were performed by standard non-compartmental analysis. Following definition of the MTD in Part A, during Part B Cycle 1, givinostat was administered at 100 mg b.i.d. and during Part B Cycle 2 was administered at 100 mg, 75 mg and 50 mg b.i.d. (since dose reductions due to TEAEs were allowed from Cycle 2 onwards, as per protocol). Results are reported for Cycle 1 Day 1 and Cycle 2 Day 28 for the doses administered during Part B. Note: PK evaluation for the givinostat 75 mg and 50 mg b.i.d. dose groups for Cycle 1 Day 1 was not applicable (since all received givinostat 100 mg b.i.d.). Additionally, concentration data for ITF2375 (Cycle 1 Day 28) in the 50 mg b.i.d. dose group was not available for PK analysis.

Measure: Assessment of Tmax of Givinostat and Metabolites (ITF2374 and ITF2375) in Part B of the Study

Time: Blood samples were collected in Part B on Cycle 1 Day 1: pre-dose and 2, 3 and 8 hours post-dose; and on Cycle 2 Day 28: pre-dose and 1, 2, 4 and 8 hours post-dose.

Description: PK evaluation of givinostat and metabolites (ITF2374 and ITF2375) by assessment of Tlast following administration of givinostat for 2 cycles in Part B. PK calculations were performed by standard non-compartmental analysis. Following definition of the MTD in Part A, during Part B Cycle 1, givinostat was administered at 100 mg b.i.d. and during Part B Cycle 2 was administered at 100 mg, 75 mg and 50 mg b.i.d. (since dose reductions due to TEAEs were allowed from Cycle 2 onwards, as per protocol). Results are reported for Cycle 1 Day 1 and Cycle 2 Day 28 for the doses administered during Part B. Note: PK evaluation for the givinostat 75 mg and 50 mg b.i.d. dose groups for Cycle 1 Day 1 was not applicable (since all received givinostat 100 mg b.i.d.). Additionally, concentration data for ITF2375 (Cycle 1 Day 28) in the 50 mg b.i.d. dose group was not available for PK analysis.

Measure: Assessment of Tlast of Givinostat and Metabolites (ITF2374 and ITF2375) in Part B of the Study

Time: Blood samples were collected in Part B on Cycle 1 Day 1: pre-dose and 2, 3 and 8 hours post-dose; and on Cycle 2 Day 28: pre-dose and 1, 2, 4 and 8 hours post-dose.

Description: PK evaluation of givinostat and metabolites (ITF2374 and ITF2375) by assessment of AUClast following administration of givinostat for 2 cycles in Part B. PK calculations were performed by standard non-compartmental analysis and AUClast was calculated using the linear trapezoidal rule. Following definition of the MTD in Part A, during Part B Cycle 1, givinostat was administered at 100 mg b.i.d. and during Part B Cycle 2 was administered at 100 mg, 75 mg and 50 mg b.i.d. (since dose reductions due to TEAEs were allowed from Cycle 2 onwards, as per protocol). Results are reported for Cycle 1 Day 1 and Cycle 2 Day 28 for the for the doses administered during Part B. Note: PK evaluation for the givinostat 75 mg and 50 mg b.i.d. dose groups for Cycle 1 Day 1 was not applicable (since all received givinostat 100 mg b.i.d.). Additionally, concentration data for ITF2375 (Cycle 1 Day 28) in the 50 mg b.i.d. dose group was not available for PK analysis.

Measure: Assessment of AUClast of Givinostat and Metabolites (ITF2374 and ITF2375) in Part B of the Study

Time: Blood samples were collected in Part B on Cycle 1 Day 1: pre-dose and 2, 3 and 8 hours post-dose; and on Cycle 2 Day 28: pre-dose and 1, 2, 4 and 8 hours post-dose.

Description: PK evaluation of givinostat and metabolites (ITF2374 and ITF2375) by assessment of AUC0-12 following administration of givinostat for 2 cycles in Part B. PK calculations were performed by standard non-compartmental analysis and AUClast was calculated using the linear trapezoidal rule. Following definition of the MTD in Part A, during Part B Cycle 1, givinostat was administered at 100 mg b.i.d. and during Part B Cycle 2 was administered at 100 mg, 75 mg and 50 mg b.i.d. (since dose reductions due to TEAEs were allowed from Cycle 2 onwards, as per protocol). Results are reported for Cycle 1 Day 1 and Cycle 2 Day 28 for the doses administered during Part B. Note: PK evaluation for the givinostat 75 mg and 50 mg b.i.d. dose groups for Cycle 1 Day 1 was not applicable (since all received givinostat 100 mg b.i.d.). Additionally, concentration data for ITF2374 (Cycle 1 Day 28) across all dose groups and for ITF2375 in the 50 mg b.i.d. dose group was not available for PK analysis.

Measure: Assessment of AUC0-12 of Givinostat and Metabolites (ITF2374 and ITF2375) in Part B of the Study

Time: Blood samples were collected in Part B on Cycle 1 Day 1: pre-dose and 2, 3 and 8 hours post-dose; and on Cycle 2 Day 28: pre-dose and 1, 2, 4 and 8 hours post-dose.

24 Effects of Sympathicomimetic Agonists on the Disease Course and Mutant Allele Burden in Patients With JAK2-mutated Myeloproliferative Neoplasms. A Multicenter Phase II Trial.

The aim of this phase II study is to test a novel concept in the treatment of patients with myeloproliferative neoplasms (MPN), a disease of the bone marrow. With no current cure available, MPN are a group of chronic leukemias (blood cancers) in which patients produce too many blood cells. These increased blood cell numbers cause problems to the patient such as bleedings or thrombosis and some patients may progress to acute leukemia, a life threatening condition. Most MPN patients have a gene mutation called JAK2-V617F. The disease is maintained by mutant MPN stem cells that reside in the bone marrow in specialized locations called "niches". These niches need connections to the nervous system. New findings show that these connections are destroyed by the presence of the mutated MPN stem cells. Research teams found that some drugs (beta3-sympathicomimetics) can restore these damaged niches and at the same time reduce the MPN disease manifestation in a mouse model of MPN. Such sympathicomimetic drugs are already being used to treat patients with asthma or hyperactive bladder. These drugs have shown to have only few side effects. The study tests the effects of the beta-3-sympathicomimetic drug Mirabegron (Betmiga®) on MPN disease in 39 patients that carry a JAK2-V617F mutation. The hypothesis is that Mirabegron will have a beneficial effect on bone marrow niche cells and will thereby improve the disease manifestation in MPN patients. This study should provide a rapid answer whether targeting the nervous system of the niche cells could be useful for patients with MPN and warrants to be tested in larger and more long-term studies.

NCT02311569
Conditions
  1. Myeloproliferative Neoplasm
  2. Primary Myelofibrosis
  3. Essential Thrombocythemia
  4. Polycythemia Vera
Interventions
  1. Drug: Mirabegron
MeSH:Neoplasms Polycythemia Vera Primary Myelofibrosis Myeloproliferative Disorders Polycythemia Thrombocytosis Thrombocythemia, Essential
HPO:Myeloproliferative disorder Neoplasm Polycythemia Thrombocytosis

Most MPN patients have a gene mutation called JAK2-V617F. --- V617F ---

The study tests the effects of the beta-3-sympathicomimetic drug Mirabegron (Betmiga®) on MPN disease in 39 patients that carry a JAK2-V617F mutation. --- V617F ---

Patients are defined as success for this endpoint, if they show a reduction of the JAK2-V617F allelic burden of 50% or more 24 weeks ± 4 weeks after registration when compared to baseline, and if they did not start a new MPN treatment before. --- V617F ---

Reduction in the burden of mutated alleles of ≥25% at 24 weeks (Red-25@24): Patients are defined as success for the Red-25@24 endpoint, if they show a reduction of the Jak2-V617F allelic burden of 25% or more 24 weeks ± 4 weeks after registration when compared to baseline, and if they did not start a new MPN treatment before. --- V617F ---

Reduction in the burden of mutated alleles of ≥25% at 12 weeks (Red-25@12) defined in the same way as the Red-25@24 endpoint, but evaluated at 12 weeks ± 4 weeks after registration.. Inclusion Criteria: - Histologically or cytologically confirmed diagnosis of JAK2-V617F positive ET, PV or PMF at primary diagnosis or pretreated - JAK2-V617F mutant allele burden > 20% in the peripheral blood at study entry - Patient must give written informed consent before registration - WHO performance status 0-2 - Age ≥ 18 years - Adequate hematological values: neutrophils ≥ 1.5 x 109/L, platelets ≥ 100 x 109/ L - Adequate hepatic function: bilirubin ≤ 1.5 x ULN, AST/ALT/AP ≤ 2.5 x ULN - Adequate renal function (calculated creatinine clearance > 50 mL/min, according to the formula of Cockcroft-Gault) - Women are not breastfeeding. --- V617F ---

Reduction in the burden of mutated alleles of ≥25% at 12 weeks (Red-25@12) defined in the same way as the Red-25@24 endpoint, but evaluated at 12 weeks ± 4 weeks after registration.. Inclusion Criteria: - Histologically or cytologically confirmed diagnosis of JAK2-V617F positive ET, PV or PMF at primary diagnosis or pretreated - JAK2-V617F mutant allele burden > 20% in the peripheral blood at study entry - Patient must give written informed consent before registration - WHO performance status 0-2 - Age ≥ 18 years - Adequate hematological values: neutrophils ≥ 1.5 x 109/L, platelets ≥ 100 x 109/ L - Adequate hepatic function: bilirubin ≤ 1.5 x ULN, AST/ALT/AP ≤ 2.5 x ULN - Adequate renal function (calculated creatinine clearance > 50 mL/min, according to the formula of Cockcroft-Gault) - Women are not breastfeeding. --- V617F --- --- V617F ---

Inclusion Criteria: - Histologically or cytologically confirmed diagnosis of JAK2-V617F positive ET, PV or PMF at primary diagnosis or pretreated - JAK2-V617F mutant allele burden > 20% in the peripheral blood at study entry - Patient must give written informed consent before registration - WHO performance status 0-2 - Age ≥ 18 years - Adequate hematological values: neutrophils ≥ 1.5 x 109/L, platelets ≥ 100 x 109/ L - Adequate hepatic function: bilirubin ≤ 1.5 x ULN, AST/ALT/AP ≤ 2.5 x ULN - Adequate renal function (calculated creatinine clearance > 50 mL/min, according to the formula of Cockcroft-Gault) - Women are not breastfeeding. --- V617F ---

Inclusion Criteria: - Histologically or cytologically confirmed diagnosis of JAK2-V617F positive ET, PV or PMF at primary diagnosis or pretreated - JAK2-V617F mutant allele burden > 20% in the peripheral blood at study entry - Patient must give written informed consent before registration - WHO performance status 0-2 - Age ≥ 18 years - Adequate hematological values: neutrophils ≥ 1.5 x 109/L, platelets ≥ 100 x 109/ L - Adequate hepatic function: bilirubin ≤ 1.5 x ULN, AST/ALT/AP ≤ 2.5 x ULN - Adequate renal function (calculated creatinine clearance > 50 mL/min, according to the formula of Cockcroft-Gault) - Women are not breastfeeding. --- V617F --- --- V617F ---

Three genes are frequently mutated in MPN and are implicated to be the phenotypic driver mutations: more than 95% of PV patients carry a somatic JAK2-V617F mutation, while about half of the remaining PV patients (2-3%) display mutations in JAK2 exon 12. Thus, almost all patients with PV have somatic mutations in the JAK2 gene. --- V617F ---

The mutational profiles of ET and PMF are more diverse: JAK2-V617F is found in 50-60% of the patients, whereas the recently described mutations in calreticulin (CALR) occur in 20-25% of the patients. --- V617F ---

Ruxolitinib, recently approved for PMF with splenomegaly, is effective in reducing spleen size and improving quality of life, but has little effect on the JAK2-V617F mutant allele burden and has so far not been reported to induce remissions. --- V617F ---

Furthermore, in a mouse model of MPN expressing the human JAK2-V617F mutation, this effect was found to be caused by early glial and sympathetic nerve damage and apoptosis of nestin+ MSCs triggered by the mutant HSCs. --- V617F ---

Mice with JAK2-V617F driven MPN treated with a beta-3-sympathicomimetic agonist not only restored nestin+ MSCs numbers, but also showed correction of thrombocytosis, neutrophilia, and bone marrow fibrosis, and efficiently reduced mutant hematopoietic progenitor numbers in bone marrow and peripheral blood. --- V617F ---

Primary Outcomes

Description: Primary endpoint of the trial is reduction in the burden of mutated alleles of ≥50% at 24 weeks (Red-50@24). Patients are defined as success for this endpoint, if they show a reduction of the JAK2-V617F allelic burden of 50% or more 24 weeks ± 4 weeks after registration when compared to baseline, and if they did not start a new MPN treatment before. All other evaluable patients will be considered as failures for this endpoint.

Measure: Reduction in the burden of mutated alleles of ≥50% at 24 weeks.

Time: at 24 weeks

Secondary Outcomes

Description: Reduction in the burden of mutated alleles of ≥50% at 12 weeks (Red-50@12) defined in the same way as the primary endpoint, but evaluated at 12 weeks ± 4 weeks after registration.

Measure: Reduction in the burden of mutated alleles of ≥50%

Time: at 12 weeks

Description: Reduction in the burden of mutated alleles of ≥25% at 24 weeks (Red-25@24): Patients are defined as success for the Red-25@24 endpoint, if they show a reduction of the Jak2-V617F allelic burden of 25% or more 24 weeks ± 4 weeks after registration when compared to baseline, and if they did not start a new MPN treatment before. All other evaluable patients will be considered as failures for this endpoint.

Measure: Reduction in the burden of mutated alleles of ≥25%

Time: at 24 weeks

Description: Reduction in the burden of mutated alleles of ≥25% at 12 weeks (Red-25@12) defined in the same way as the Red-25@24 endpoint, but evaluated at 12 weeks ± 4 weeks after registration.

Measure: Reduction in the burden of mutated alleles of ≥25%

Time: at 12 weeks

25 A Phase II, Multicenter, Open Label, Single Arm Study of SAR302503 in Subjects Previously Treated With Ruxolitinib and With a Current Diagnosis of Intermediate or High-Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis

Primary Objective: - To evaluate the efficacy of once daily dose of SAR302503 in subjects previously treated with ruxolitinib and with a current diagnosis of intermediate-1 with symptoms, Intermediate-2 or high-risk primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (Post-PV MF), or post-essential thrombocythemia myelofibrosis (Post-ET MF) based on the reduction of spleen volume at the end of 6 treatment cycles; Secondary Objectives: - To evaluate the effect of SAR302503 on Myelofibrosis (MF) associated symptoms as measured by the modified Myelofibrosis Symptom Assessment Form (MFSAF) diary - To evaluate the durability of splenic response - To evaluate the splenic response to SAR302503 by palpation at the end of Cycle 6 - To evaluate the splenic response to SAR302503 at the end of Cycle 3 - To evaluate the effect of SAR302503 on the Janus kinase 2 (JAK2) V617F allele burden - To evaluate the safety and tolerability of SAR302503 in this population - To evaluate plasma concentrations of SAR302503 for population PK analysis, if warranted

NCT01523171
Conditions
  1. Hematopoietic Neoplasm
Interventions
  1. Drug: SAR302503
MeSH:Hematologic Neoplasms Primary Myelofibrosis
HPO:Hematological neoplasm Leukemia

Phase II, Open Label, Single Arm Study of SAR302503 In Myelofibrosis Patients Previously Treated With Ruxolitinib Primary Objective: - To evaluate the efficacy of once daily dose of SAR302503 in subjects previously treated with ruxolitinib and with a current diagnosis of intermediate-1 with symptoms, Intermediate-2 or high-risk primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (Post-PV MF), or post-essential thrombocythemia myelofibrosis (Post-ET MF) based on the reduction of spleen volume at the end of 6 treatment cycles; Secondary Objectives: - To evaluate the effect of SAR302503 on Myelofibrosis (MF) associated symptoms as measured by the modified Myelofibrosis Symptom Assessment Form (MFSAF) diary - To evaluate the durability of splenic response - To evaluate the splenic response to SAR302503 by palpation at the end of Cycle 6 - To evaluate the splenic response to SAR302503 at the end of Cycle 3 - To evaluate the effect of SAR302503 on the Janus kinase 2 (JAK2) V617F allele burden - To evaluate the safety and tolerability of SAR302503 in this population - To evaluate plasma concentrations of SAR302503 for population PK analysis, if warranted Response Rate (RR), defined as the proportion of subjects who have a ≥35% reduction from baseline in volume of spleen at the end of Cycle 6 as measured by Magnetic Resonance Imaging (MRI) (or CT scan in subjects with contraindications for MRI). --- V617F ---

Primary Outcomes

Measure: Response Rate (RR), defined as the proportion of subjects who have a ≥35% reduction from baseline in volume of spleen at the end of Cycle 6 as measured by Magnetic Resonance Imaging (MRI) (or CT scan in subjects with contraindications for MRI)

Time: 6 months

Secondary Outcomes

Measure: Symptom Response Rate (SRR): Proportion of subjects with a ≥50% reduction from baseline to the end of Cycle 6 in the total symptom score using the modified MFSAF

Time: 6 months

Measure: Duration of spleen response, measured by MRI (or CT scan in subjects with contraindications for MRI)

Time: 6 months

Measure: Proportion of subjects with a ≥50% reduction in length of spleen by palpation from baseline at the end of Cycle 6

Time: 6 months

Measure: Response Rate at the end of Cycle 3, defined as the proportion of subjects who have a ≥35% reduction from baseline in volume of spleen at the end of Cycle 3 as measured by MRI (or CT scan in subjects with contraindications for MRI)

Time: 6 months

Measure: Percent change of spleen volume at the end of Cycles 3 and 6 from baseline as measured by MRI (or CT scan in subjects with contraindications for MRI)

Time: 6 months

Measure: Safety, as assessed by clinical, laboratory, ECG, and vital sign events; graded by the NCI CTCAE v4.03

Time: approximately 5 years

Measure: Plasma concentrations of SAR302503

Time: 4 months

Measure: The effect of SAR302503 on the JAK2V617F allele burden

Time: 2 years

26 Tazemetostat Expanded Access Program for Adults With Epithelioid Sarcoma

A multicenter, open-label expanded access program to provide access to tazemetostat to Epithelioid Sarcoma (ES) patients in serious need who are otherwise unable to participate in a clinical study or whom access is not available through marketed product in the US.

NCT04225429
Conditions
  1. Epithelioid Sarcoma
Interventions
  1. Drug: Tazemetostat
MeSH:Sarcoma
HPO:Sarcoma Soft tissue sarcoma

JAK2 V617F) observed in cytogenetic testing and DNA sequencing. --- V617F ---


27 A Prospective, Single-center Clinical Trial of Pegylated Interferon Alfa-2b Versus Interferon Alfa Therapy in the Treatment of Childhood Essential Thrombocythemia

Objectives: To compare the efficacy and safety in children (<18 years) diagnosed as essential thrombocythemia treated with the Pegylated Interferon Alfa-2b vs. Interferon Alfa. Study Design: A prospective, open-label, nonrandomized, single-center clinical trial

NCT04226950
Conditions
  1. Essential Thrombocytopenia
Interventions
  1. Drug: Recombinant Interferon Alpha
  2. Drug: Pegylated interferon alfa-2b
MeSH:Thrombocytopenia Thrombocytosis Thrombocythemia, Essential
HPO:Thrombocytopenia Thrombocytosis

- Platelet count ≥ 450 × 109 / L for more than 6 months(If the patient has JAK2 V617F, CALR or MPL gene mutation, the history may be less than 6 months) - Platelet count ≥ 1000 × 109 / L at screening - The guardians has provided written informed consent prior to enrollment Exclusion Criteria: - Known to meet the criteria for primary myelofibrosis or polycythemia vera by 2016 WHO criteria - Presence of any life-threatening co-morbidity - Secondary thrombocytosis - Familial thrombocytosis - Resistance, or intolerance, or any contraindications to interferon - Interferon is used in the past 1 month before enrollment - Patients with previous or present thrombosis or active bleeding - WBC<4× 109 / L - HGB<110g/L - Poor control of thyroid dysfunction - Patients with a prior malignancy within the last 3 years - Patients with severe cardiac or pulmonary dysfunction - Severe renal damage (creatinine clearance < 30 ml / min) - Severe liver dysfunction (ALT or AST > 2.5×ULN) - Patients diagnosed as diabetes with poor control - Patients with hepatitis B virus, hepatitis C virus replication or HIV infection - Patients with a history of drug / alcohol abuse (within 2 years before the study) - Patients that have participated in other experimental researches within one month before enrollment - History of psychiatric disorder - Any other circumstances that the investigator considers that the patient is not suitable to participate in the trial Inclusion Criteria: - <18 years old - Male or Female - Diagnosis of essential thrombocythemia according to the 2016 WHO criteria. --- V617F ---

- Platelet count ≥ 450 × 109 / L for more than 6 months(If the patient has JAK2 V617F, CALR or MPL gene mutation, the history may be less than 6 months) - Platelet count ≥ 1000 × 109 / L at screening - The guardians has provided written informed consent prior to enrollment Exclusion Criteria: - Known to meet the criteria for primary myelofibrosis or polycythemia vera by 2016 WHO criteria - Presence of any life-threatening co-morbidity - Secondary thrombocytosis - Familial thrombocytosis - Resistance, or intolerance, or any contraindications to interferon - Interferon is used in the past 1 month before enrollment - Patients with previous or present thrombosis or active bleeding - WBC<4× 109 / L - HGB<110g/L - Poor control of thyroid dysfunction - Patients with a prior malignancy within the last 3 years - Patients with severe cardiac or pulmonary dysfunction - Severe renal damage (creatinine clearance < 30 ml / min) - Severe liver dysfunction (ALT or AST > 2.5×ULN) - Patients diagnosed as diabetes with poor control - Patients with hepatitis B virus, hepatitis C virus replication or HIV infection - Patients with a history of drug / alcohol abuse (within 2 years before the study) - Patients that have participated in other experimental researches within one month before enrollment - History of psychiatric disorder - Any other circumstances that the investigator considers that the patient is not suitable to participate in the trial Essential Thrombocytopenia Thrombocytopenia Thrombocytosis Thrombocythemia, Essential This is a prospective, open-label, nonrandomized, single-center clinical trial between Interferon Alfa and Pegylated Interferon Alfa-2b in childhood essential thrombocythemia (<18 years). --- V617F ---

Primary Outcomes

Description: Proportion of subjects with a platelet count <600×109/L after 3 months of treatment will be evaluated.

Measure: Change in platelet count

Time: 3 months

Secondary Outcomes

Description: To compare the complete hematologic response rates between different treatment groups

Measure: The complete hematologic response rates

Time: 3 months

Description: Time to response in platelet count (<600×109/L) between different treatment groups

Measure: Time to response in platelet count

Time: 3 months

Description: To compare the proportion of subjects that display change on key biomarkers of the disease- JAK2V617F, CALR, MPL mutations.

Measure: Impact of therapy on key biomarkers

Time: 12 months

Description: To estimate incidence of major cardiovascular and thrombotic events (defined as cardiovascular death, myocardial infarction, stroke, transient ischemic attack, pulmonary embolism, Budd Chiari syndrome, deep vein thrombosis, and any other clinically relevant thrombotic event) while on active treatment or observation following end of treatment between different treatment groups

Measure: Incidence of major cardiovascular and thrombotic events

Time: 12 months

Description: To estimate incidence of development of myelodysplastic disorders, myelofibrosis, or leukemic transformation between different treatment groups

Measure: Incidence of development of myelodysplastic disorders, myelofibrosis, or leukemic transformation.

Time: 12 months

Description: To compare the proportion of subjects that display change in Myeloproliferative Neoplasm Symptom Assessment Form total symptom score (0-100 scores, higher scores mean a worse outcome) between different treatment groups.

Measure: Change in Myeloproliferative Neoplasm Symptom Assessment Form total symptom score

Time: 3 months

Description: To compare incidence of specific pre-defined toxicity including fatigue, flu-like symptoms, dizziness, injection site necrosis, dyspnea, pain, depression, blurred Vision, insomnia, anorexia, weight Loss, weakness, pruritis, sweating, fever, decreased Libido, hot Flashes, flushing.

Measure: Specific pre-defined toxicity

Time: 12 months

Description: To compare the proportion of subjects that display change on bone marrow histopathology

Measure: Impact of therapy on bone marrow histopathology

Time: 12 months

Description: To compare the proportion of subjects that display change on cytogenetic abnormalities.

Measure: Impact of therapy on cytogenetic abnormalities

Time: 12 months

Description: To compare the incidence of death while on active treatment or observation following end of treatment

Measure: Death while on active treatment or observation following end of treatment

Time: 12 months

28 Tazemetostat Expanded Access Program for Adults With Solid Tumors

Patients with following conditions are eligible to enroll in the EAP: - Epithelioid Sarcoma (ES) - Spindle cell sarcoma - Sinonasal carcinoma - Small Cell Carcinoma of the Ovary Hypercalcemic Type (SCCOHT) - Thoracic sarcoma - Poorly differentiated chordoma These conditions must be serious or life-threatening at the time of enrollment and appropriate, comparable, or satisfactory alternative treatments must have been tried without clinical success. Patients with conditions not listed above are not eligible for the tazemetostat EAP

NCT03874455
Conditions
  1. Epithelioid Sarcoma
  2. Spindle Cell Sarcoma
  3. Sinonasal Carcinoma
  4. Small Cell Carcinoma of the Ovary Hypercalcemic Type
  5. Thoracic Sarcoma
  6. Poorly Differentiated Chordoma
Interventions
  1. Drug: Tazemetostat
MeSH:Carcinoma Sarcoma Chordoma Carcinoma, Small Cell Small Cell Lung Carcinoma Carcinoma, Ovarian Epithelial
HPO:Carcinoma Chordoma Sarcoma Small cell lung carcinoma Soft tissue sarcoma

JAK2 V617F) observed in cytogenetic testing and DNA sequencing. --- V617F ---


29 A Pilot Study of Tazemetostat and MK-3475 (Pembrolizumab) in Advanced Urothelial Carcinoma

This phase I/II trial studies the side effects and best dose of tazemetostat and how well it works when given together with pembrolizumab in treating patients with urothelial carcinoma that has spread to nearby tissue or lymph nodes or other places in the body (locally advanced/metastatic). Tazemetostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving tazemetostat and pembrolizumab may work better in treating patients with urothelial carcinoma compared to pembrolizumab without tazemetostat.

NCT03854474
Conditions
  1. Locally Advanced Urothelial Carcinoma
  2. Metastatic Urothelial Carcinoma
  3. Stage III Bladder Cancer AJCC v8
  4. Stage IIIA Bladder Cancer AJCC v8
  5. Stage IIIB Bladder Cancer AJCC v8
  6. Stage IV Bladder Cancer AJCC v8
  7. Stage IVA Bladder Cancer AJCC v8
  8. Stage IVB Bladder Cancer AJCC v8
Interventions
  1. Biological: Pembrolizumab
  2. Drug: Tazemetostat
MeSH:Carcinoma Urinary Bladder Neoplasms Carcinoma, Transitional Cell
HPO:Bladder neoplasm Carcinoma

JAK2 V617F) observed in cytogenetic testing and deoxyribonucleic acid (DNA) sequencing are not eligible - Patients with a prior history of T-cell lymphoblastic lymphoma (T-LBL) or T-cell acute lymphoblastic leukemia (T-ALL) are not eligible - Patients who have received prior PD-L1/PD-1/PD-L2 or EZH2 inhibitor therapy are not eligible - Patients who have had a prior monoclonal antibody within 4 weeks prior to study day 1 are not eligible - Patients with a known additional malignancy that is progressing or requires active treatment are not eligible. --- V617F ---

Primary Outcomes

Description: Response rates will be summarized in each cohort by proportions and 95% exact confidence intervals. Time to progression will be summarized using the Kaplan-Meier product limit curve.

Measure: Objective response rate (ORR)

Time: Up to 1 year

Secondary Outcomes

Description: Will be assessed using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 5. All adverse events will be summarized as to type, grade, timing, frequency and attribution using frequencies and percentages

Measure: Incidence of adverse events

Time: Up to 30 days after treatment discontinuation

Other Outcomes

Description: Will determine if EZH2, H3K27me3 and mutations in genes associated with histone methylation determine disease response to EZH2 and PD1. Each gene will be related to response using Fisher's exact test.

Measure: EZH2 and H3K27me3 chromatin methylation and mutations in genes associated with histone methylation

Time: Baseline

30 PCM1-JAK2 Fusion Gene Detection in Patients With Therapy Related Myelodysplastic Syndrome / Acute Myeloid Leukemia Patients

The term "therapy-related" leukemia is descriptive and is based on a patient's history of exposure to cytotoxic agents. Although a causal relationship is implied, the mechanism remains to be proven. These neoplasms are thought to be the direct consequence of mutational events induced by the prior therapy Therapy-related myelodysplastic syndromes / acute myeloid leukemia (t- MDS / t-AML) is now considered a single entity, called therapy-related myeloid neoplasms based on the current World Health Organization WHO classification2,. It is a well-recognized clinical syndrome occurring as a late complication following Cytotoxic agents and ionizing radiotherapy in the treatment of most cancer types: Hodgkin lymphoma (HL), non-Hodgkin lymphoma (NHL), acute lymphoblastic leukemia (ALL), sarcoma, and ovarian and testicular cancerThe incidence of t-MDS/AML following conventional therapy ranges from 0.8% to 6.3% at 20 years. The median time to development of t-MDS/AML is 3 to 5 years, with the risk decreasing markedly after the first decade Two types of t-MDS/AML are recognized in the WHO classification depending on the causative therapeutic exposure: an alkylating agent/radiation-related type and a topoisomerase II inhibitor-related type. Alkylating agent-related t-MDS/AML usually appears 4 to 7 years after exposure to the mutagenic agent .The reciprocal translocation t(8;9) (p22;p24) between the short arm of chromosome 8 and the long arm of chromosome 9 is a recurrent abnormality that fuses the Janus activated kinase 2 (JAK2) to the human autoantigen pericentriolar material 1 gene (PCM1) , with breakage and reunion at bands 8p11 and 9q3410Due to PCM1-JAK2 gene fusion, the coiled-coil domains of PCM1 mediate an oligomerization that brings together the linked JAK2 domains resulting in a constitutively activated tyrosine kinase domain of JAK2The most common mechanism for JAK2 activation in hematologic malignancies is the point mutation at position 617 (V617F). The consequences of JAK2 activation are neoplastic transformation and abnormal cell proliferation in various malignancies - So, translocations involving the JAK2 locus are considered of oncogenic importance in acute leukemias and myelodysplastic/ myeloproliferative diseases. - Patients with this abnormality present with broad clinical spectrum ranging from chronic to acute hematological diseases with myeloid or lymphoid appearance

NCT03943394
Conditions
  1. Detection of PCM1-JAK2 Fusion Gene by FISH in the Two Types of t-MDS/AML and Relationship Between PCM1-JAK2 Fusion Gene and Cumulative Dose, Dose Intensity
Interventions
  1. Other: fresh samples are obtained from patients for detction of PCM1- JAK2 fusion gene

Alkylating agent-related t-MDS/AML usually appears 4 to 7 years after exposure to the mutagenic agent .The reciprocal translocation t(8;9) (p22;p24) between the short arm of chromosome 8 and the long arm of chromosome 9 is a recurrent abnormality that fuses the Janus activated kinase 2 (JAK2) to the human autoantigen pericentriolar material 1 gene (PCM1) , with breakage and reunion at bands 8p11 and 9q3410Due to PCM1-JAK2 gene fusion, the coiled-coil domains of PCM1 mediate an oligomerization that brings together the linked JAK2 domains resulting in a constitutively activated tyrosine kinase domain of JAK2The most common mechanism for JAK2 activation in hematologic malignancies is the point mutation at position 617 (V617F). --- V617F ---

The most common mechanism for JAK2 activation in hematologic malignancies is the point mutation at position 617 (V617F). --- V617F ---

Primary Outcomes

Description: Using fresh sample from patients with myeloid neoplasm to search for PCM1-JAK2 fusion gene in the 2 types of thaerap related myeloid neoplasm , studying relationship between PCM1-JAK2 and dose intensity and time of exposure, and studying relationship between PCM1-JAK2 and other cytogenetic abnormalities by using FISH technique and

Measure: Detection of PCM1-JAK2fusion gene

Time: 24 months

31 Phase II Study of P1101 in Early Myelofibrosis

This pilot phase II trial studies P1101 (polyethyleneglycol [PEG]-proline-interferon alpha-2b) in treating patients with myelofibrosis. PEG-proline-interferon alpha-2b is a substance that can improve the body's natural response and may slow the growth of myelofibrosis.

NCT02370329
Conditions
  1. Primary Myelofibrosis
  2. Secondary Myelofibrosis
Interventions
  1. Other: Laboratory Biomarker Analysis
  2. Biological: PEG-Proline-Interferon Alfa-2b
  3. Other: Quality-of-Life Assessment
MeSH:Primary Myelofibrosis

To evaluate the impact of P1101 on bone marrow and histological features of myelofibrosis including cytogenetics, blast percentage, fibrosis, and JAK2-V617F allele burden by cohort (early vs intermediate-2/high risk). --- V617F ---

Primary Outcomes

Description: The proportion of successes will be estimated by the number of successes divided by the total number of evaluable patients. Confidence intervals for the true success proportion will be calculated according to the approach of Duffy and Santner.

Measure: Best overall response (CR, PR, or CI) as determined by International Working Group Criteria

Time: Up to 3 years

Secondary Outcomes

Description: The maximum grade for each type of adverse event will be recorded for each patient, and frequency tables will be reviewed to determine patterns. Additionally, the relationship of the adverse event(s) to the study treatment will be taken into consideration.

Measure: Incidence of adverse events, as measured by National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0 (NCI CTCAE v4)

Time: Up to 3 years

Description: The distribution of survival time will be estimated using the method of Kaplan-Meier.

Measure: Survival time

Time: Time from registration to death due to any cause, assessed up to 3 years

Other Outcomes

Description: Patient-reported symptoms and QOL will be described at each time point using the mean, confidence interval, median, and range. Changes in individual symptoms, changes in a symptom scale composed of symptoms specific to MF patients, and changes in the MPN TSS will be investigated. Graphical procedures will include stream plots of individual patient scores and plots of average values over time. Correlational analyses will be done to determine the relationships among patients-reported symptoms and QOL, as well as with clinical outcomes and clinician-assessed symptoms.

Measure: Changes in patient-reported symptoms and QOL as measured by MPN-SAF

Time: Baseline to up to 3 years

32 A Phase I, Open-label Multi-dose Pharmacokinetic and Safety Study of Oral Tazemetostat in Subjects With Moderate and Severe Hepatic Impairment With Advanced Malignancies

This is a phase 1, 2-part, global, multicenter, open-label, PK, safety and tolerability study of oral tazemetostat in subjects with either advanced solid tumors, or hematological malignancies and normal hepatic function or moderate, or severe hepatic impairment.

NCT04241835
Conditions
  1. Hepatic Impairment
  2. Advanced Malignant Solid Tumor
Interventions
  1. Drug: Tazemetostat
MeSH:Liver Diseases
HPO:Abnormality of the liver Decreased liver function Elevated hepatic transaminase

JAK2 V617F) observed in cytogenetic testing and DNA sequencing 13. --- V617F ---

Primary Outcomes

Description: When administered as a single and multi-dose in subjects with advanced malignancies and moderate or severe hepatic impairment, compared with subjects with advanced malignancies and normal hepatic function

Measure: To evaluate the pharmacokinetics (PK) of tazemetostat and its metabolite EPZ 6930, AUC0-t: area under the plasma concentration-time curve from time 0 to the time of the last quantifiable concentration

Time: 0 to 72 hours post dose on Day 1 and Day 15

Description: When administered as a single and multi-dose in subjects with advanced malignancies and moderate or severe hepatic impairment, compared with subjects with advanced malignancies and normal hepatic function

Measure: To evaluate the pharmacokinetics (PK) of tazemetostat and its metabolite EPZ 6930, AUC0-∞: area under the plasma concentration-time curve from time 0 extrapolated to infinity

Time: 0 to 72 hours post dose on Day 1 and Day 15

Description: When administered as a single and multi-dose in subjects with advanced malignancies and moderate or severe hepatic impairment, compared with subjects with advanced malignancies and normal hepatic function

Measure: To evaluate the pharmacokinetics (PK) of tazemetostat and its metabolite EPZ 6930, AUC0-72: area under the plasma concentration-time curve from time 0 to 72 hours post dose

Time: 0 to 72 hours post dose on Day 1 and Day 15

Description: When administered as a single and multi-dose in subjects with advanced malignancies and moderate or severe hepatic impairment, compared with subjects with advanced malignancies and normal hepatic function

Measure: To evaluate the pharmacokinetics (PK) of tazemetostat and its metabolite EPZ 6930, Cmax: observed maximum plasma concentration

Time: 0 to 72 hours post dose on Day 1 and Day 15

Description: When administered as a single and multi-dose in subjects with advanced malignancies and moderate or severe hepatic impairment, compared with subjects with advanced malignancies and normal hepatic function

Measure: To evaluate the pharmacokinetics (PK) of tazemetostat and its metabolite EPZ 6930, Tmax: observed time at Cmax

Time: 0 to 72 hours post dose on Day 1 and Day 15

Description: When administered as a single and multi-dose in subjects with advanced malignancies and moderate or severe hepatic impairment, compared with subjects with advanced malignancies and normal hepatic function

Measure: To evaluate the pharmacokinetics (PK) of tazemetostat and its metabolite EPZ 6930, λz: terminal phase elimination rate constant

Time: 0 to 72 hours post dose on Day 1 and Day 15

Description: When administered as a single and multi-dose in subjects with advanced malignancies and moderate or severe hepatic impairment, compared with subjects with advanced malignancies and normal hepatic function

Measure: To evaluate the pharmacokinetics (PK) of tazemetostat and its metabolite EPZ 6930, t1/2: terminal elimination half-life

Time: 0 to 72 hours post dose on Day 1 and Day 15

Secondary Outcomes

Description: Severity of adverse events experienced by all subjects with at least 1 dose or partial dose of tazemetostat will be evaluated by the Investigator based on the CTCAE, version 5.0

Measure: To evaluate the number of participants with treatment-emergent adverse events as assessed by CTCAE v5.0

Time: Through study completion, an average of 1 year

Description: Investigators will note any new clinically significant findings (e.g., not noted at screening) or changes in intensity of conditions that occurred after the initial tazemetostat administration

Measure: To evaluate the number of abnormalities or changes in intensity of conditions noted during the physical exam

Time: Through study completion, an average of 1 year

Description: Investigators will note any clinically significant changes from baseline in systolic and diastolic blood pressure measured in units of millimeters of mercury (mmHg)

Measure: To evaluate change in blood pressure

Time: Through study completion, an average of 1 year

Description: Investigators will note any clinically significant changes from baseline in heart rate measured in units of beats per minute (BPM)

Measure: To evaluate change in heart rate

Time: Through study completion, an average of 1 year

Description: Investigators will note any clinically significant changes from baseline in body temperature measured in degrees Fahrenheit or Celsius

Measure: To evaluate change in body temperature

Time: Through study completion, an average of 1 year

Description: Investigators will note any changes in concomitant medications from baseline in all subjects with at least 1 dose or partial dose of tazemetostat

Measure: To evaluate changes in concomitant medications

Time: Through study completion, an average of 1 year

Description: Investigators will report any clinically significant changes from baseline in the RR interval (sec) as noted by a 12 lead electrocardiogram (ECG)

Measure: To evaluate change in electrical activity of the heartbeat, RR interval

Time: Through study completion, an average of 1 year

Description: Investigators will report any clinically significant changes from baseline in the PR interval (sec) as noted by a 12 lead electrocardiogram (ECG)

Measure: To evaluate change in electrical activity of the heartbeat, PR interval

Time: Through study completion, an average of 1 year

Description: Investigators will report any clinically significant changes from baseline in the QRS complex (sec) as noted by a 12 lead electrocardiogram (ECG)

Measure: To evaluate change in electrical activity of the heartbeat, QRS complex

Time: Through study completion, an average of 1 year

Description: Investigators will report any clinically significant changes from baseline in the QT interval (sec) as noted by a 12 lead electrocardiogram (ECG)

Measure: To evaluate change in electrical activity of the heartbeat, QT interval

Time: Through study completion, an average of 1 year

Description: Investigators will note any clinically significant changes in hematological clinical laboratory values from baseline in all subjects with at least 1 dose or partial dose of tazemetostat using laboratory reference ranges

Measure: To evaluate changes in clinical laboratory values, hematology

Time: Through study completion, an average of 1 year

Description: Investigators will note any clinically significant changes in serum chemistry clinical laboratory values from baseline in all subjects with at least 1 dose or partial dose of tazemetostat using laboratory reference ranges

Measure: To evaluate changes in clinical laboratory values, serum chemistry

Time: Through study completion, an average of 1 year

Description: Investigators will note any clinically significant changes in urinalysis clinical laboratory values from baseline in all subjects with at least 1 dose or partial dose of tazemetostat using laboratory reference ranges

Measure: To evaluate changes in clinical laboratory values, urinalysis

Time: Through study completion, an average of 1 year

33 Modulation of Morbidity and Disease Progression in Polycythemia Vera (PV) and Essential Thrombocythemia (ET) Patients With Obstructive Sleep Apnea (OSA) by CPAP

This early phase I trial studies how well the use of a continuous positive airway pressure (CPAP) machine works in treating obstructive sleep apnea in patients with polycythemia vera or essential thrombocythemia. Obstructive sleep apnea is a condition where a person stops breathing during sleep, and is estimated to affect 30 to 50 percent of patients with polycythemia vera or essential thrombocythemia. A patient with obstructive sleep apnea typically snores, has disrupted sleep, experiences morning headaches, and has daytime sleepiness. Patients diagnosed with obstructive sleep apnea are typically treated with a device called CPAP. The CPAP provides pressurized air that keeps upper air passages open during sleep and may prevent them from narrowing or collapsing as occurs during snoring or sleep apnea.

NCT03972943
Conditions
  1. CALR Gene Mutation
  2. Essential Thrombocythemia
  3. JAK2 Gene Mutation
  4. MPL Gene Mutation
  5. Obstructive Sleep Apnea Syndrome
  6. Polycythemia Vera
Interventions
  1. Procedure: Continuous Positive Airway Pressure
  2. Other: Patient Observation
  3. Other: Questionnaire Administration
MeSH:Polycythemia Vera Apnea Sleep Apnea Syndromes Sleep Apnea, Obstructive Polycythemia Thrombocytosis Thrombocythemia, Essential
HPO:Apnea Obstructive sleep apnea Polycythemia Sleep apnea Thrombocytosis

Paired Wilcoxon tests will be used to analyze variables that are highly skewed or otherwise non-Gaussian in distribution.. Change in JAK2 V617F allele burden. --- V617F ---

Primary Outcomes

Description: Will be tested at the two-sided 0.025 significance level to provide overall control of the type I error for the co-primary endpoints at 0.05. The endpoints will be summarized by mean, median, range, standard deviation, interquartile range and boxplots. Scatterplots will be used to show bivariate associations. An assessment of normality will be made prior to statistical testing. Paired t tests will be used to analyze endpoints that are sufficiently Gaussian in distribution. Paired Wilcoxon tests will be used to analyze variables that are highly skewed or otherwise non-Gaussian in distribution.

Measure: Change in Myeloproliferative Neoplasm Symptom Assessment Form - Total Symptom Score (MPN-SAF TSS)

Time: Baseline, after 3 months, and after 6 months on trial

Description: Will be tested at the two-sided 0.025 significance level to provide overall control of the type I error for the co-primary endpoints at 0.05. The endpoints will be summarized by mean, median, range, standard deviation, interquartile range and boxplots. Scatterplots will be used to show bivariate associations. An assessment of normality will be made prior to statistical testing. Paired t tests will be used to analyze endpoints that are sufficiently Gaussian in distribution. Paired Wilcoxon tests will be used to analyze variables that are highly skewed or otherwise non-Gaussian in distribution.

Measure: Change in JAK2 V617F allele burden

Time: Baseline, after 3 months, and after 6 months on trial

Other Outcomes

Description: Assessed by Snoring, Tiredness, Observed Apnea, Blood Pressure, Body Mass Index, Age, Neck Circumference and Gender (STOP-BANG) questionnaire. The proportion of patients whose results indicate a diagnosis of OSA will be calculated. All patients with a diagnosis of OSA, regardless of whether they are enrolled to the treatment component of the study, will be counted towards the assessment of prevalence. An assessment of normality will be made prior to statistical testing. Paired t tests will be used to analyze endpoints that are sufficiently Gaussian in distribution. Paired Wilcoxon tests will be used to analyze variables that are highly skewed or otherwise non-Gaussian in distribution.

Measure: Proportion of patients with a diagnosis of obstructive sleep apnea (OSA)

Time: During the OSA screening

Description: The endpoints will be summarized by mean, median, range, standard deviation, interquartile range and boxplots. Scatterplots will be used to show bivariate associations. An assessment of normality will be made prior to statistical testing. Paired t tests will be used to analyze endpoints that are sufficiently Gaussian in distribution. Paired Wilcoxon tests will be used to analyze variables that are highly skewed or otherwise non-Gaussian in distribution.

Measure: Leucocytes, platelets, red cell counts, and tumor necrosis factor (TNF) analysis

Time: Baseline, after 3 months, and after 6 months on trial

Description: Will be measured in blood samples taken from all patients. OSA-related adverse events reported in the Treatment Cohort at these timepoints will be correlated with these marker levels. Pearson or Spearman correlation will be used to assess correlation between thrombo-inflammatory markers and oximetric abnormalities.

Measure: Thrombotic and inflammatory marker levels for all patients

Time: Baseline, after 3 months, and after 6 months on trial

34 Hydroxyurea in Pulmonary Arterial Hypertension

Pulmonary arterial hypertension (PAH) is a serious and eventually fatal disease damaging the lungs and the heart. It results from narrowing and eventual blockage of small blood vessels in the lung, due to abnormal proliferation of cells in the blood vessel (arterial). Patients with PAH suffer from fatigue, shortness of breath, low oxygen levels, blood clots and heart failure. No therapies reverse the disease process in the lung arteries, however there are three approved drugs that can temporarily dilate the vessels and improve symptoms. However, all three drugs have significant side effects and toxicities, they do not work effectively in many patients, survival remains on average only 2 to 3 years once symptoms begin, and none of these drugs prevent the underlying disease process in the small arteries of the lung. PAH is known to develop in patients with a pre-existing class of bone marrow diseases called myeloproliferative disorders (MPDs). We and others have recently shown that patients with PAH have bone marrow changes similar to those seen in patients with MPDs, even without other signs and symptoms of those bone marrow diseases such as anemia or high platelet and white blood cell counts. Compared to healthy volunteers, patients with PAH have a higher frequency of immature stem and progenitor cells able to produce blood cells and vascular wall cells in their bone marrow. They also have higher circulating numbers of these cells in the blood, and increased localization of these cells in the lung blood vessels. When immature bone marrow cells from PAH patients and normal volunteers were infused into mice, the mice receiving PAH marrow cells developed similar lung and heart problems to PAH patients, suggesting that the bone marrow problem is a primary cause of the lung problems, and that the increased numbers of immature bone marrow cells in the bone marrow and blood of PAH patients causes the lung blood vessel disease. The drug hydroxyurea is used to inhibit the abnormally high level of bone marrow cell proliferation in patients with MPDs. It has been shown to reduce the numbers of circulating immature bone marrow cells in patients with MPDs. Hydroxyurea has been available for almost fifty years, and has been used to treat patients with MPDs, sickle cell anemia, and congenital heart disease for very prolonged periods of time, up to twenty or more years in individual patients. It has an excellent long-term safety profile and few side effects and is generally well tolerated. It does not appear to result in an increased rate of leukemia even with many years of treatment. In the current protocol, we hypothesize that treating patients with PAH with hydroxyurea will decrease the level of circulating immature bone marrow cells and interrupt the abnormal narrowing and occlusion of lung arteries. We will treat patients with moderately severe primary (no known underlying cause) PAH with 6 months of hydroxyurea, carefully monitoring side effects and adjusting dosage as necessary, and measure the effect on circulating immature cells, lung blood vessel pressures, other blood markers of active PAH, and exercise tolerance.

NCT01950585
Conditions
  1. Pulmonary Hypertension
Interventions
  1. Drug: Hydroxyurea
MeSH:Hypertension, Pulmonary Familial Primary Pulmonary Hypertension Hypertension
HPO:Hypertension Pulmonary arterial hypertension

- HIV positivity - Moribund status or concurrent hepatic, renal, cardiac, neurologic, pulmonary, infectious, or metabolic disease of such severity that it would preclude the patient s ability to tolerate protocol therapy, or that death within 30 days is likely - Presence of 9;22 BCR/ABL translocation as detected by conventional bone marrow cytogenetics or PCR for BCR/ABL transcript, or presence of JAK2 V617F mutation in bone marrow or peripheral blood cells. --- V617F ---

Primary Outcomes

Measure: The change in concentration of CD34+ circulating progenitors from baseline to 6 months (24 weeks (+/- 7 days)) on hydroxyurea.

Time: ongoing

35 Concomitant Ruxolitinib Induction and Maintenance With Cytarabine Based Chemotherapy in Secondary Acute Myelogenous Leukemia Evolving From Myeloproliferative Neoplasm

This trial aimed to investigate the therapeutic efficacy of ruxolitinib in combination with cytotoxic chemotherapy for post-myeloproliferative neoplasm secondary acute myeloid leukemia.

NCT03558607
Conditions
  1. Secondary Acute Myelogenous Leukemia Evolving From Myeloproliferative Disorder
Interventions
  1. Drug: Ruxolitinib
MeSH:Leukemia Neoplasms Neoplasm Metastasis Leukemia, Myeloid Leukemia, Myeloid, Acute Myeloproliferative Disorders
HPO:Acute megakaryocytic leukemia Acute myeloid leukemia Leukemia Myeloid leukemia Myeloproliferative disorder Neoplasm

JAK2 V617F mutation, which is a hallmark of MPN, has been reported to be carried in approximately 35-50% of patients with post-MPN AML. --- V617F ---

Primary Outcomes

Measure: complete remission rate

Time: After 12 months from induction chemotherapy

Measure: complete remission with incompletre recovery rate

Time: After 12 months from induction chemotherapy

Secondary Outcomes

Description: from the date of transplantation to death from any cause

Measure: Overall survival

Time: 3, 6, 12, 24 months after induction chemotherapy

Description: from the date of transplantation to the date of disease progression or death from any cause

Measure: Progression-free survival

Time: 3, 6, 12, 24 months after induction chemotherapy

Description: according to CTCAE version 4.03

Measure: Toxicity profile

Time: 3, 6, 12, 24 months after induction chemotherapy

36 Arterial Function and Atherosclerosis in Patients With JAK2 V167F Positive Essential Thrombocythemia

The aim of the study is to examine (a) whether patients with JAK2 V617F positive ET in comparison to age-and sex-matched, apparently healthy control subjects show more advanced progression of arterial stiffness, pulse-wave velocity and coronary calcium score in a 4 year observation period, and (b) whether the burden of JAK2 V617F mutation correlates with the measured vascular parameters. All subjects will be examined twice. The first visit already took place between the years 2014 - 2015 and the second visit will take place between 2018-2019. All participants will have signed their informed consent before entering the study. Each visit will consist of completing a structured questionnaire (on personal and family medical history, risk factors for CVD and medication), physical examination, donating a blood sample for laboratory tests and undergoing carotid ultrasound and coronary calcium measurement oft the extent of coronary artery calcification. At the first and the second examination the JAK2 V617F allele burden, i.e. the percentage of mutated alleles, will be determined from genomic DNA in peripheral blood.

NCT03828422
Conditions
  1. Atherosclerosis
Interventions
  1. Diagnostic Test: imaging
MeSH:Atherosclerosis Thrombocytosis Thrombocythemia, Essential
HPO:Atherosclerosis Thrombocytosis Type IV atherosclerotic lesion

Arterial Function and Atherosclerosis in Essential Thrombocythemia The aim of the study is to examine (a) whether patients with JAK2 V617F positive ET in comparison to age-and sex-matched, apparently healthy control subjects show more advanced progression of arterial stiffness, pulse-wave velocity and coronary calcium score in a 4 year observation period, and (b) whether the burden of JAK2 V617F mutation correlates with the measured vascular parameters. --- V617F ---

Arterial Function and Atherosclerosis in Essential Thrombocythemia The aim of the study is to examine (a) whether patients with JAK2 V617F positive ET in comparison to age-and sex-matched, apparently healthy control subjects show more advanced progression of arterial stiffness, pulse-wave velocity and coronary calcium score in a 4 year observation period, and (b) whether the burden of JAK2 V617F mutation correlates with the measured vascular parameters. --- V617F --- --- V617F ---

At the first and the second examination the JAK2 V617F allele burden, i.e. the percentage of mutated alleles, will be determined from genomic DNA in peripheral blood. --- V617F ---

Change of carotid artery stiffness (expressed by beta-stiffness index and pulse wave velocity) in JAK2 V617F positive ET patients in comparison to healthy control subjects in a 4-year period.. Do patients with JAK2 V617F positive ET in comparison to age-and sex-matched, apparently healthy control subjects show more advanced progression of carotid artery stiffness (expressed as two interrelated parameters, the beta-stiffness index and the pulse wave velocity) in a 4 year observation period?. --- V617F ---

Change of carotid artery stiffness (expressed by beta-stiffness index and pulse wave velocity) in JAK2 V617F positive ET patients in comparison to healthy control subjects in a 4-year period.. Do patients with JAK2 V617F positive ET in comparison to age-and sex-matched, apparently healthy control subjects show more advanced progression of carotid artery stiffness (expressed as two interrelated parameters, the beta-stiffness index and the pulse wave velocity) in a 4 year observation period?. --- V617F --- --- V617F ---

Change of carotid artery plaque score in JAK2 V617F positive ET patients in comparison to healthy control subjects in a 4-year period.. Do patients with JAK2 V617F positive ET in comparison to age-and sex-matched, apparently healthy control subjects show more advanced progression of carotid plaque score in a 4 year observation period? --- V617F ---

Change of carotid artery plaque score in JAK2 V617F positive ET patients in comparison to healthy control subjects in a 4-year period.. Do patients with JAK2 V617F positive ET in comparison to age-and sex-matched, apparently healthy control subjects show more advanced progression of carotid plaque score in a 4 year observation period? --- V617F --- --- V617F ---

Thus, the carotid plaque score ranges from 0 (absence of plaques, best) to 6 (plaques present in all segments on both sides, worst outcome).. Change of coronary calcium burden in JAK2 V617F positive ET patients in comparison to healthy control subjects in a 4-year period.. Do patients with JAK2 V617F positive ET in comparison to age-and sex-matched, apparently healthy control subjects show more advanced progression of coronary calcium score in a 4 year observation period?. --- V617F ---

Thus, the carotid plaque score ranges from 0 (absence of plaques, best) to 6 (plaques present in all segments on both sides, worst outcome).. Change of coronary calcium burden in JAK2 V617F positive ET patients in comparison to healthy control subjects in a 4-year period.. Do patients with JAK2 V617F positive ET in comparison to age-and sex-matched, apparently healthy control subjects show more advanced progression of coronary calcium score in a 4 year observation period?. --- V617F --- --- V617F ---

Change of digital endothelial function, expressed as the Reactive Hyperemia Index, in JAK2 V617F positive ET patients in comparison to healthy control subjects in a 4-year period.. Do patients with JAK2 V617F positive ET in comparison to age-and sex-matched, apparently healthy control subjects show greater changes digital endothelial function, expressed as the Reactive Hyperemia Index (RHI), in a 4 year observation period? --- V617F ---

Change of digital endothelial function, expressed as the Reactive Hyperemia Index, in JAK2 V617F positive ET patients in comparison to healthy control subjects in a 4-year period.. Do patients with JAK2 V617F positive ET in comparison to age-and sex-matched, apparently healthy control subjects show greater changes digital endothelial function, expressed as the Reactive Hyperemia Index (RHI), in a 4 year observation period? --- V617F --- --- V617F ---

RHI ranges from 1 (no augmentation of pulsation with reactive hyperemia, i.e. worst outcome) to values above 2 (good endothelial response to reactive hyperemia).. Association of the JAK2 V617F mutation burden with the coronary calcium burden.. Quantification of JAK2 V617F mutation burden and its correlation with the coronary calcium burden.. Inclusion Criteria: - patients with JAK2 V617F positive essential thrombocythemia - age-and sex-matched apparently healthy control subjects Exclusion Criteria: - personal history of any atherosclerotic vascular disease (myocardial infarction, angina pectoris, peripheral arterial disease, aortic disease, transient ischemic attack or ischemic stroke) - chronic kidney disease stage 3 and above - known cancer - chronic inflammatory disease - autoimmune disease - pregnancy Inclusion Criteria: - patients with JAK2 V617F positive essential thrombocythemia - age-and sex-matched apparently healthy control subjects Exclusion Criteria: - personal history of any atherosclerotic vascular disease (myocardial infarction, angina pectoris, peripheral arterial disease, aortic disease, transient ischemic attack or ischemic stroke) - chronic kidney disease stage 3 and above - known cancer - chronic inflammatory disease - autoimmune disease - pregnancy Atherosclerosis Atherosclerosis Thrombocytosis Thrombocythemia, Essential 1. Patients and control subjects Patients are selected from the database of the Department of Haematology at University Medical Centre Ljubljana, Slovenia, who were diagnosed with JAK2 V617F positive ET between 2011 and 2014. --- V617F ---

RHI ranges from 1 (no augmentation of pulsation with reactive hyperemia, i.e. worst outcome) to values above 2 (good endothelial response to reactive hyperemia).. Association of the JAK2 V617F mutation burden with the coronary calcium burden.. Quantification of JAK2 V617F mutation burden and its correlation with the coronary calcium burden.. Inclusion Criteria: - patients with JAK2 V617F positive essential thrombocythemia - age-and sex-matched apparently healthy control subjects Exclusion Criteria: - personal history of any atherosclerotic vascular disease (myocardial infarction, angina pectoris, peripheral arterial disease, aortic disease, transient ischemic attack or ischemic stroke) - chronic kidney disease stage 3 and above - known cancer - chronic inflammatory disease - autoimmune disease - pregnancy Inclusion Criteria: - patients with JAK2 V617F positive essential thrombocythemia - age-and sex-matched apparently healthy control subjects Exclusion Criteria: - personal history of any atherosclerotic vascular disease (myocardial infarction, angina pectoris, peripheral arterial disease, aortic disease, transient ischemic attack or ischemic stroke) - chronic kidney disease stage 3 and above - known cancer - chronic inflammatory disease - autoimmune disease - pregnancy Atherosclerosis Atherosclerosis Thrombocytosis Thrombocythemia, Essential 1. Patients and control subjects Patients are selected from the database of the Department of Haematology at University Medical Centre Ljubljana, Slovenia, who were diagnosed with JAK2 V617F positive ET between 2011 and 2014. --- V617F --- --- V617F ---

RHI ranges from 1 (no augmentation of pulsation with reactive hyperemia, i.e. worst outcome) to values above 2 (good endothelial response to reactive hyperemia).. Association of the JAK2 V617F mutation burden with the coronary calcium burden.. Quantification of JAK2 V617F mutation burden and its correlation with the coronary calcium burden.. Inclusion Criteria: - patients with JAK2 V617F positive essential thrombocythemia - age-and sex-matched apparently healthy control subjects Exclusion Criteria: - personal history of any atherosclerotic vascular disease (myocardial infarction, angina pectoris, peripheral arterial disease, aortic disease, transient ischemic attack or ischemic stroke) - chronic kidney disease stage 3 and above - known cancer - chronic inflammatory disease - autoimmune disease - pregnancy Inclusion Criteria: - patients with JAK2 V617F positive essential thrombocythemia - age-and sex-matched apparently healthy control subjects Exclusion Criteria: - personal history of any atherosclerotic vascular disease (myocardial infarction, angina pectoris, peripheral arterial disease, aortic disease, transient ischemic attack or ischemic stroke) - chronic kidney disease stage 3 and above - known cancer - chronic inflammatory disease - autoimmune disease - pregnancy Atherosclerosis Atherosclerosis Thrombocytosis Thrombocythemia, Essential 1. Patients and control subjects Patients are selected from the database of the Department of Haematology at University Medical Centre Ljubljana, Slovenia, who were diagnosed with JAK2 V617F positive ET between 2011 and 2014. --- V617F --- --- V617F --- --- V617F ---

RHI ranges from 1 (no augmentation of pulsation with reactive hyperemia, i.e. worst outcome) to values above 2 (good endothelial response to reactive hyperemia).. Association of the JAK2 V617F mutation burden with the coronary calcium burden.. Quantification of JAK2 V617F mutation burden and its correlation with the coronary calcium burden.. Inclusion Criteria: - patients with JAK2 V617F positive essential thrombocythemia - age-and sex-matched apparently healthy control subjects Exclusion Criteria: - personal history of any atherosclerotic vascular disease (myocardial infarction, angina pectoris, peripheral arterial disease, aortic disease, transient ischemic attack or ischemic stroke) - chronic kidney disease stage 3 and above - known cancer - chronic inflammatory disease - autoimmune disease - pregnancy Inclusion Criteria: - patients with JAK2 V617F positive essential thrombocythemia - age-and sex-matched apparently healthy control subjects Exclusion Criteria: - personal history of any atherosclerotic vascular disease (myocardial infarction, angina pectoris, peripheral arterial disease, aortic disease, transient ischemic attack or ischemic stroke) - chronic kidney disease stage 3 and above - known cancer - chronic inflammatory disease - autoimmune disease - pregnancy Atherosclerosis Atherosclerosis Thrombocytosis Thrombocythemia, Essential 1. Patients and control subjects Patients are selected from the database of the Department of Haematology at University Medical Centre Ljubljana, Slovenia, who were diagnosed with JAK2 V617F positive ET between 2011 and 2014. --- V617F --- --- V617F --- --- V617F --- --- V617F ---

RHI ranges from 1 (no augmentation of pulsation with reactive hyperemia, i.e. worst outcome) to values above 2 (good endothelial response to reactive hyperemia).. Association of the JAK2 V617F mutation burden with the coronary calcium burden.. Quantification of JAK2 V617F mutation burden and its correlation with the coronary calcium burden.. Inclusion Criteria: - patients with JAK2 V617F positive essential thrombocythemia - age-and sex-matched apparently healthy control subjects Exclusion Criteria: - personal history of any atherosclerotic vascular disease (myocardial infarction, angina pectoris, peripheral arterial disease, aortic disease, transient ischemic attack or ischemic stroke) - chronic kidney disease stage 3 and above - known cancer - chronic inflammatory disease - autoimmune disease - pregnancy Inclusion Criteria: - patients with JAK2 V617F positive essential thrombocythemia - age-and sex-matched apparently healthy control subjects Exclusion Criteria: - personal history of any atherosclerotic vascular disease (myocardial infarction, angina pectoris, peripheral arterial disease, aortic disease, transient ischemic attack or ischemic stroke) - chronic kidney disease stage 3 and above - known cancer - chronic inflammatory disease - autoimmune disease - pregnancy Atherosclerosis Atherosclerosis Thrombocytosis Thrombocythemia, Essential 1. Patients and control subjects Patients are selected from the database of the Department of Haematology at University Medical Centre Ljubljana, Slovenia, who were diagnosed with JAK2 V617F positive ET between 2011 and 2014. --- V617F --- --- V617F --- --- V617F --- --- V617F --- --- V617F ---

40 patients (14 male and 26 female) with JAK2 V617F positive ET without clinically apparent cardiovascular disease signed the informed consent and were enrolled in the study in 2014 - 2015 for the first examination and 36 (12 male and 24 female) of them are expected to participate also in 2018-19. --- V617F ---

3. JAK2 V617F/G1849T allele burden The ipsogen JAK2 MutaQuant Kit, Qiagen (ZDA) (Ref: No. 673523) will be used for the detection and quantification of JAK2 V617F/G1849T allele in genomic DNA extracted from peripheral blood of patients and also control subjects. --- V617F ---

3. JAK2 V617F/G1849T allele burden The ipsogen JAK2 MutaQuant Kit, Qiagen (ZDA) (Ref: No. 673523) will be used for the detection and quantification of JAK2 V617F/G1849T allele in genomic DNA extracted from peripheral blood of patients and also control subjects. --- V617F --- --- V617F ---

A SNP specific primer selectively amplifies the JAK2 V617F allele which is detected with a real-time qPCR instrument that quantifies the PCR products. --- V617F ---

The JAK2 V617F allele burden will be calculated and expressed as the percentage of JAK2 V617F mutated alleles throughout the whole JAK2 record. --- V617F ---

The JAK2 V617F allele burden will be calculated and expressed as the percentage of JAK2 V617F mutated alleles throughout the whole JAK2 record. --- V617F --- --- V617F ---

The association between the parameters of vascular function / morphology and the JAK2 V617F allele burden will be assessed by the Pearson correlation coefficient. --- V617F ---

Primary Outcomes

Description: Do patients with JAK2 V617F positive ET in comparison to age-and sex-matched, apparently healthy control subjects show more advanced progression of carotid artery stiffness (expressed as two interrelated parameters, the beta-stiffness index and the pulse wave velocity) in a 4 year observation period?

Measure: Change of carotid artery stiffness (expressed by beta-stiffness index and pulse wave velocity) in JAK2 V617F positive ET patients in comparison to healthy control subjects in a 4-year period.

Time: the first visit in 2014-2015 and the second visit in 2018-2019

Description: Do patients with JAK2 V617F positive ET in comparison to age-and sex-matched, apparently healthy control subjects show more advanced progression of carotid plaque score in a 4 year observation period? Scoring of atherosclerotic plaques will be done according to the Rotterdam Study. The presence of at least one plaque in each segment of the extracranial carotid arterial bed, (the common carotid artery and the bulb, the internal carotid artery and the external carotid artery) on either side is scored 1 point. Thus, the carotid plaque score ranges from 0 (absence of plaques, best) to 6 (plaques present in all segments on both sides, worst outcome).

Measure: Change of carotid artery plaque score in JAK2 V617F positive ET patients in comparison to healthy control subjects in a 4-year period.

Time: the first visit in 2014-2015 and the second visit in 2018-2019

Description: Do patients with JAK2 V617F positive ET in comparison to age-and sex-matched, apparently healthy control subjects show more advanced progression of coronary calcium score in a 4 year observation period?

Measure: Change of coronary calcium burden in JAK2 V617F positive ET patients in comparison to healthy control subjects in a 4-year period.

Time: the first visit in 2014-2015 and the second visit in 2018-2019

Description: Do patients with JAK2 V617F positive ET in comparison to age-and sex-matched, apparently healthy control subjects show greater changes digital endothelial function, expressed as the Reactive Hyperemia Index (RHI), in a 4 year observation period? The RHI is the ratio of the pletysmographic amplitude of the digital arteries during maximal reactive hyperemia and the basal amplitude. RHI ranges from 1 (no augmentation of pulsation with reactive hyperemia, i.e. worst outcome) to values above 2 (good endothelial response to reactive hyperemia).

Measure: Change of digital endothelial function, expressed as the Reactive Hyperemia Index, in JAK2 V617F positive ET patients in comparison to healthy control subjects in a 4-year period.

Time: the first visit in 2014-2015 and the second visit in 2018-2019

Description: Quantification of JAK2 V617F mutation burden and its correlation with the coronary calcium burden.

Measure: Association of the JAK2 V617F mutation burden with the coronary calcium burden.

Time: at inclusion in the years 2014-2015, and at the second visit in 2018-2019

37 A Phase 2 Study of LY2784544 in Patients With Myeloproliferative Neoplasms

The primary purpose of this study is to measure the response rate in participants with the myeloproliferative neoplasms (MPNs), polycythemia vera (PV), essential thrombocythemia (ET), or myelofibrosis (MF) when treated with LY2784544, including those who have demonstrated an intolerance to, failure of primary response to, or have demonstrated disease progression while on ruxolitinib.

NCT01594723
Conditions
  1. Neoplasms, Hematologic
Interventions
  1. Drug: 120 mg LY2784544
MeSH:Neoplasms Hematologic Neoplasms Myeloproliferative Disorders
HPO:Hematological neoplasm Leukemia Myeloproliferative disorder Neoplasm

Inclusion Criteria: - Have a diagnosis of polycythemia vera (PV), essential thrombocythemia (ET), or myelofibrosis (MF) as defined by the World Health Organization (WHO) diagnostic criteria for myeloproliferative neoplasms (Swerdlow et al. 2008) and meet the following additional subtype specific criteria: - PV: have failed or is intolerant of standard therapies or refuses to take standard medications - ET: have failed or is intolerant of standard therapies or refuses to take standard medications - MF (participants with MF must meet at least 1 of the following): have intermediate 1, intermediate 2, or high-risk MF according to the Dynamic International Prognostic Scoring System (DIPPS Plus) for Primary Myelofibrosis (Gangat et al. 2011); or have symptomatic MF with spleen greater than 10 centimeter (cm) below left costal margin; or have post-polycythemic MF; or have post-ET MF - All PV, ET, and MF participants must meet the following criteria: o Have a quantifiable level of janus kinase 2 with a valine to phenylalanine substitution at amino acid 617 (JAK2 V617F) mutation. --- V617F ---

This inclusion criterion will not apply to the subset of participants in Cohorts 10 and 11 that must be negative for the JAK2 V617F mutation - Are ≥ 18 years of age - Have given written informed consent prior to any study-specific procedures - Have adequate organ function, including: Hepatic: Direct bilirubin ≤1.5 times upper limits of normal (ULN), alanine transaminase (ALT), and aspartate transaminase (AST) ≤2.5 times ULN; Renal: Serum creatinine ≤1.5 times ULN; Bone Marrow Reserve: Absolute neutrophil count (ANC) ≥1000/microliter (mcL), platelets ≥50,000/mcL for participants with ET or PV and ≥25,000/mcL for participants with MF - Have a performance status of 0, 1, or 2 on the Eastern Cooperative Oncology Group (ECOG) scale - Have discontinued all previous approved therapies for Myeloproliferative Neoplasms (MPNs), including any chemotherapy, immunomodulating therapy (for example, thalidomide, interferon-alpha), immunosuppressive therapy (for example, corticosteroids >10 mg/day prednisone or equivalent), radiotherapy, and erythropoietin, thrombopoietin, or granulocyte colony stimulating factor for at least 14 days and recovered from the acute effects of therapy. --- V617F ---

An exception to this criterion will be allowed for participants with a prior history of Budd-Chiari Syndrome who are being treated with warfarin or one of its derivatives - Have received a hematopoietic stem cell transplant - Have a second primary malignancy that in the judgment of the Investigator and Sponsor may affect the interpretation of results - Have an active fungal, bacterial, and/or known viral infection including human immunodeficiency virus (HIV) or viral (A, B, or C) hepatitis (screening is not required) - Have a history of congestive heart failure with New York Heart Association (NYHA) Class >2 (NYHA Class 1 and 2 are eligible), unstable angina, recent myocardial infarction (within 6 months prior to administration of study drug), or documented history of ventricular arrhythmia Inclusion Criteria: - Have a diagnosis of polycythemia vera (PV), essential thrombocythemia (ET), or myelofibrosis (MF) as defined by the World Health Organization (WHO) diagnostic criteria for myeloproliferative neoplasms (Swerdlow et al. 2008) and meet the following additional subtype specific criteria: - PV: have failed or is intolerant of standard therapies or refuses to take standard medications - ET: have failed or is intolerant of standard therapies or refuses to take standard medications - MF (participants with MF must meet at least 1 of the following): have intermediate 1, intermediate 2, or high-risk MF according to the Dynamic International Prognostic Scoring System (DIPPS Plus) for Primary Myelofibrosis (Gangat et al. 2011); or have symptomatic MF with spleen greater than 10 centimeter (cm) below left costal margin; or have post-polycythemic MF; or have post-ET MF - All PV, ET, and MF participants must meet the following criteria: o Have a quantifiable level of janus kinase 2 with a valine to phenylalanine substitution at amino acid 617 (JAK2 V617F) mutation. --- V617F ---

Primary Outcomes

Measure: Percentage of Participants with an Objective Response (Objective Response Rate)

Time: Baseline until Disease Progression (PD) or Participant Stops Study (Estimated up to 24 Months)

Secondary Outcomes

Measure: Percentage of Participants with a Molecular Response (Molecular Response Rate)

Time: Baseline until PD or Participant Stops Study (Estimated up to 24 Months)

Measure: Percentage of Participants with Hematological Improvement (Hematological Improvement Rate)

Time: Baseline until PD or Participant Stops Study (Estimated up to 24 Months)

Measure: Change in Spleen Size

Time: Baseline until PD or Participant Stops Study (Estimated up to 24 Months)

Measure: Change in Bone Marrow Fibrosis Grade

Time: Baseline until PD or Participant Stops Study (Estimated up to 24 Months)

Measure: Change in Number of Thrombotic or Hemorrhagic Events

Time: 3 Months prior to Study Drug (historic) until PD or Participant Stops Study (Estimated up to 24 Months)

Measure: Change in Number of Phlebotomies and Transfusions

Time: Baseline until PD or Participant Stops Study (Estimated up to 24 Months)

Measure: Duration of Response

Time: Confirmed Response to PD or Death from Any Cause (Estimated up to 24 Months)

Measure: Time to Best Response

Time: Baseline to Confirmed Response (Estimated up to 6 Months)

Measure: Change in Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF)

Time: Baseline until PD or Participant Stops Study (Estimated up to 24 Months)

Measure: Time to Treatment Failure

Time: Baseline to PD, Death from Any Cause or Participant Stops Study (Estimated up to 24 Months)

Measure: Time to Disease Progression

Time: Baseline to Measured PD (Estimated up to 24 Months)

Measure: Progression Free Survival (PFS)

Time: Baseline to PD or Death from Any Cause (Estimated up to 24 Months)

Measure: Change in Activities of Daily Living (ADL)/ Instrumental Activities of Daily Living (IADL)

Time: Baseline until PD or Participant Stops Study (Estimated up to 24 Months)

Measure: Change in EuroQol - 5 dimensions (EQ-5D) Index Score

Time: Baseline until PD or Participant Stops Study (Estimated up to 24 Months)

Measure: Change in International Prognosis Scoring System Scales (IPSS)

Time: Baseline until PD or Participant Stops Study (Estimated up to 24 Months)

Measure: Pharmacokinetics (PK): Maximum Concentration (Cmax) of LY2784544

Time: Predose up to Day 84

Measure: PK: Time of Maximal Concentration (Tmax) of LY2784544

Time: Predose up to Day 84

Measure: Change in Liver Size

Time: Baseline until PD or Participant Stops Study (Estimated up to 24 Months)

Measure: Change in 6-item Physician Symptom Assessment

Time: Baseline until PD or Participant Stops Study (Estimated up to 24 Months)

38 Efficacy of Tyrosine Kinase Inhibition in Reducing Eosinophilia in Patients With Myeloid and/or Steroid-Refractory Hypereosinophilic Syndrome

The purpose of this study is to evaluate the safety and efficacy of the tyrosine kinase inhibitor, imatinib mesylate (Gleevec ) in reducing peripheral blood eosinophilia in patients with the myeloid form of hypereosinophilic syndrome (HES). Patients with the hypereosinophilic syndrome who meet a set of criteria designed to select patients with the myeloid form of the disease, as well as patients without myeloid disease who are refractory to standard therapy for HES, will be admitted on this protocol. A thorough clinical evaluation will be performed with emphasis on potential sequelae of eosinophil-mediated tissue damage. A baseline bone marrow will be obtained to exclude leukemia or lymphoma and to assess the degree and nature of eosinophilopoiesis. Bone marrow, blood cells and/or serum will also be collected to test for the presence of a recently described mutation that is associated with imatinib-responsiveness in HES, and to provide reagents (such as DNA, RNA, and specific antibodies) and for use in the laboratory to address issues related to the mechanism of action of imatinib mesylate in HES. Imatinib mesylate will be initiated at a dose of 400 mg daily, the FDA-approved dose for the treatment of chronic myelogenous leukemia. In patients who demonstrate a complete clinical and hematologic response to imatinib therapy and who do not have life-threatening disease, the dose will be decreased gradually to 100mg daily and then discontinued. In order to minimize bone marrow suppression, other myelosuppressive agents will be tapered and discontinued during the first week of therapy with imatinib mesylate. Complete blood counts will be performed weekly for the first month and biweekly thereafter. Clinical assessments will be performed every three months to assess progression of end organ damage. In patients who demonstrate a complete clinical and hematologic response to imatinib therapy and who do not have life-threatening disease, the dose will be decreased gradually to 100 mg daily and then discontinued. In the event of clinical, hematologic or molecular relapse during the taper, the imatinib dose will be increased to a maximum of 600 mg daily to achieve a second remission. Laboratory monitoring will be performed as above except for molecular monitoring which will be monitored monthly if drug is discontinued or molecular relapse occurs. Once a stable dosing regimen is achieved for greater than or equal to 6 months in subjects who have undergone dose descalation or greater than or equal to 2 years in subjects receiving 300-400 mg of imatinib daily who did not qualify for dose de-escalation, the frequency of NIH visits and end organ assessments will be decreased to 6 months, with molecular monitoring every 3 months and monthly routine laboratory assessments.

NCT00044304
Conditions
  1. Eosinophilic Myeloid Neoplasm
  2. Hypereosinophilic Syndrome
Interventions
  1. Drug: Imatinib
  2. Drug: Ruxolitinib
MeSH:Hypereosinophilic Syndrome Syndrome

abnormal tyrosine kinase (i.e., FIP1L1-PDGFRA, JAK2 V617F). --- V617F ---

Primary Outcomes

Description: The percentage of subjects who reach and eosinophil count in the normal range

Measure: peripheral blood absolute eosinophil count.

Time: one month (for imatinib) and 3 months (for ruxolitinib).

Secondary Outcomes

Description: The % of subjects who reach an eosinophil count in the normal range

Measure: peripheral blood eosinophil count

Time: 3,6,9 and 12 months

Description: The % of subjects who reach an eosinophil count below 1500/mm3

Measure: peripheral blood eosinophil count

Time: 1, 3, 6, 9, and 12 months

Description: The % of subjects who achieve molecular remission on therapy

Measure: abnormal tyrosine kinase (i.e., FIP1L1-PDGFRA, JAK2 V617F)

Time: every 3 months for 5 years

Description: The duration of remission following cessation of therapy

Measure: clinical, hematologic and molecular remission

Time: every 3 months for 5 years

39 A Large-scale Trial Testing the Intensity of CYTOreductive Therapy to Prevent Cardiovascular Events In Patients With Polycythemia Vera (PV)

CYTO-PV is a phase III Prospective, Randomized, Open-label, with Blinded Endpoint evaluation (PROBE), multi-center, clinical trial in patients with diagnosis of Polycythemia vera (PV) treated at the best of recommended therapies (e.g.adequate control of standard cardiovascular risk factors). Irrespective of randomized interventions, all patients will be administered low-dose aspirin (when not contraindicated), i.e.the standard antithrombotic treatment in PV patients. The purpose of this study to demonstrate that a more intensive cytoreductive therapy, plus low-dose aspirin when not contraindicated, with phlebotomy and/or hydroxyurea (HU), aimed at maintaining hematocrit (HCT) < 45% is more effective than a less intensive cytoreduction (either with phlebotomy or HU plus low-dose aspirin when not contraindicated) maintaining HCT in the range of 45-50% in the reduction of CV deaths plus thrombotic events (stroke, acute coronary syndrome [ACS], transient ischemic attack [TIA], pulmonary embolism [PE], splanchnic thrombosis, deep vein thrombosis [DVT], and any other clinically relevant thrombotic event), in patients with Polycythemia Vera treated at the best of recommended therapies (e.g. adequate control of standard cardiovascular risk factors).

NCT01645124
Conditions
  1. Polycythemia Vera
Interventions
  1. Drug: Hydroxyurea
  2. Procedure: Phlebotomy
MeSH:Polycythemia Vera Polycythemia
HPO:Polycythemia

However, both pragmatic reasons and the consideration of the clinical condition under study (see: age, comorbidity, polytherapy) support the decision to adopt a generalized policy of surveillance specifically on: Hypotension or syncope after phlebotomy; renal dysfunction (creatinine); liver dysfunction (ALT, AST, symptoms); White blood cell count; Platelet count; Bleeding.. Inclusion Criteria: Males and females aged 18 years or more are eligible for the study if they meet all the following inclusion criteria: - New diagnosis of PV according to WHO 2007 diagnostic criteria including Jak 2 V617F mutation status; - Old diagnosis of PV confirmed with JAK-2 positivity and clinical course of the disease; - Ability and willingness to comply with all study requirements; - Written informed consent (obtained before any study specific procedure). --- V617F ---

Inclusion Criteria: Males and females aged 18 years or more are eligible for the study if they meet all the following inclusion criteria: - New diagnosis of PV according to WHO 2007 diagnostic criteria including Jak 2 V617F mutation status; - Old diagnosis of PV confirmed with JAK-2 positivity and clinical course of the disease; - Ability and willingness to comply with all study requirements; - Written informed consent (obtained before any study specific procedure). --- V617F ---

Primary Outcomes

Description: To demonstrate that in patients with PV treatment with aggressive cytoreductive therapy aimed at maintaining HCT < 45% is more effective than cytoreductive therapy aimed at maintaining HCT between 45 and 50% in the reduction CV deaths plus thrombotic events (PEP: stroke, acute coronary syndrome [ACS], transient ischemic attack [TIA], pulmonary embolism [PE], abdominal thrombosis, deep vein thrombosis [DVT], and peripheral arterial thrombosis). The minimum clinically relevant beneficial effect is set at a 30% reduction of risk of the PEP.

Measure: Reduction of PEP (Primary End Point)defined as CV deaths plus thrombotic events

Time: Expected average of 5 years

Secondary Outcomes

Description: The events included in the PEP, arterial and venous thrombosis, major and minor thrombosis as well as hospitalization for any reason, hospitalization for CV reason, malignancy and PV-related malignancy (progression to myelofibrosis, myelodysplastic or leukemic transformation) will be analyzed separately to assess the full benefit/risk profile of experimental treatments.

Measure: PEP plus minor thrombosis, hospitalization and malignancy

Time: Expected average of 5 years

Other Outcomes

Description: Background knowledge suggests that no specific safety precautions are to be adopted for phlebotomy and HU administration. However, both pragmatic reasons and the consideration of the clinical condition under study (see: age, comorbidity, polytherapy) support the decision to adopt a generalized policy of surveillance specifically on: Hypotension or syncope after phlebotomy; renal dysfunction (creatinine); liver dysfunction (ALT, AST, symptoms); White blood cell count; Platelet count; Bleeding.

Measure: Aadverse Events

Time: Expected average of 5 years

40 A Phase III, Randomised, Open-label, Multicenter International Trial Comparing Ruxolitinib With Either HydRoxycarbamIDe or Interferon Alpha as First Line ThErapy for High Risk Polycythemia Vera

The trial will be a phase III, randomised-controlled, multi-centre, international, open-label trial consisting of ruxolitinib versus best available therapy, where best available therapy is a choice of interferon alpha, any formulation permitted (IFN) or hydroxycarbamide (HC), and which will be elected by the Investigator prior to randomisation.

NCT04116502
Conditions
  1. Polycythemia Vera
Interventions
  1. Drug: Ruxolitinib
  2. Drug: Hydroxycarbamide
  3. Drug: Interferon-Alpha
MeSH:Polycythemia Vera Polycythemia
HPO:Polycythemia

Peripheral blood JAK2 V617F allele burden. --- V617F ---

Symptom burden/(QALY)quality of life years gained 7. Health economics including cost utility and cost effectiveness analyses 8. Peripheral blood JAK2 V617F allele burden according to ELN response criteria 9. Rates of discontinuation 10. --- V617F ---

Primary Outcomes

Description: Event Free Survival

Measure: Event Free Survival (EFS)

Time: the time from randomisation to the date of the first major thrombosis/haemorrhage, death,transformation to Myelodisplastic Syndromes, Acute Myeloid Leukaemia or Post-polycythemia Vera Myelofibrosis, if within the ~3 year trial period

Secondary Outcomes

Description: As defined in the protocol, combined and split to venous and arterial

Measure: Major thrombosis

Time: Occuring while on treatment (over 3 years)

Description: As defined in the protocol

Measure: Major haemorrhage

Time: Occuring while on treatment (over 3 years)

Description: Transformation to PPV-MF

Measure: Transformation to PPV-MF

Time: Occuring while on treatment (over 3 years)

Description: Transformation to MDS and/or AML

Measure: Transformation to MDS and/or AML

Time: Occuring while on treatment (over 3 years)

Description: As defined by ELN response criteria at 1 year

Measure: Complete Haematological remission (CHR)

Time: 1 year post-treatment

Description: As measured via MPN-SAF

Measure: Symptom burden/Quality of life (MPN-SAF)

Time: Questionnaires collected at baseline, weeks 12, 26, 39, 55, months 15, 18, 24, 30 and 36

Description: As measured via MDASI

Measure: Symptom burden/Quality of life (MDASI)

Time: Questionnaires collected at baseline, weeks 12, 26, 39, 55, months 15, 18, 24, 30 and 36

Description: As measured via EQ-5D

Measure: Symptom burden/Quality of life (EQ-5D)

Time: Questionnaires collected at baseline, weeks 12, 26, 39, 55, months 15, 18, 24, 30 and 36

Description: Including cost utility and cost effectiveness analyses as defined by the protocol (e.g. QALYs)

Measure: Health economics

Time: At the end of the trial (trial duration of approximately 8 years)

Description: According to ELN response criteria

Measure: Peripheral blood JAK2 V617F allele burden

Time: At baseline and annually throughout the trial (from baseline until approximately 3 years post-randomisation)

Description: Trial discontinuation

Measure: Rates of discontinuation

Time: From treatment prior to protocol defined 3 years

Description: collected according to CTCAE version 4.0 and the MITHRIDATE protocol

Measure: Rate and severity of adverse events

Time: Continuous throughout the trial (from randomisation until approximately 3 years post-randomisation))

Description: in patients with splenomegaly

Measure: Spleen response

Time: Response at 1 year post randomisation

Description: Time free from venesection

Measure: Time free from venesection

Time: Defined as the mean time between venesections while on trial treatment (treatment duration of 3 years)

Description: Malignancy independent to the original diagnosis

Measure: Secondary malignancy

Time: Occuring throughout the trial (from randomisation until approximately 3 years post-randomisation)

Description: Change in QRisk score

Measure: Change in QRisk score

Time: Collected at baseline and years 1, 2 and 3

Other Outcomes

Description: Progression of marrow fibrosis (bone marrow collected and analysed at the Weatherall Institute of Molecular Medicine (WIMM) in Oxford

Measure: Progression of marrow fibrosis

Time: Occuring throughout the trial (from randomisation to approximately 3 years post-randomisation)

Description: Impact of treatment on molecular signatures of disease (as analysed by the WIMM in Oxford)

Measure: Impact of treatment on molecular signatures of disease

Time: Occuring throughout the trial (from randomisation to approximately 3 years post-randomisation)

Description: within the stem/progenitor cell compartment (as analysed by the WIMM in Oxford)

Measure: Clonal involvement

Time: Occuring throughout the trial (from randomisation to approximately 3 years post-randomisation)

Description: (acquisition of additional mutations, as analysed by the WIMM in Oxford)

Measure: Clonal evolution

Time: Occuring throughout the trial (from randomisation to approximately 3 years post-randomisation)

Description: of other disease-association mutations (as analysed by the WIMM in Oxford)

Measure: Reduction of peripheral blood allele burden

Time: Occuring throughout the trial (from randomisation to approximately 3 years post-randomisation)

Description: and any change over time (as analysed by the WIMM in Oxford)

Measure: Assessment of the prevalence of clonality markers for haematological disease

Time: Occuring throughout the trial (from randomisation to approximately 3 years post-randomisation)

Description: (angina, acute coronary syndrome, acute MI; arrhythmia)

Measure: Cardiac event

Time: Occuring throughout the trial (from randomisation to approximately 3 years post-randomisation)

Description: Pulmonary hypertension as assessed clinically

Measure: Pulmonary hypertension

Time: Occuring throughout the trial (from randomisation to approximately 3 years post-randomisation)

Description: e.g. angiogram, angioplasty, CABG

Measure: Coronary intervention

Time: Occuring throughout the trial (from randomisation to approximately 3 years post-randomisation)

Description: e.g. LVEF% on ECHO/MUGA and/or NYHA classification

Measure: Deterioration in cardiac function

Time: Occuring throughout the trial (from randomisation to approximately 3 years post-randomisation)

Description: TIA, haemorrhagic CVA, non-haemorrhagic CVA

Measure: Cerebrovascular event

Time: Occuring throughout the trial (from randomisation to approximately 3 years post-randomisation)

Description: peripheral vascular disease: claudication, carotid stenosis

Measure: Arterial vascular event

Time: Occuring throughout the trial (from randomisation to approximately 3 years post-randomisation)

Description: including DVT, PE, Cerebral, splanchnic, other

Measure: Venous thrombosis

Time: Occuring throughout the trial (from randomisation to approximately 3 years post-randomisation)

Description: Pregnancy loss

Measure: Pregnancy loss

Time: Occuring throughout the trial (from randomisation to approximately 3 years post-randomisation)

41 Long-term Study Evaluating the Effect of Givinostat in Patients With JAK2V617F Positive Chronic Myeloproliferative Neoplasms

This is a multicenter, open label, long-term study testing the long-term safety, tolerability and efficacy of givinostat in patients with Polycythemia Vera, Essential Thrombocythemia, primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis following core protocols in chronic myeloproliferative neoplasms and/or patient-named compassionate use program (if regulated/allowed by the local regulations, e.g. for Italy D.M. 8/5/2003 "Uso terapeutico di medicinale sottoposto a sperimentazione clinica" published on G.U. n. 173 of 28 July 2003, and the following amendments). Patients will continue at their last tolerable dose and treatment schedule of givinostat monotherapy. If patients previously received givinostat in combination with other drugs during a core protocol or a compassionate use program (if regulated/allowed by the local regulations, e.g. for Italy D.M. 8/5/2003 "Uso terapeutico di medicinale sottoposto a sperimentazione clinica" published on G.U. n. 173 of 28 July 2003, and the following amendments), they will be treated at the last tolerable dose of the combination. Assessment of safety and efficacy will be performed at each quarterly visit and each visit will also include laboratory tests and ECG examination. During the visits the clinical benefit will be assessed by Investigator according to the revised European LeukemiaNet response criteria (for PV and ET) and EUMNET response criteria (for MF). The dose of Givinostat will be modified for protocol specified toxicities. The treatment may continue up to Marketing Authorization of givinostat, currently planned in the next 5 years (note: only for Germany, this long-term study is initially limited up to 2 years of treatment). Patients may discontinue study treatment at any time and remain on study therapy as long as they derive clinical benefit. Safety will be monitored at each visit throughout the entire duration of the study. In case the approved label will not cover the whole study population, givinostat will be provided by the Sponsor to those patients not fulfilling the criteria for the approved label of the drug that are still deriving benefit from givinostat at the time of its commercial availability.

NCT01761968
Conditions
  1. Chronic Myeloproliferative Neoplasms
Interventions
  1. Drug: givinostat
MeSH:Neoplasms Myeloproliferative Disorders
HPO:Myeloproliferative disorder Neoplasm

reduction of the allele burden of the mutated Janus Kinase 2 in the position V617F). --- V617F ---

Primary Outcomes

Description: To obtain information on the long-term efficacy of givinostat in patients with chronic myeloproliferative neoplasms following core protocols or compassionate use program: Number of patients experiencing adverse events; Type, incidence, and severity of treatment-related adverse events. To determine the long term safety and tolerability of givinostat in patients with chronic myeloproliferative neoplasms following core protocols or compassionate use program: For Polycythemia Vera and Essential Thrombocythemia, Complete response and partial response rate according to the revised clinico-haematological European LeukemiaNet response criteria; For Myelofibrosis, complete response, major response, moderate response and minor response rate according to European Myelofibrosis Network response criteria. Note that these assessment will be repeated periodically (each 3 months) during the study. In fact, the treatment will continue up to Marketing Authorisation of givinostat.

Measure: Long-term safety and efficacy

Time: 3 months

Other Outcomes

Description: To evaluate the effect of givinostat on each single response parameter according to the revised European LeukemiaNet (for Polycythemia Vera and Essential Thrombocythemia) and European European Myelofibrosis Network response criteria (for Myelofibrosis). Note that this assessment will be repeated periodically (each year) during the study. In fact, the treatment will continue up to Marketing Authorisation of givinostat.

Measure: Clinical exploratory endpoint

Time: 1 year

Description: To evaluate the molecular response (i.e. reduction of the allele burden of the mutated Janus Kinase 2 in the position V617F). Note that this assessment will be repeated periodically (each year) during the study. In fact, the treatment will continue up to Marketing Authorisation of givinostat.

Measure: Molecular exploratory endpoint

Time: 1 year

Description: To identify potential other markers predictive of clinical benefit of givinostat (e.g. potential pharmacodynamic markers). Note that this assessment will be repeated periodically (each year) during the study. In fact, the treatment will continue up to Marketing Authorisation of givinostat.

Measure: Biomolecular exploratory endpoint

Time: 1 year

42 A Phase II Single-Arm Study of the Efficacy and Safety of Oral Rigosertib in Patients With Myelofibrosis (MF) and Anemia

The goal of this clinical research study is to learn if rigosertib can help to control MF in patients with anemia. The safety of this drug will also be studied. This is an investigational study. Rigosertib is not FDA-approved or commercially available. It is currently being used for research purposes only. The study doctor can explain how the study drug is designed to work. Up to 35 participants will be enrolled in this study. All will be enrolled at MD Anderson.

NCT02730884
Conditions
  1. Leukemia
  2. Myelofibrosis
  3. Anemia
  4. Splenomegaly
Interventions
  1. Drug: Rigosertib
  2. Behavioral: Questionnaire
MeSH:Anemia Primary Myelofibrosis Splenomegaly
HPO:Anemia Splenomegaly

Measurement of JAK2 V617F allele burden in Bone Marrow (BM) samples, if not done within 6 months prior to Screening, must be provided with the Screening BM biopsy/aspirate report (patients are eligible regardless of JAK2 mutation status); 3. Anemia or RBC-transfusion dependence defined as follows: a) Anemia: defined for the purpose of this protocol as 1) a hemoglobin level <10 g/L on every determination over 84 days before study-entry, without red blood cell (RBC)-transfusions, or 2) a hemoglobin level <10 g/L on a patient that is receiving RBC-transfusions periodically but not meeting criteria for transfusion-dependent patient as defined below. --- V617F ---

Primary Outcomes

Description: Spleen response defined as ≥ 35% spleen volume reduction from Baseline, which must be confirmed by MRI or CT measurement per revised International Working Group for Myelofibrosis Research and Treatment (IWG MRT) response criteria.

Measure: Number of Participants With Spleen Volume Response

Time: Baseline and 48 weeks

Description: Anemia response defined as the proportion of transfusion-independent patients with Hgb increase of at least 2 g/dL from Baseline or the proportion of transfusion-dependent patients becoming transfusion independent for at least 12 weeks as defined in 2013 International Working Group for Myelofibrosis Research and Treatment (IWG-MRT) criteria.

Measure: Participants With Anemia Response

Time: Baseline and 48 weeks

Secondary Outcomes

Description: Symptoms response defined as the proportion of patients achieving ≥ 50% reduction in the Myeloproliferative Neoplasm Symptom Assessment Form Total Symptom Score (MPN-SAF TSS) at any time before Week 48.

Measure: Symptoms Response

Time: 48 weeks

43 An Open-Label Study of Oral CEP-701 in Patients With Polycythemia Vera or Essential Thrombocytosis With the JAK2 V617F Mutation

This is an 18-week open-label, multicenter study to evaluate the efficacy and tolerability of CEP-701 (lestaurtinib) treatment in patients with Polycythemia Vera (PV) and patients with Essential Thrombocytosis (ET).

NCT00586651
Conditions
  1. Polycythemia Vera
  2. Essential Thrombocytosis
Interventions
  1. Drug: lestaurtinib
MeSH:Polycythemia Vera Polycythemia Thrombocytosis Thrombocythemia, Essential
HPO:Polycythemia Thrombocytosis

An Open-Label Study of Oral CEP-701 in Patients With Polycythemia Vera or Essential Thrombocytosis With the JAK2 V617F Mutation. --- V617F ---

Determine whether a specific reduction in the JAK2 V617F allele has been indicated in this study.. null. --- V617F ---

- The patient has a detectable JAK2 V617F mutation. --- V617F ---

Primary Outcomes

Measure: Determine whether a specific reduction in the JAK2 V617F allele has been indicated in this study.

Time: 18 weeks +

Secondary Outcomes

Measure: - improvements in hemoglobin values, neutrophil count, and platelet count. - reduction in dose of hydroxyurea - reduction in splenic enlargement - rate of phlebotomy

Time: 18 weeks +

44 Danish Study of Low-dose Interferon Alpha Versus Hydroxyurea in the Treatment of Philadelphia Chromosome Negative (Ph-)Chronic Myeloid Neoplasms.

The purpose of the study is to compare the efficacy and toxicity including quality of life of two types of low-dose interferon alpha compounds (PegIntron and Pegasys) with hydroxyurea (Hydrea), and to investigate the occurence of neutralizing antibodies against recombinant interferon.

NCT01387763
Conditions
  1. Polycythemia Vera
  2. Essential Thrombocythemia
  3. Primary Myelofibrosis
Interventions
  1. Drug: PegIntron
  2. Drug: Pegasys
  3. Drug: PegIntron
  4. Drug: Pegasys
  5. Drug: Hydrea
MeSH:Neoplasms Polycythemia Vera Primary Myelofibrosis Polycythemia Thrombocytosis Thrombocythemia, Essential
HPO:Neoplasm Polycythemia Thrombocytosis

Molecular responses (JAK V617F allele burden) are assessed by qPCR according to the ELN guidelines.. toxicity (discontinuation of therapy due to intolerability). --- V617F ---

In 2005 major breakthrough in our understanding of the molecular pathophysiology was achieved with the identification of the JAK2 V617F mutation which is present in almost all patients with PV (98%) and about half of patients with ET and PMF. --- V617F ---

Within recent years IFN-alpha has demonstrated a capacity of inducing deep molecular remission (evaluated by JAK2 V617F qPCR) and normalisation of bone marrow morphology. --- V617F ---

If patients have a sustained deep molecular response (below 1 % JAK2 V617F mutated alleles for 12 months) therapy will be stopped to asses the sustainability of the remission off therapy.Patients over the age of 75 and intolerant or resistant to hydroxyurea will be offered rescue treatment with orally busulfan (Myleran). --- V617F ---

Primary Outcomes

Description: Molecular responses (JAK V617F allele burden) are assessed by qPCR according to the ELN guidelines.

Measure: molecular response (changes from baseline)

Time: 18, 36 and 60 months

Secondary Outcomes

Description: The proportion of patients treated with PegIntron, Pegasys and Hydrea who need to discontinue therapy due to intolerability

Measure: toxicity (discontinuation of therapy due to intolerability)

Time: 18 months

Description: Quality of life will be evaluated according to EORTC QLQ C-30 and MPN-SAF

Measure: Quality of life (changes from baseline)

Time: 4, 12, 24, 36, 48 and 60 months

Description: A bone marrow sample will be evaluated in order to detect and grade changes in bone marrow morphology.

Measure: Histopathological response (changes from baseline)

Time: 36 and 60 months

Description: investigation of the sustainability of an obtained molecular remission (< 1% JAK2V617F mutated alleles) after discontinuation of interferon- alpha( Pegasys, PegIntron, Multiferon) or Hydrea.

Measure: Sustained molecular response (changes from level at time of discontinuation of therapy)

Time: 12, 24 and 36 months

Description: Proportion of patients treated with Peintron and Pegasys who have developed neutralizing antibodies.

Measure: Neutralizing antibodies against PegIntron and Pegasys

Time: 24 months

Description: Hematological response will be evaluated according to the ELN guidelines.

Measure: hematological response

Time: 12 months

45 A Multicenter, Open Label Phase I/II Study of CEP-701 (Lestaurtinib) in Adults With Myelofibrosis

Myelofibrosis is the gradual replacement of bone marrow (place where most new blood cells are produced) by fibrous tissue which reduces the body's ability to produce new blood cells and results in the development of chronic anemia (low red blood cell count). One of the main distinctions of myelofibrosis is "extramedullary hematopoesis", the migration or traveling of the blood-forming cells out of the bones to other parts of the body, such as the liver or spleen, resulting in an enlarged spleen and liver. Treatment for myelofibrosis is unsatisfactory and there is no medication that is specifically used in the treatment of myelofibrosis. There is a protein that is found to be present in the majority of myelofibrosis patients (JAK2) and the drug Lestaurtinib is being studied to see if it will stop this protein from functioning and thereby help control the disease. This study is divided into two Phases (1 & 2). In phase 1 we will be looking for the dose of study medication (Lestaurtinib) that will be the highest dose a patient can take without experiencing serious side effects, maximum tolerated dose (MTD). In phase 2, after the MTD dose has been established in phase 1, we will be investigating how well CEP-701 (Lestaurtinib) works at suppressing the protein (JAK2). The investigators also wish to find out important biologic characteristics or features of myelofibrosis through an additional correlative biomarker study (MPD-RC #107). The correlative biomarker study is a study that is related to the main study, but is looking to answer different questions than the main study. The purpose of the biomarker study is to understand the causes of MPD and to develop improved methods for the diagnosis and treatment of these diseases, while the main study is trying to find out how well CEP-701 (Lestaurtinib) will work in treating the myeloproliferative disease.

NCT00668421
Conditions
  1. Myelofibrosis
  2. Essential Thrombocythemia
  3. Polycythemia Vera
Interventions
  1. Drug: CEP-701 (Lestaurtinib)
MeSH:Polycythemia Vera Primary Myelofibrosis Polycythemia Thrombocytosis Thrombocythemia, Essential
HPO:Polycythemia Thrombocytosis

To estimate the efficacy of a novel kinase inhibitor in subjects with myelofibrosis, as determined by a reduction in JAK2 V617F allele frequency in peripheral blood neutrophils.. null. --- V617F ---

3. The subject has a detectable JAK2 V617F mutation. --- V617F ---

Primary Outcomes

Measure: To determine the safety and maximum tolerated dose of a novel kinase inhibitor in subjects with myelofibrosis.

Time: 2 years

Measure: To estimate the efficacy of a novel kinase inhibitor in subjects with myelofibrosis, as determined by a reduction in JAK2 V617F allele frequency in peripheral blood neutrophils.

Time: 2 years

Secondary Outcomes

Measure: To estimate the incidence, severity, and attribution of treatment-emergent adverse events.

Time: 2 years

Measure: To estimate the rate of complete or major clinical-hematological response from treatment with Lestaurtinib (CEP-701) in this subject population as measured by the EUMNET response criteria.

Time: 2 years

46 A Phase 1 Study of LY2784544 in Patients With JAK2 V617F-Positive Myeloproliferative Disorders

The purpose of this study is to find out the safe dose range of the study drug in patients with myeloproliferative disorders.

NCT01134120
Conditions
  1. Myeloproliferative Disorders
  2. Thrombocythemia, Essential
  3. Polycythemia Vera
  4. Primary Myelofibrosis
Interventions
  1. Drug: LY2784544
MeSH:Polycythemia Vera Primary Myelofibrosis Polycythemia Thrombocytosis Myeloproliferative Disorders Thrombocythemia, Essential
HPO:Myeloproliferative disorder Polycythemia Thrombocytosis

A Phase 1 Study of LY2784544 in Patients With JAK2 V617F-Positive Myeloproliferative Disorders. --- V617F ---

has post-ET MF - Have a quantifiable JAK2 V617F mutation - Have discontinued all previous approved therapies for myeloproliferative disorders, including any chemotherapy, immunomodulating therapy (for example, thalidomide, interferon-alpha), immunosuppressive therapy (for example, corticosteroids greater than 10 mg/day prednisone or equivalent), radiotherapy, and erythropoietin, thrombopoietin, or granulocyte colony stimulating factor for at least 14 days and recovered from the acute effects of therapy. --- V617F ---

Primary Outcomes

Measure: Determination of a recommended Phase 2 dosing regimen

Time: Time of first dose until last dose

Measure: Number of participants with clinical significant effects

Time: Time of first dose until last dose

Secondary Outcomes

Measure: Preliminary pharmacokinetics of LY2784544 (Cmax)

Time: Part A1: Day 1,2,15, and 29; Part A2: Day 7, 14, 21, 28, 29, 56, and 57; Part B: Day 1, 29, 57, and 113

Measure: Preliminary pharmacokinetics of LY2784544 (AUC)

Time: Part A1: Day 1,2,15, and 29; Part A2: Day 7, 14, 21, 28, 29, 56, and 57; Part B: Day 1, 29, 57, and 113

Measure: Malignant clone burden

Time: Part A1: Baseline (2 times), Weeks 13, 21 and every 6 months while patient is on study; Parts A2 and B: Baseline (2 times), Weeks 5, 8, 17, 25 and every 6 months while patient is on study

47 A Phase 1 Study of Ruxolitinib, Steroids and Lenalidomide for Relapsed/Refractory Multiple Myeloma (RRMM) Patients

This is a phase 1, multicenter, open-label study evaluating the safety and efficacy of ruxolitinib, steroids and lenalidomide among MM patients who currently show progressive disease.

NCT03110822
Conditions
  1. Multiple Myeloma
Interventions
  1. Drug: Ruxolitinib Oral Tablet [Jakafi]
  2. Drug: Lenalidomide
  3. Drug: Methylprednisolone
MeSH:Multiple Myeloma Neoplasms, Plasma Cell
HPO:Multiple myeloma

The activating JAK2 V617F mutation results in uncontrolled cytokine and growth factor signaling, and is believed to play a key role in the pathophysiology of myeloproliferative neoplasms. --- V617F ---

Primary Outcomes

Description: MTD will be determined by measuring incidence of the dose-limiting toxicities (DLTs) per dose level, of ruxolitinib in combination with steroids and lenalidomide for MM patients currently with progressive disease.

Measure: Determination of maximum tolerated dose (MTD) of ruxolitinib in combination with steroids and lenalidomide [Tolerability].

Time: 30 months

Description: Safety will be measured by counting the occurrence of adverse events throughout the study, graded via Common Terminology Criteria for Adverse Events (CTCAE) v 4.03 criteria

Measure: Incidence of Treatment-Emergent Adverse Events [Safety]

Time: 54 months

Secondary Outcomes

Description: Overall response rate (ORR) is defined as CR + VGPR + PR

Measure: Overall response rate (ORR) as a measure of efficacy

Time: 54 months

Description: Clinical benefit rate is defined as ORR + MR

Measure: Clinical benefit rate (CBR) as a measure of efficacy

Time: 54 months

Description: Progression-free survival will be measured in months as the time from initiation of therapy to progressive disease or death from any cause, whichever occurs first

Measure: Progression Free Survival (PFS)

Time: 54 months

Description: Time to response, defined as the time from the initiation of therapy to the first evidence of confirmed clinical benefit defined as > minimal response (MR, including patients who achieved a complete response (CR), very good partial response (VGPR), partial response (PR), or MR

Measure: Assessment of the time to response as a measure of efficacy

Time: 54 months

Description: Duration of response, defined as the time (in months) from the first response to progressive disease

Measure: Assessment of the duration of response as a measure of efficacy

Time: 54 months

Description: Overall survival, defined as the time (in months) from initiation of therapy to death from any cause or last follow-up visit

Measure: Assessment of the overall survival (OR) as a measure of efficacy

Time: 54 months

Description: Response to initial therapy (ruxolitinib and methylprednisolone alone) will be compared to the response to therapy with addition of lenalidomide (ruxolitinib, lenalidomide, methylprednisolone)

Measure: Assessment of response in additional cohort

Time: 54 months

48 Phase 1 Study of Lentivirally Transduced T Cells Engineered to Contain Anti-CD123 Linked to TCRζ and 4-1BB Signaling Domains in Pediatric Subjects With Refractory or Relapsed Acute Myeloid Leukemia

Phase 1 open-label study to estimate the safety, manufacturing feasibility, and efficacy of intravenously administered, lentivirally transduced T cells expressing anti-CD123 chimeric antigen receptors expressing tandem TCRζ and 4-1BB (TCRζ /4-1BB) costimulatory domains in pediatric subjects with relapsed/refractory Acute Myeloid Leukemia (AML).

NCT04678336
Conditions
  1. Acute Myeloid Leukemia, in Relapse
  2. Acute Myeloid Leukemia, Pediatric
  3. Acute Myeloid Leukemia, Refractory
Interventions
  1. Biological: CART123 cells; cyclophosphamide; fludarabine
MeSH:Leukemia Leukemia, Myeloid Leukemia, Myeloid, Acute
HPO:Acute megakaryocytic leukemia Acute myeloid leukemia Leukemia Myeloid leukemia

Patients with somatic JAK2 V617F mutation by PCR or next generation sequencing. --- V617F ---

Primary Outcomes

Description: Occurrence of adverse events that are possibly, probably, or definitely related to CART123 cells

Measure: Safety of CART123 in AML subjects

Time: 5 Years

Description: Percentage of manufacturing products that meet release criteria

Measure: Manufacturing feasibility

Time: 5 Years

Secondary Outcomes

Description: Overall Response Rate (ORR) at 28 +/- 5 days Standard morphologic complete response criteria (malignant blasts < 5% with count recovery) Malignant blasts < 5% without count recovery, and Minimal residual disease assessment

Measure: Efficacy of CART123 cells in AML subjects evaluated by ORR at Day 28 using standard clinical criteria

Time: 15 Years

Description: Reduction of blast count in the peripheral blood and marrow using standard clinical criteria (CBC with differential count, marrow aspirate with differential count) and flow cytometry

Measure: Efficacy of CART123 cells in AML subjects evaluated by reduction of blast count in the peripheral blood and marrow using standard clinical criteria and flow cytometry

Time: 15 Years

Description: Overall survival (OS) and progression-free survival (PFS) and cause(s) of death for all subjects a. PFS will be followed until the time of first relapse or receipt of additional therapy, excluding alloHCT for marrow aplasia.

Measure: Overall survival (OS) and progression-free survival (PFS)

Time: 15 Years

Description: Time between date of when the response criteria of CR/CRi was met to the date of relapse

Measure: Duration of response (DOR)

Time: 15 Years

Description: Percentage of subjects proceeding to alloHCT (or second allogeneic HCT)

Measure: Need for rescue alloHCT

Time: 15 Years

Other Outcomes

Description: The duration of in vivo survival of CART123 cells ("persistence") is defined as the period of time above the limit of detection of Q-PCR for peripheral blood CART123 transgene sequences and/or flow cytometry for scFv surface expression.

Measure: Determine persistence and trafficking of CART123 cells

Time: 15 Years

49 Phase II Trial of Erlotinib in Patients With JAK-2 V617F Positive Polycythemia Vera

The primary objective of this study is to determine the overall response rate to erlotinib in patients with polycythemia vera (PV). Response rate will be assessed by improvement in the complete blood count, ultrasound of the spleen, and JAK2 molecular status. It is purposed in this study to explore a possible molecular targeting of the driving mechanism of PV.

NCT01038856
Conditions
  1. Polycythemia Vera
Interventions
  1. Drug: Erlotinib
MeSH:Polycythemia Vera Polycythemia
HPO:Polycythemia

Phase II Trial of Erlotinib in Patients With JAK-2 V617F Positive Polycythemia Vera. --- V617F ---

Trial of Erlotinib in Patients With JAK-2 V617F Positive Polycythemia Vera The primary objective of this study is to determine the overall response rate to erlotinib in patients with polycythemia vera (PV). --- V617F ---

Primary Outcomes

Measure: Overall Response Rate to Include Complete Hematological Response, Complete Molecular Response, Partial Hematological Response, and Minimal Hematological Response

Time: Day 15

Secondary Outcomes

Description: Grade 3 or grade 4 toxicities as measured by CTCAE v3.0

Measure: Incidence of Toxicities

Time: First assessment at day 15, subsequent assessments at 28 day intervals for an average of 1 year

Measure: Improvement in Splenomegaly Size

Time: 4 months, end of treatment and 12 months end of treatment

Measure: Decrease of Mutant JAK2V617F Allele Burden

Time: every 2 months until end of treatment and 12 months after end of treatment

50 A Phase II, Multicenter Study of the EZH2 Inhibitor Tazemetostat in Adult Subjects With INI1-Negative Tumors or Relapsed/Refractory Synovial Sarcoma

This is a Phase II, multicenter, open-label, single arm, 2-stage study of tazemetostat 800 mg BID (twice daily) and 1600 mg QD (once daily). Subjects will be screened for eligibility within 21 days of the planned date of the first dose of tazemetostat and enrolled into one of 8 cohorts: Cohort using tazemetostat 800 mg BID - Cohort 1 (Closed for enrollment): MRT, RTK, ATRT, and selected tumors with rhabdoid features, including small cell carcinoma of the ovary hypercalcemic type [SCCOHT], also known as malignant rhaboid tumor of the ovary [MRTO] - Cohort 2 (Closed for enrollment): Relapsed or refractory synovial sarcoma with SS18-SSX rearrangement - Cohort 3 (Closed for enrollment): Other INI1 negative tumors or any solid tumor with an EZH2 gain of function (GOF) mutation, including: epithelioid malignant peripheral nerve sheath tumor (EMPNST), extraskeletal myxoid chondrosarcoma (EMC), myoepithelial carcinoma, other INI1-negative malignant tumors with Sponsor approval (e.g., dedifferentiated chordoma) any solid tumor with an EZH2 GOF mutation including but not limited to Ewing's sarcoma and melanoma - Cohort 4 (Closed for enrollment): Renal medullary carcinoma (RMC) - Cohort 5 (Closed for enrollment): Epithelioid sarcoma (ES) - Cohort 6 (Opened for enrollment): Epithelioid sarcoma (ES) undergoing mandatory tumor biopsy - Cohort 7 (Opened for enrollment): Poorly differentiated chordoma (or other chordoma with Sponsor approval) Cohort using tazemetostat 1600 mg QD • Cohort 8 (Opened for enrollment): Epitheliod sarcoma Subjects will be dosed in continuous 28-day cycles. (Note: if treatment with study drug is discontinued prior to completing 2 years, subjects will be followed for a maximum duration of 2 years from start of study drug dosing.) Response assessment will be performed every 8 weeks while on study. Treatment with tazemetostat will continue until disease progression, unacceptable toxicity or withdrawal of consent, or termination of the study.

NCT02601950
Conditions
  1. Malignant Rhabdoid Tumors (MRT)
  2. Rhabdoid Tumors of the Kidney (RTK)
  3. Atypical Teratoid Rhabdoid Tumors (ATRT)
  4. Selected Tumors With Rhabdoid Features
  5. Synovial Sarcoma
  6. INI1-negative Tumors
  7. Malignant Rhabdoid Tumor of Ovary
  8. Renal Medullary Carcinoma
  9. Epithelioid Sarcoma
  10. Poorly Differentiated Chordoma (or Other Chordoma With Sponsor Approval)
  11. Any Solid Tumor With an EZH2 GOF Mutation
Interventions
  1. Drug: Tazemetostat
MeSH:Neoplasms Sarcoma Sarcoma, Synovial Rhabdoid Tumor Chordoma Carcinoma, Medullary Kidney Neoplasms
HPO:Chordoma Neoplasm Renal neoplasm Sarcoma Soft tissue sarcoma Synovial sarcoma

JAK2 V617F) observed in cytogenetic testing and DNA sequencing. --- V617F ---

Primary Outcomes

Measure: Number of subjects with objective response using disease appropriate standardized response criteria

Time: Assessed every 8 weeks for duration of study participation which is estimated to be 24 months

Description: The number of subjects with CR, PR, or stable disease (SD) at 16 week assessment

Measure: Progression-free survival (PFS) rate for Cohort 2 (Relapsed/Refractory Synovial Sarcoma)

Time: 16 weeks of treatment

Measure: Assess the effects of tazemetostat on tumor immune priming for Cohort 6

Time: Through study completion, an average of 2 years

Measure: Assess the safety and tolerability of tazemetostat 1600 mg QD for Cohort 8

Time: Through study completion, an average of 2 years

Secondary Outcomes

Measure: Duration of response in subjects in Cohorts 1, 2, 3, 4, 5, 6 and 7 and in Cohorts 1, 3, 4, 5, 6 and 7 combined for subjects achieving a complete response (CR) and partial response (PR) following oral administration of tazemetostat 800 mg BID

Time: Assess every 8 weeks for duration of study participation which is estimated to be 24 months

Description: The number of subjects with confirmed CR, PR or SD at 32 week assessment

Measure: Disease control rate (DCR) in subjects with epithelioid sarcoma (Cohort 5) and epithelioid sarcoma undergoing mandatory biopsy (Cohort 6) following oral administration of tazemetostat 800 mg BID

Time: 32 weeks of treatment

Description: ORR (confirmed CR+PR, RECIST 1.1)

Measure: Overall response rate ORR for Cohort 2 (relapsed/refractory synovial sarcoma) and Cohort 6 (epithelioid sarcoma undergoing mandatory biopsy) following oral administration of tazemetostat 800 mg BID

Time: Assessed every 8 weeks for duration of study participation which is estimated to be 24 months

Description: The time from date of first dose of study treatment to the earlier of the date of first documented disease progression or date of death due to any cause

Measure: PFS for each cohort

Time: 24, 32 and 56 weeks of treatment

Description: The time from the date of the first dose of study treatment to the date of death due to any cause

Measure: OS for each cohort

Time: 24, 32 and 56 weeks of treatment

Measure: Incidence of treatment-emergent adverse events as a measure of safety and tolerability

Time: Adverse events assessed from first dose through 30 days post last dose

Measure: Pharmacokinetics profile of tazemetotstat and its metabolite (plasma): Cmax

Time: Days 1 and 15

Measure: Pharmacokinetics profile of tazemetotstat and its metabolite (plasma): Tmax

Time: Days 1 and 15

Measure: Pharmacokinetics profile of tazemetotstat and its metabolite (plasma): AUC(0-t)

Time: Days 1 and 15

Measure: Pharmacokinetics profile of tazemetotstat and its metabolite (plasma): AUC(0-12)

Time: Days 1 and 15

Measure: Pharmacokinetics profile of tazemetotstat and its metabolite (plasma): t1/2

Time: Days 1 and 15

Measure: Pharmacokinetics profile of tazemetotstat and its metabolite (plasma): CL/F

Time: Days 1, 15, 29, 43, and 57

Measure: Pharmacokinetics profile of tazemetotstat and its metabolite (plasma): Vd/F

Time: Days 1, 15, 29, 43, and 57

Measure: Pharmacokinetics profile of tazemetotstat and its metabolite (plasma): Ka

Time: Days 1, 15, 29, 43, and 57

Measure: Pharmacokinetics profile of tazemetotstat and its metabolite (plasma): Ctrough

Time: Days 29, 43 and 57

Description: IHC assessments of changes in the level of H3K27-Me3 following tazemetostat dosing

Measure: Investigate the pharmacodynamics (PD) effects of tazemetostat in tumor tissue

Time: At week 8

Measure: Duration of response in subjects with epithelioid sarcoma in Cohort 8 at 1600 mg QD.

Time: Assess every 8 weeks for duration of study participation which is estimated to be 24 months

Description: The number of subjects with confirmed CR, PR or SD at 32 week assessment

Measure: Disease control rate (DCR) in subjects with epithelioid sarcoma (Cohort 8) following oral administration of tazemetostat 1600 mg QD

Time: 32 weeks of treatment

Description: ORR (confirmed CR+PR, RECIST 1.1)

Measure: Overall response rate ORR for subjects with epithelioid sarcoma (Cohort 8) following oral administration of tazemetostat 1600 mg QD

Time: Assessed every 8 weeks for duration of study participation which is estimated to be 24 months

51 A Phase 1 Study of the EZH2 Inhibitor Tazemetostat in Pediatric Subjects With Relapsed or Refractory INI1-Negative Tumors or Synovial Sarcoma

This is a Phase I, open-label, dose escalation and dose expansion study with BID (suspension) and TID (tablet) oral dose of tazemetostat. Subjects will be screened for eligibility within 14 days of the planned first dose of tazemetostat. A treatment cycle will be 28 days. Response assessment will be evaluated after 8 weeks of treatment and subsequently every 8 weeks while on study. The study has two parts: Dose Escalation and Dose Expansion. Dose escalation for subjects with the following relapsed/refractory malignancies: - Rhabdoid tumors: - Atypical teratoid rhabdoid tumor (ATRT) - Malignant rhabdoid tumor (MRT) - Rhabdoid tumor of kidney (RTK) - Selected tumors with rhabdoid features - INI1-negative tumors: - Epithelioid sarcoma - Epithelioid malignant peripheral nerve sheath tumor - Extraskeletal myxoid chondrosarcoma - Myoepithelial carcinoma - Renal medullary carcinoma - Other INI1-negative malignant tumors (e.g., dedifferentiated chordoma) (with Sponsor approval) - Synovial Sarcoma with a SS18-SSX rearrangement Dose Expansion at the MTD or the RP2D - Cohort 1 -(closed to enrollment) ATRT - Cohort 2 - MRT/RTK/selected tumors with rhabdoid features - Cohort 3 - INI-negative tumors: - Epithelioid sarcoma - Epithelioid malignant peripheral nerve sheath tumor - Extraskeletal myxoid chondrosarcoma - Myoepithelial carcinoma - Renal medullary carcinoma - Chordoma (poorly differentiated or de-differentiated) - Other INI1-negative malignant tumors (e.g., dedifferentiated chordoma) with Sponsor approval - Cohort 4 -(closed to enrollment) Tumor types eligible for Cohorts 1 through 3 or synovial sarcoma with SS18-SSX rearrangement

NCT02601937
Conditions
  1. Rhabdoid Tumors
  2. INI1-negative Tumors
  3. Synovial Sarcoma
  4. Malignant Rhabdoid Tumor of Ovary
Interventions
  1. Drug: Tazemetostat
MeSH:Neoplasms Sarcoma Sarcoma, Synovial Rhabdoid Tumor
HPO:Neoplasm Sarcoma Soft tissue sarcoma Synovial sarcoma

JAK2 V617F) observed in cytogenetic testing and DNA sequencing. --- V617F ---

Primary Outcomes

Description: The incidence and severity of treatment-emergent adverse events (AEs) qualifying as protocol-defined DLTs in Cycle 1 will guide establishment of the protocol defined RP2D and/or MTD

Measure: To determine the MTD or the RP2D (Dose Escalation)

Time: 1 cycle/28 days

Measure: Dose expansion: Number of subjects with objective response using disease appropriate standardized response criteria

Time: Assessed every 8 weeks for duration of study participation which is estimated to be 24 months

Secondary Outcomes

Measure: Dose escalation: Number of subjects with objective response using disease appropriate standardized response criteria

Time: Assessed every 8 weeks for duration of study participation which is estimated to be 24 months

Measure: Dose Expansion: Progression-free survival (PFS)

Time: At 24 and 56 weeks post treatment using Kaplan-Meier method

Measure: Dose Expansion: Overall Survival (OS)

Time: At 24 and 56 weeks post treatment using Kaplan-Meier method

Measure: Incidence of treatment-emergent adverse events as a measure of safety and tolerability

Time: Adverse events assessed from first dose through 30 days post last dose

Measure: Pharmacokinetics profile of tazemetostat and its metabolite (plasma): Cmax

Time: Days 1 and 15

Measure: Pharmacokinetics profile of tazemetostat and its metabolite (plasma): Tmax

Time: Days 1 and 15

Measure: Pharmacokinetics profile of tazemetostat and its metabolite (plasma): AUC(0-t)

Time: Days 1 and 15

Measure: Pharmacokinetics profile of tazemetostat and its metabolite (plasma): AUC(0-12)

Time: Days 1 and 15

Measure: Pharmacokinetics profile of tazemetostat and its metabolite (plasma): t1/2

Time: Days 1 and 15

Measure: Pharmacokinetics profile of tazemetostat and its metabolite (plasma): CL/F

Time: Day 15

Measure: Pharmacokinetics profile of tazemetostat and its metabolite (plasma): Vd/F

Time: Day 15

Measure: Pharmacokinetics profile of tazemetostat and its metabolite (plasma): Ka

Time: Day 15

Measure: Pharmacokinetics profile of tazemetostat and its metabolite (plasma): Ctrough

Time: Day 1 of cycles 2, 3 and 4

52 JAK2 Mutation May Predict Response and Guide First Line Treatment in Rheumatoid Arthritis

This study included 76 newly diagnosed RA patients and 50 matched controls. Basal JAK2 mutation was assessed by PCR in blood samples, TNF-α and IL 6 were measured by ELISA in serum of patients and controls. All patients started therapy with conventional synthetic DMARDs (including methotrexate). Response assessment at 3rd month was evaluated by DAS28 and ACR response criteria. JAK2 mutation was correlated with different clinical and laboratory parameters of patients.

NCT04667988
Conditions
  1. Response Assessment in Newly Diagnosed RA Patients at 3rd Month Was Evaluated by DAS28 and ACR in Relation to JAK Expression
Interventions
  1. Diagnostic Test: JAK expression
MeSH:Arthritis Arthritis, Rheumatoid
HPO:Arthritis Polyarticular arthritis Rheumatoid arthritis

Impact of pretreatment JAK2 mutation on response of Rheumatoid Arthritis patients to first line csDMARDS.. Inclusion Criteria: - New case RA patients - good liver and renal function Exclusion Criteria: - Other autoimmune diss - Malignancy - Active viral infection - pregnancy and lactation Inclusion Criteria: - New case RA patients - good liver and renal function Exclusion Criteria: - Other autoimmune diss - Malignancy - Active viral infection - pregnancy and lactation Response Assessment in Newly Diagnosed RA Patients at 3rd Month Was Evaluated by DAS28 and ACR in Relation to JAK Expression Arthritis Arthritis, Rheumatoid PCR detection of the JAK-2 V617F mutation using ASO specific PCR Genetic marker: The detection of jak2 V617F mutation were done by using the following primers (JAK2 Reverse: 5' CTGAATAGTCCTACAGTGTTTTCAGTTTCA 3', JAK2 Forward (specific): 5' AGCATTTGGTTTTAAATTATGGAGTATATT 3' and JAK2 Forward (internal control): 5' ATCTATAGTCATGCTGAAAGTAGGAGAAAG 3'). --- V617F ---

Impact of pretreatment JAK2 mutation on response of Rheumatoid Arthritis patients to first line csDMARDS.. Inclusion Criteria: - New case RA patients - good liver and renal function Exclusion Criteria: - Other autoimmune diss - Malignancy - Active viral infection - pregnancy and lactation Inclusion Criteria: - New case RA patients - good liver and renal function Exclusion Criteria: - Other autoimmune diss - Malignancy - Active viral infection - pregnancy and lactation Response Assessment in Newly Diagnosed RA Patients at 3rd Month Was Evaluated by DAS28 and ACR in Relation to JAK Expression Arthritis Arthritis, Rheumatoid PCR detection of the JAK-2 V617F mutation using ASO specific PCR Genetic marker: The detection of jak2 V617F mutation were done by using the following primers (JAK2 Reverse: 5' CTGAATAGTCCTACAGTGTTTTCAGTTTCA 3', JAK2 Forward (specific): 5' AGCATTTGGTTTTAAATTATGGAGTATATT 3' and JAK2 Forward (internal control): 5' ATCTATAGTCATGCTGAAAGTAGGAGAAAG 3'). --- V617F --- --- V617F ---

Primary Outcomes

Description: Impact of pretreatment JAK2 mutation on response of Rheumatoid Arthritis patients to first line csDMARDS.

Measure: JAK2 mutation expression in newly diagnosed RA patients

Time: 6 months

53 A Phase 2 Study Of Ruxolitinib In Low-Risk Essential Thrombocythemia And Polycythemia Vera With Significant Symptom Burden

This research is being done to see if the drug ruxolitinib is effective in reducing the symptoms caused by low-risk essential thrombocythemia (ET) and polycythemia vera (PV). - This research study involves the study drug Ruxolitinib.

NCT04644211
Conditions
  1. Essential Thrombocythemia
  2. Polycythemia Vera
Interventions
  1. Drug: Ruxolitinib
MeSH:Polycythemia Vera Polycythemia Thrombocytosis Thrombocythemia, Essential
HPO:Polycythemia Thrombocytosis

Exclusion Criteria: - Essential thrombocythemia patients who are high risk by IPSET-R criteria (age > 60 with JAK2 V617F mutation and/or history of thrombosis).1 Polycythemia vera patients who are high risk by NCCN guidelines (age > 60 and/or history of thrombosis). --- V617F ---

Primary Outcomes

Description: Percentage of patients with >50% change in Myeloproliferative Neoplasm Symptom Assessment Total Symptom Score (MPN-SAF TSS), which has use in major clinical trials and as symptom assessment in all patients in clinical practice. Modeling has established baseline MPN-SAF TSS cut-off scores (total MPN-SAF TSS >20 or an individual component score >5) at which symptomatic treatment would be significantly beneficial

Measure: Percentage of patients who achieve >50% reduction from baseline to Myeloproliferative Neoplasm Symptom Assessment Total Symptom Score

Time: baseline to 12 weeks

Secondary Outcomes

Description: Evaluate the efficacy of ruxolitinib in improving hematologic remission rates, as measured by International Working Group (IWG) working criteria ET: Platelet count ≤ 400 x 109/L, WBC count <10 x 109/L, and absence of leukoerythroblastosis PV: hematocrit <45% and WBC count <10 x 109/L

Measure: Proportion of patients achieving complete hematologic rate at week 12

Time: Week 12

Description: Evaluate the efficacy of ruxolitinib in improving hematologic remission rates, as measured by International Working Group (IWG) working criteria ET: Platelet count ≤ 400 x 109/L, WBC count <10 x 109/L, and absence of leukoerythroblastosis PV: hematocrit <45% and WBC count <10 x 109/L

Measure: Proportion of patients achieving complete hematologic rate at 24 Weeks

Time: Week 24

Description: Myeloproliferative Neoplasm Symptom Assessment Total Symptom Score (MPN-SAF TSS) for use in major clinical trials and as symptom assessment in all patients in clinical practice. Modeling has established baseline MPN-SAF TSS cut-off scores (total MPN-SAF TSS >20 or an individual component score >5) at which symptomatic treatment would be significantly beneficial. Scale title includes absence of symptom (0) and worst imaginable symptoms (10) per question, with minimum score 0 and maximum score 100. Higher scores indicate worse outcomes.

Measure: Best MPN-SAF TSS score

Time: 12 Weeks

Description: Myeloproliferative Neoplasm Symptom Assessment Total Symptom Score (MPN-SAF TSS) for use in major clinical trials and as symptom assessment in all patients in clinical practice. Modeling has established baseline MPN-SAF TSS cut-off scores (total MPN-SAF TSS >20 or an individual component score >5) at which symptomatic treatment would be significantly beneficial. . Scale title includes absence of symptom (0) and worst imaginable symptoms (10) per question, with minimum score 0 and maximum score 100. Higher scores indicate worse outcomes.

Measure: Best MPN-SAF TSS score

Time: 24 Weeks

Description: Spleen volume reduction will be measured as the change in percentage spleen volume from baseline at 12 weeks as measured by CT, or MRI in patients with medical contraindication to CT. Summary statistics will be used to describe changes in spleen volume. Volume will be calculated by a computer-assisted perimeter method based on Sorenson et al. Spleen and liver volume will be obtained by outlining the circumference of the organ and determining the volume using the validated technique of least squares

Measure: Percentage of change in Spleen Volume

Time: baseline to 12 weeks

Description: descriptions and grading scales found in the revised NCI Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 will be utilized for AE reporting

Measure: Number of Participants with Treatment Related Adverse Events as Assessed by CTCAE v 5.0

Time: All patients who initiate treatment with study drug up to 60 months

54 Natural Killer Cells and Polycythemia Vera (Vaquez's Disease)

Natural Killer cells (NK) are pivotal cells of innate immunity, that sense defective expression of HLA class I molecules and are complementary to specific cytotoxic T lymphocytes. A defect in NK cell cytotoxicity has been described in some hematopoietic malignancies such as acute myeloid leukemia, multiple myeloma, myelodysplastic syndroms. This defect is at least partially linked to a decreased or absent expression of some activating NK cell molecules, more particularly the so-called Natural Cytotoxicity Receptors (NCRs) NKp30, NKp44 and NKp46. Some old publications have demonstrated defective NK cytotoxicity in myeloproliferative syndroms (chronic myeloid leukemia, primary thrombocytosis, polycythemia vera). The investigators more particularly focused their attention on polycythemia vera (Vaquez's disease), a myeloproliferative disease characterized by the recently describet mutation V617F of the JAK2 tyrosine kinase. The investigators will precise the mechanisms leading to this cytotoxicity defect, the investigators also will evaluate the implication of V617F mutation on NK physiology, and will study the interactions between NK cells and hematopoietic progenitors.

NCT01284712
Conditions
  1. Polycythemia Vera
Interventions
  1. Biological: blood sample
MeSH:Polycythemia Vera Polycythemia
HPO:Polycythemia

The investigators more particularly focused their attention on polycythemia vera (Vaquez's disease), a myeloproliferative disease characterized by the recently describet mutation V617F of the JAK2 tyrosine kinase. --- V617F ---

The investigators will precise the mechanisms leading to this cytotoxicity defect, the investigators also will evaluate the implication of V617F mutation on NK physiology, and will study the interactions between NK cells and hematopoietic progenitors. --- V617F ---

Primary Outcomes

Measure: To describe immunologic anomalies in polycythemia vera

Time: 2 years

55 A Phase IIA Study of the Histone-deacetylase Inhibitor ITF2357 in Patients With JAK-2 V617F Positive Chronic Myeloproliferative Diseases

Primary Objective: To evaluate efficacy and safety of ITF2357 in the treatment of patients with JAK2V617F positive myeloproliferative diseases [Polycythemia Vera (PV), Essential Thrombocytosis (ET), Myelofibrosis (MF)]. Efficacy was evaluated by ad hoc haematological and clinical criteria for PV and ET, and by internationally established response criteria (EUMNET criteria) for MF. Safety was evaluated by number of subjects experiencing an Adverse Event (AE), type, frequency, severity, timing and relatedness of AEs, including changes in vital signs and clinical laboratory results. Secondary Objective: To evaluate the JAK2 mutated allele burden by quantitative Real-Time Polymerase Chain Reaction (qRTPCR).

NCT00606307
Conditions
  1. Myeloproliferative Diseases
Interventions
  1. Drug: ITF2357
MeSH:Myeloproliferative Disorders
HPO:Myeloproliferative disorder

A Phase IIA Study of the Histone-deacetylase Inhibitor ITF2357 in Patients With JAK-2 V617F Positive Chronic Myeloproliferative Diseases. --- V617F ---

Phase IIA Study of the HDAC Inhibitor ITF2357 in Patients With JAK-2 V617F Positive Chronic Myeloproliferative Diseases Primary Objective: To evaluate efficacy and safety of ITF2357 in the treatment of patients with JAK2V617F positive myeloproliferative diseases [Polycythemia Vera (PV), Essential Thrombocytosis (ET), Myelofibrosis (MF)]. --- V617F ---

A serious AE (SAE) is defined as an untoward (unfavourable) medical occurrence that at any dose results in death, or is life-threatening or requires inpatient hospitalisation or prolongation of existing hospitalisation, or results in persistent or significant disability/incapacity or is a congenital anomaly/birth defect.. Inclusion Criteria: - Signed Informed Consent Form - Male or female, age ≥ 18 years - Confirmed diagnosis of PV/ET/MF according to the revised World Health Organisation criteria - JAK-2 V617F positivity - In need of cytoreductive therapy when hydroxyurea is not indicated (e.g. --- V617F ---

positive serology IgM) - Known HIV infection - Active hepatitis B and/or C infection - History of other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates use of an investigational drug or that might affect interpretation of the results of the study or render the subject at high risk from treatment complications - Eastern Cooperative Oncology Group (ECOG) performance status 3 or greater - Platelets count <100x109/L within 14 days before enrolment - Absolute neutrophil count <1.2x109/L within 14 days before enrolment - Percentage of blast cells in peripheral blood >10% within 14 days before enrolment - Serum creatinine >2xULN (Upper limit of normal) - Total serum bilirubin >1.5xULN - Serum AST (aspartate aminotransferase) / ALT (alanine aminotransferase) > 3xULN - Interferon alpha within 14 days before enrolment - Hydroxyurea within 14 days before enrolment - Anagrelide within 7 days before enrolment - Any other investigational drug within 28 days before enrolment Inclusion Criteria: - Signed Informed Consent Form - Male or female, age ≥ 18 years - Confirmed diagnosis of PV/ET/MF according to the revised World Health Organisation criteria - JAK-2 V617F positivity - In need of cytoreductive therapy when hydroxyurea is not indicated (e.g. --- V617F ---

Primary Outcomes

Description: Patients with Objective Response were defined as those patients achieving a complete, major, moderate or minor (only for Myelofibrosis patients) response during the experimental treatment course. The "best response" is reported hereunder by intensity of response.

Measure: Number of Patients With Objective Responses (Complete, Major, Moderate or Minor Responses), in Terms of Best Overall Response

Time: Every single week from week 1 to week 24 of treatment

Secondary Outcomes

Description: This outcome was assessed by quantitative real time Polymerase Chain Reaction (RT PCR). At each time point, the number of patients is the following: Screening: N=29 Week 12: N=20 Week 24: N=18 EOT: N=24. End of treatment corresponds to the last visit performed before treatment discontinuation.

Measure: Change in JAK2 Mutated Allele Burden

Time: At screening, at week 12, at week 24, at the end of treatment (EOT) visit

Description: An adverse event (AE) is any untoward occurrence in a patient or clinical investigation subject administered with a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An AE can therefore be any unfavourable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. The adverse events must to be followed to the end of study (28 days after the last study drug intake). A serious AE (SAE) is defined as an untoward (unfavourable) medical occurrence that at any dose results in death, or is life-threatening or requires inpatient hospitalisation or prolongation of existing hospitalisation, or results in persistent or significant disability/incapacity or is a congenital anomaly/birth defect.

Measure: Number of Subject Experiencing an Adverse Event

Time: At weekly visits (Days 8, 15, 22, 36, 43, 50, 64, 71, 78, 99, 127, 155); At monthly visits (Days 29, 57, 85 113, 141,169); at end of treatment visit

56 Risk Factors for Variceal Bleeding in Egyptian Patients With Non-Cirrhotic Portal Hypertension

Background & Aims: Non-cirrhotic portal hypertension (NCPH) represents a relatively infrequent group of conditions. This work aimed at determining causes of NCPH and evaluating the role of some clinical, laboratory, imaging and endoscopic parameters in prediction of variceal bleeding in an Egyptian cohort with NCPH. Methods: Sixty patients with non-cirrhotic portal hypertension and oesophageal varices were included. All underwent complete clinical evaluation, laboratory investigations, Color Doppler ultrasonography, platelet count/spleen diameter (mm) ratio and upper gastrointestinal endoscopy. Patients were classified into two groups according to variceal bleeding: (1) Group I: twenty six patients with history of bleeding or had an attack of bleeding during one year follow-up; and (2) Group II: thirty four patients without bleeding.

NCT02635815
Conditions
  1. Portal Hypertension
Interventions
  1. Procedure: Upper gastrointestinal endoscopy
MeSH:Hypertension, Portal Hypertension
HPO:Hypertension Portal hypertension

It was done only for patients with Budd-Chiari syndrome and extrahepatic portal vein thrombosis: anticardiolipin antibodies, lupus anticoagulant, antinuclear antibodies, protein C, S, antithrombin III, factor V Leiden G1691A mutation, prothrombin gene G20210A mutation, methylene tetrahydrofolate reductase C677T mutation by PCR, Janus tyrosine kinase-2 (JAK II) V617F mutation by PCR (to exclude myeloproliferative disorders) and flow cytometry for CD55 and CD59 (to exclude paroxysmal nocturnal hemoglobinuria); (4) Abdominal ultrasonography: for liver size, echogenicity, spleen size, portal vein diameter and ascites; (5) Color Doppler ultrasonographic study: was done in the morning after an overnight fasting using a color Doppler unit with a 3.5 MHz convex probe for confirmation of portal vein (PV) patency and diameter, mean PV flow velocity (mean PVV) (cm/sec), PV direction of flow, splenic vein patency and diameter, presence of portosystemic collaterals and patency of hepatic veins; (6) Platelet count/spleen diameter ratio: calculated as: platelet count/ maximum spleen bipolar diameter by ultrasound in mm; (7) Ultrasonography guided liver biopsy: for diagnosis of NCPH and exclusion of cirrhotic portal hypertension; and (8) Upper gastrointestinal endoscopy using the Pentax video endoscope EG 3440. --- G1691A --- --- G20210A --- --- C677T --- --- V617F ---

Primary Outcomes

Measure: The presence or absence of variceal bleeding within one year of follow up.

Time: 1 year

57 A Phase I Study of Oral Arsenic Trioxide With or Without Ascorbic Acid in Adults With Myelofibrosis

This phase I trial studies the side effects and best dose of arsenic trioxide with or without ascorbic acid in treating patients with myelofibrosis. Drugs used in chemotherapy, such as arsenic trioxide, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving arsenic acid together with ascorbic acid may kill more cancer cells.

NCT01014546
Conditions
  1. Essential Thrombocythemia
  2. Polycythemia Vera
  3. Primary Myelofibrosis
Interventions
  1. Drug: Arsenic Trioxide
  2. Dietary Supplement: Ascorbic Acid
  3. Other: Laboratory Biomarker Analysis
  4. Other: Pharmacological Study
MeSH:Polycythemia Vera Primary Myelofibrosis Polycythemia Thrombocytosis Thrombocythemia, Essential
HPO:Polycythemia Thrombocytosis

To estimate the efficacy of arsenic trioxide with ascorbic acid in subjects with myelofibrosis, as determined by a reduction in Janus kinase 2 (JAK2) V617F, JAK22T875N, and mutations of the thrombopoietin receptor (MPL515L/K) allele frequency in peripheral blood neutrophils. --- V617F ---

Primary Outcomes

Description: The frequency of toxicities will be tabulated by grade across all dose levels and courses. The frequency of toxicities will also be tabulated for the dose chosen as the MTD.

Measure: Adverse events, and their attribution throughout the study

Time: Up to 30 days post-treatment

Description: DLT is defined as any non-hematologic treatment-emergent grade 3 or greater adverse event deemed possibly, probably, or definitely related to the study drug. Exceptions are grade 3 nausea or vomiting, unless in the setting of maximal antiemetic treatment. Hematologic toxicities are not included in the definition of a DLT. The frequency of toxicities will be tabulated by grade across all dose levels and cycles.

Measure: Dose-limiting toxicity (DLT) as assessed by the National Cancer Institute (NCI) Common Toxicity Criteria (CTC) version 3.0 (Stage 1)

Time: At 28 days

Description: The frequency of toxicities will be tabulated by grade across all dose levels and cycles. The frequency of toxicities will also be tabulated for the dose chosen as the MTD.

Measure: Maximum tolerated dose (MTD), defined as the dose level at which 0 or 1 of 6 subjects experience DLT, and 2 of 3 or 2 of 6 experience DLT at the next higher dose level, assessed by the NCI CTC version 3.0 (Stage 1)

Time: At 28 days

Secondary Outcomes

Measure: Change in absolute number of circulating CD34+ cells in the peripheral blood (Stage 2 only)

Time: Baseline to 24 weeks

Measure: Change in JAK2/MPL (Stage 2 only)

Time: Baseline to 24 weeks

Description: Including: sVCAM-1, NE, MMP-2, MMP-9, SDF-1, TGF-B, and VEGF.

Measure: Change in plasma levels of chemokines as measured by ELISA (Stage 2)

Time: Baseline to 24 weeks

Description: Including: sVCAM-1, NE, MMP-2, MMP-9, SDF-1, TGF-B, and VEGF.

Measure: Change in plasma levels of cytokines as measured by ELISA (Stage 2)

Time: Baseline to 24 weeks

Description: Including: soluble vascular cell adhesion molecule 1 (sVCAM-1), neutrophil elastase (NE), matrix metalloproteinases 2 and 9 (MMP-2 and MMP-9), stromal cell derived growth factor-1 (SDF-1), TGF-B, and VEGF.

Measure: Change in plasma levels of proteases as measured by enzyme-linked immunosorbent assay (ELISA) (Stage 2)

Time: Baseline to 24 weeks

Measure: Disease response assessed using the IWG-MRT response criteria

Time: Up to 24 weeks

58 Extension Study After Completion of Phase 2 Single Arm Study of Efficacy and Safety of P1101 for Polycythemia Vera (PV) Patients for Whom the Current Standard of Treatment is Difficult to Apply (Study A19-201)

This is an extension study after completion of Phase 2 single arm study to investigate efficacy and safety of P1101 for adult Japanese patients with PV.

NCT04655092
Conditions
  1. Polycythemia Vera (PV)
Interventions
  1. Biological: P1101 (Rropeginterferon alfa-2b)
MeSH:Polycythemia Vera Polycythemia
HPO:Polycythemia

Changes in JAK2 V617F mutant allelic burden value every 52 weeks over time. --- V617F ---

Primary Outcomes

Description: CHR will be defined as follows. Hematocrit <45% phlebotomy-free (absence of phlebotomy during the previous 12 weeks) Platelet count ≤ 400 x 10^9/L WBC count ≤ 10 x 10^9/L

Measure: Maintenance rate of phlebotomy-free complete hematologic response (CHR) every 52 weeks

Time: Through study completion, an average of 2 year

Secondary Outcomes

Description: Baseline is defined as Week 52 in Study A19-201

Measure: Changes in hematocrit every 52 weeks over time

Time: Through study completion, an average of 2 year

Description: Baseline is defined as Week 52 in Study A19-201

Measure: Changes in white blood cell every 52 weeks over time

Time: Through study completion, an average of 2 year

Description: Baseline is defined as Week 52 in Study A19-201

Measure: Changes in platelet count every 52 weeks over time

Time: Through study completion, an average of 2 year

Description: Baseline is defined as Week 52 in Study A19-201

Measure: Changes in red blood cell count every 52 weeks over time

Time: Through study completion, an average of 2 year

Description: Baseline is defined as Week 52 in Study A19-201

Measure: Changes in spleen size every 52 weeks over time

Time: Through study completion, an average of 2 year

Description: Baseline is defined as Week 52 in Study A19-201

Measure: Necessity of phlebotomy

Time: Through study completion, an average of 2 year

Description: Baseline is defined as Week 52 in Study A19-201

Measure: Proportion of subjects without thrombotic or hemorrhagic events

Time: Through study completion, an average of 2 year

Description: Baseline is defined as Week 52 in Study A19-201

Measure: Changes in JAK2 V617F mutant allelic burden value every 52 weeks over time

Time: Through study completion, an average of 2 year

Other Outcomes

Description: Bone marrow histological remission was defined as the disappearance of hypercellularity and trilineage growth (panmyelosis), and absence of >grade 1 reticulin fibrosis in the subjects who gave informed consent in Study A19-201

Measure: Bone marrow histological remission (optional)

Time: Through study completion, an average of 2 year


HPO Nodes


HP:0002664: Neoplasm
Genes 1522
SF3B1 GFI1B IGF2 FIBP RPS7 WT1 COL7A1 TREX1 HSPG2 CASP8 SLC22A18 MC1R TFE3 KRAS PLAG1 OFD1 BRAF NUMA1 KRT16 PSENEN CTPS1 APC SOX9 FANCM OPCML CDKN2A RPS15A CTNNB1 SDHD EDN3 FCN3 NELFA GJC2 MALT1 HPGD GLI1 CD70 SPINK1 LETM1 PMS1 LRP5 HNF1B EXT1 TCF4 ELMO2 MET ANTXR1 KRT16 KRT10 PAX4 SETBP1 TERT WT1 SMARCB1 GJB6 HRAS STK11 BUB1B GNPTAB MYD88 MCC GJB2 BRCA1 TP63 PDGFRL TARS1 NF1 FGFR3 KARS1 BARD1 BRIP1 GATA2 IL1RN BRAF CD81 TNFRSF13B TYROBP AR LIG4 KLF11 ABL1 MVK BMPR1A PIK3CA B3GALT6 SLC37A4 SOS1 TSC1 FGFR3 ATRX FANCG TET2 KIT SRP72 MPL TP53 SMAD4 EVC2 MAPRE2 DLST BRCA1 DICER1 HRAS AKT1 RNR1 TSC1 TNPO3 XRCC4 DNMT3A NEUROD1 THPO MN1 NOD2 SRSF2 PPM1D FLT4 ATP7A IL7 KRAS GDNF WNT10A EPAS1 COL1A1 IL1B MRAP ADAMTS3 PRKCD SUFU PTCH1 ERCC3 KRT14 CXCR4 HOXD13 IGF2 LIG4 PALB2 BLM NRAS ERCC3 FOXP1 SDHD TP53 PKD2 PDX1 TINF2 ADA2 MYF6 RHBDF2 POU6F2 PHKG2 CDKN2A RUNX1 ERCC2 MAP2K2 WT1 USB1 GATA4 FGFR2 ACD CR2 MUTYH ARL6IP6 FAH MSH2 RASA1 NEK1 SOX6 NR0B1 LIG4 CDKN2B NF1 NF1 POLE RPL35 SRY SDHAF2 FANCL CPLX1 FAS PRKAR1A PHB SDHA CALR PIK3R1 FAN1 TET2 TMEM216 RSPO1 SEMA3D MDM4 SDHD HRAS NUP214 GJA1 PIK3CA CCND1 RNF6 MSH2 C11ORF95 MVK MCM4 FLI1 TINF2 KIAA0753 ECM1 ARSA ERCC2 SOX2 SDHC SLC26A2 MPL VANGL1 PUF60 RAD51D POT1 CR2 ESCO2 FOXE1 PMVK SRY GJB4 TRIM37 KIT EXT2 PDGFB KIF1B FANCF IGF2R MLH1 GDNF PIK3CA ASCC1 ASCL1 TCIRG1 APPL1 RPS19 BCL10 IGF2 NRAS FLT3 STAT1 BCL10 RMRP GNAI3 KRAS GPR101 BAP1 NKX2-1 MAX BMPR1A DDB2 SMARCB1 RAD51 FGFR3 ALX4 BTK MSH6 NOTCH3 DICER1 CXCR4 CCBE1 RET WT1 TP53 PALLD RNASEH2B WT1 ATR CCND1 KCNQ1OT1 SMAD4 AHCY STK11 FANCC TRNK BCL6 SMAD4 SKIV2L HMBS TP53 TERT PHOX2B SNAI2 BRAF TCOF1 FANCI NRAS REST SDHC HBB HFE CREBBP MET SEC23A CEP57 CTLA4 TRIM28 SMAD7 GNAS BRCA2 PALB2 FGF8 SBDS RET ALK GJB2 CPLANE1 GPC3 TCTN3 PTEN RB1 INTU CYP26C1 LEMD3 PRLR CDON NLRP1 GPR101 DHH HNF4A MMEL1 DNASE1L3 RASGRP1 ATRX CHEK2 FANCA SPRED1 DNM2 FLT4 CHEK2 RPS19 KLLN HACE1 HNF1A PTPN11 CDKN1B GAS1 BRCA2 KCNQ1OT1 NPM1 FGFR3 MC1R MINPP1 PTPN11 TSC2 ABCA5 BRCA2 PLCB4 SCN11A HNF1A BRAF RB1 CBL ARHGAP26 SUFU PTPRJ C1S APC IRF5 GNAQ GDNF TERT MYSM1 XPC TMC8 COL4A5 ERBB3 SLC26A4 CD96 NSUN2 PDGFRA FERMT1 TYR DNAJC21 MSH2 SH3GL1 TUBB RET BRAF ESR1 PAX3 RHBDF2 RTL1 WRN DYNC2LI1 ELANE EXOC6B RPS26 EWSR1 VHL PIGA GCGR POU6F2 RNF43 POLE BRAF MNX1 SFTPA2 CDH23 ASCL1 APC ACVR1 PIGL BAX RAG2 RSPO1 MSH3 PGM3 FGF3 FANCE MPL TP53 COL7A1 BUB1 TET2 PALB2 ACTB PNP SDHC EDN3 XPA TMC6 NEK1 GNA11 KAT6B KRT1 RUNX1 PAX7 NOTCH1 ENG CTNNB1 ETV6 MPLKIP PARN CDKN2A PTPN3 STAG3 MDM2 TP53 LAMC2 NBEAL2 VAMP7 GNA14 DCLRE1C CBL GCDH FANCC AXIN2 PYGL SOS1 BLK WRAP53 IDH1 KRAS CCM2 APC ASXL1 ATP7B ERCC3 SF3B1 EP300 BRCA2 MGAT2 NRTN CDKN2A DICER1 PMS1 RPS10 TBC1D24 FAH BRCA2 ASXL1 BCR C2CD3 KRAS IDH1 IGLL1 RASA1 BRCA2 CHEK2 PTCH1 RNF113A BRAF MBTPS2 EDNRB IGHM PDGFRB RAF1 MEN1 FASLG TUBB NDUFAF6 FOXI1 TGFBR1 EPCAM CYLD SDHB APC CYP2D6 TAF1 KRT17 BRCA1 BUB1B BAP1 GDF2 BUB1B ERCC2 TP53 KRT5 GATA2 BRCA1 RAD54B MRE11 STAC3 DNMT3A MLH1 BCHE EDN3 CDKN1B AURKA NRAS FLCN IDH2 EDN1 ESCO2 USF3 IGH POT1 ACVRL1 JAK2 NBN NRAS SQSTM1 TMEM127 ZFPM2 SLC12A3 NTHL1 ADA CHIC2 STAT3 SETBP1 FANCB FIBP STAT3 STK11 MLLT10 SFTPC HDAC4 NUP214 GLI2 SLX4 TSC1 ERCC6 TP53 CLCNKB KLF6 OGG1 JAK2 PAX6 RECQL4 RPL31 MYO1H FH RPGRIP1L SLC45A2 RPL10 RPL10 HMBS GDF5 TNFRSF10B PIK3CA GABRD TP53 BRCA2 SEMA4A BCR PALB2 ASXL1 KRT6B CCDC22 SAMD9 DMPK DCC ERCC5 RPL5 CTNNB1 RPS27 TRNS2 PTCH1 PTEN TFAP2A RPS24 RPL35A RET AXIN1 HNF1B ARMC5 UBE2T SRP54 SSX2 DKC1 ERCC3 JAK2 GNA11 LAMB3 GJB2 NFKB1 KCNQ1 GLI3 PIK3CA KANSL1 CASP8 MYC RECQL4 ACAN CACNA1S BDNF KIF11 MDH2 MSL3 FGFR1 TERF2IP HFE NFKB2 TOP2A GFI1 SRD5A3 PHKA2 MAX POLE MAP2K1 EYA1 RNF43 ALX3 SETD2 ERCC4 CTLA4 SIX3 LEMD3 OCRL CDH23 DZIP1L MSH3 AR CDC73 PDGFRL TWIST1 POU2AF1 DKC1 CALR LIN28B KRT6A GATA1 MC1R DIS3L2 CD28 CDC73 ADA2 UROD CIB1 TSR2 WNT5A TET2 PHOX2B BMPER KIT DLC1 MSTO1 H19-ICR SLC25A13 ADAR TMEM67 BMPR1A MLH3 POLR1C KRT6B FH EFL1 TERC BUB3 FOXC2 NOTCH3 KIT NSD1 FGFR2 SLC6A17 MAP3K1 TRIP13 MEG3 RRAS2 BMPR1A NF1 DPM1 LIG4 PARN RHOH BRCA2 NF1 TAF15 RFWD3 VHL H19 BCR KRAS VANGL2 KRAS SDHD DVL3 BIN1 ABL1 GPC3 HAX1 FANCA GDNF NHP2 IGF2 VHL CCL2 EXTL3 RUNX1 PRKCD BLNK MSH6 SLC22A18 IL2RG PTH1R SDHB AIP WDPCP APC KCNJ10 ASPSCR1 OCA2 TP53 WT1 SPRTN TET2 TAL1 L2HGDH KIT SDHC ERCC4 GPR143 PRKN SMAD4 SEMA3C TRNS1 BRCA1 SHOX PCNA FANCG CREB1 TRNH VHL MYLK BAP1 SUFU ANTXR1 POLD1 NODAL IGH JAK2 MS4A1 MEN1 TSC2 GATA2 DHCR7 TINF2 F13B RB1 COL7A1 SCN4A BMPR1A DDB2 CDKN2A SDHD CYP11B2 IL7 ARID1B KIT FGFR1 RET CDKN2A LAMA3 CHEK2 TBX2 TBX18 HNF4A GPC4 SHH LMNA BMP2 YY1 AKT1 WT1 BAP1 FZD2 SH2B3 BTK GATA1 RAD54L ATM CTBP1 PTEN SRY RYR1 CTHRC1 MFN2 PTEN RAD21 PTEN MYC SLC26A2 TP53 CTNNB1 RAD51C NAB2 NLRP1 SUFU DLL1 PSAP SDHB REST TGFBR2 TRIP13 IGH ABCC8 IL6 CPLANE1 H19 FANCD2 FGFR2 RET PKD1 DNMT3A REST CHEK2 GNAQ MXI1 BRIP1 DYNC2LI1 GNAS TP53 GLI3 DIS3L2 NRAS PICALM WT1 BAP1 MEN1 TXNRD2 MGMT PTEN MYD88 GNAS POT1 AGGF1 BUB1 PTEN PORCN HFE NUTM1 PHOX2B MSX2 PMS2 SLX4 H19 USP9X RPL27 GNAS SEC23B CBL CD28 PKHD1 AXIN2 TRPV3 KLLN SSX1 TSC1 PPOX KRT17 CARD14 HRAS TCF3 RPL11 CC2D2A GREM1 CHEK2 AP2S1 NRAS TRNL1 ALX1 CREBBP TCTN3 TET2 ESCO2 DOCK8 NRAS STK11 GCM2 TTC37 WT1 SMAD4 DAXX MITF BCL2 DIS3L2 POLR1D TDGF1 KRAS TNFRSF13C KIT PHOX2B SF3B1 RPL15 NF1 TERT TNFRSF1B FANCD2 MLH3 IL7R GPC4 H19-ICR SLC17A9 MEN1 MST1R KIT RAD50 TJP2 DNAJC21 PDCD10 MUTYH IL12RB1 SH2D1A FGFR2 NBN KRAS KIT CASR ENPP1 SDHB HRAS IKBKG PNP EXT2 BRD4 SMARCB1 REST COL11A2 TG KIT LIG4 SUFU NBN RSPRY1 CYSLTR2 SDHD AAGAB BLM RAG1 RNF139 RB1CC1 ACD PTPN11 SLC26A2 TREX1 BMPR1B DDR2 ZAP70 MNX1 MAGT1 AIP GATA2 AR STAR IFIH1 IDH2 BRCA1 USP8 RB1 FGFRL1 SMO USP8 RMRP SLC25A11 MLH3 FUZ DOCK8 SUFU NF2 KDR KRAS RPS14 CASP10 SRP54 ZSWIM6 TBXT PTCH2 EWSR1 TNFRSF13C MTAP NQO2 RPL18 DNAJC21 GCK ERCC6 KDM6B EXT1 SBDS CCND1 SDHAF2 KCNH1 CYLD LMOD1 PDGFRA CAT CHRNG TRNQ ADA NRAS TLR2 SHOX FGFR3 BCL10 TYR KRAS COL2A1 PTCH2 SMO GBA MSTO1 TREM2 JAK2 TMEM231 MSH2 ASXL1 RET DHCR7 NBN PIK3CA NSD2 SDHB EIF2AK4 PALB2 KIF7 PTPN11 PIK3CA HLA-DRB1 STIM1 TMC6 KIF1B TNFSF15 RELA AKT1 NPM1 APC SDHA SDHB STAT6 CDKN1C CDC73 PTCH2 KANSL1 ZSWIM6 FLCN HBB LZTS1 FN1 TRAF7 ACP5 CTNNB1 MLH1 EXT2 RNASEL RNASEH2A IL2RG ATP7A CDK4 CYP11B1 MMP1 SDHB ATRX ACTG2 FOXH1 OFD1 NEK9 STS MUC5B PRKCD PTPN11 PTCH2 LRRC8A RPL26 MSH6 NNT LZTR1 CDC73 PTEN AKT1 AKT1 SASH1 HRAS ANAPC1 PTPN12 KCNJ11 TCF4 GATA2 MLH3 ERCC4 GNB1 DISP1 IDH1 BCR GANAB MSH6 NR5A1 TSC2 GFI1 TNFSF12 TRNP MAPK1 IFNG FLT4 MTM1 WWOX HABP2 RPS28 HRAS SLCO2A1 ND5 SDHB CHD7 BRIP1 SLC37A4 MC2R XRCC3 TNFRSF4 NAGS PHF21A ZIC2 PCGF2 SMARCE1 CTNNB1 SRP54 CDH1 CDK4 RPS20 KCNJ10 RAD21 RNF6 COL14A1 SMO CD19 WRN SRGAP1 CDKN2C AXIN2 GPC6 WWOX HSPA9 FOXI1 CPOX RPS17 APC2 MYH8 SERPINA1 ATM LMX1B ENG POLH TGFBR2 DHX37 VEGFC KIF1B KRT17 DDX41 SPIB CBFB HRAS BCL10 PIGL FGFR1 NSD1 F5 KCNN3 BAX PIEZO2 RECQL4 CREBBP KIT PDGFB PDE6D ABCA5 AKT1 KLHDC8B TNFSF12 EPCAM RARA MLH1 GINS1 EVC PIK3CA FANCE WIPF1 NF2 PDGFRA PRKAR1A CDH1 SDHD PRCC TRNF PTCH1 TNFRSF1B WNT10A WWOX MAD1L1 MTOR WDPCP RNASEH2C NSD2 SAMD9L FH LPP NF1 KRIT1 NTHL1 IL12A HNF1A CDH1 SMARCB1 SMARCE1 CD19 FH FDPS TRPS1 ERCC4 SMPD1 SMARCD2 BRCA1 MPL CRKL SEC23A EXT1 PERP ATM FOXE1 CDKN2B CTSC SIX1 FAM149B1 CDH1 RAD51C ALX3 DLST TRIP13 ING1 PDGFRB FLT3 COL18A1 MST1 TGIF1 TMEM107 SRSF2 TRIM28 BAP1 ANTXR2 CD79A PIK3R1 MAP3K1 NOP10 PIK3CA POLD1 KDSR CCND1 TP53 TMC8 ALK MAP2K1 CD79B SDHC ECE1 PALLD CTSA PRDM16 IVNS1ABP CALR FLNA GPR101 BRCA2 ERCC2 DYNC2H1 TFAP2A COL2A1 DVL1 TERT APC TERT TEK EXT2 TERC ALX4 OFD1 LMO1 PDGFRB RPS14 DCC RTEL1 INS TSC2 FAM20C MYH11 GPC3 SCN9A SMAD4 RASGRP1 HBB TGFBR2 RERE NDP PLA2G2A TCF4 MAD2L2 SKI AIP HMMR SDHC SNAI2 PIK3CA LMNA PGM3 ABCB11 TAL2 WT1 VHL PIK3CA TCTN3 SAMD9L ICOS GLI3 RB1 SLC25A13 SDHC DCLRE1C GCM2 VANGL1 SIX6 WT1 PMS2 KCNH1 BARD1 H19-ICR GNAS TERT CIB1 B3GALT6 GJB3 ERBB2 SDHA KRAS CDC73 TNFRSF13B TET2 FGFR3 WAS SEC23B TGFBR2 TP53 NF2 SMARCA4 NF2 SLC26A4 ANTXR2 WRAP53 FAS SAMHD1 TP53 TET2 ATP7A PTEN SH3KBP1 CARMIL2 MVD PDGFB ABCC6 G6PC1 TRNK KRAS GPC3 PTEN NF2 JAK2 DMRT3 GNAQ RAD51 GTF2H5 TMEM127 TERT RUNX1 FAT4 AR HABP2 NR4A3 EP300 MINPP1 OFD1 RASA1 DLEC1 BIRC3 AIP CD27 PHOX2B BMPR1A KCNE3 PLCD1 RAD51 KRT1 MSH3 MITF EPHB2 DHCR24 RABL3 KRT17 XRCC2 NRAS ITK VHL BICC1 RECQL4 SMARCAD1 MYCN RET CTC1 PTCH1 JAK2 SRC SDHB PHOX2B AKT1 KEAP1 JAG1 VHL LETM1 NLRP1 MEN1 BRCA2 FLCN C2CD3 RFWD3 XPA APC APC SDHD FOXO1 MAFA WHCR GPC4 MLH1 ICOS CDKN1B MTMR14 KIT DICER1 EP300 ZFHX3 MMP1 PRKAR1A KRT9 F13A1 CTNNB1 MPL INPP5E NF1 DKC1 TERT DLK1 SCN10A STS RPS29 PTEN FLCN LRBA ELANE GTF2E2 ATM PIK3CA GPR35 CYLD RAD51C CDKN1A WT1 DICER1 PIK3CA TERC PIK3CA SLC25A11 GNAS CEBPA ATP6V1B2 RET XPC EXT1 BRCA2 SH2B3 ERCC3 BRCA2 RTEL1 WASHC5 ERCC2 AKT1 KCNAB2 CYLD STK4 POLH ERCC5 CDH1 CEL XIAP MSR1 TP53 TET2 DHH PRKAR1A
HP:0000822: Hypertension
Genes 424
MAT2A WT1 LMNA HGD FN1 TRNL1 SERPINA6 YY1AP1 TRNK BBIP1 GTF2IRD1 TRNC KCNJ5 CLCN2 MGP TGFBR2 BBS1 CYP11B2 RET ARVCF KCNJ5 EGFR OSGEP SH2B3 TRNS2 SLC2A10 NKX2-5 LMNA RREB1 IFT172 LZTFL1 ND1 FBN1 FMO3 HLA-DPA1 GUCY1A1 APOB SCNN1G CEP164 BBS10 FUZ SDHB MUC1 REST ABCC6 TTC8 CLIP2 H19 ELN FGFR2 GATA5 PKD1 NF1 NPHP1 KCTD1 WNK4 HIRA GP1BB GNAS IRF5 EDA2R LMX1B NFU1 PLIN1 MEN1 SEC24C ELN GNAS COL3A1 NPHP1 SLC37A4 ERCC8 HLA-DPB1 NOTCH1 CFHR1 THSD1 SDCCAG8 DLST PKHD1 PPOX ACTN4 DNMT3A NOD2 SCNN1B C8ORF37 ECE1 XYLT1 ACTA2 GDNF CTLA4 PAM16 EPAS1 BBS4 ARL6 CCR6 DNAJB11 CDH23 ENPP1 WT1 DIS3L2 PKD2 MFAP5 GLA PKD2 NPHP1 TRNW NF1 IFT27 BANF1 CFI LMNA WNK1 WT1 ARHGAP31 SMARCAL1 FGFR2 STAT2 ACVRL1 CEP290 ADA2 NF1 SDHAF2 ENPP1 PRKAR1A IQCB1 PRTN3 TET2 SMAD6 XYLT2 NOD2 SDHD HPSE2 MYH11 SDHD COX1 PDE8B CAV1 C3 SMAD4 SCNN1G ELP1 USP8 EXT2 USP8 KIF1B SLC25A11 FBN1 CBS WDPCP BBS9 BRCC3 ACAT1 SPRY2 TRNF STAT1 SUGCT ELP1 SCNN1A GPR101 PPARG ZMPSTE24 MAX LRIG2 TRNS1 GJA1 ERCC8 BSCL2 CYP11B1 NPHP3 TRNE FIG4 CCND1 CD2AP KCTD1 TRAF3IP1 TRNK GBA TGFB2 CYTB HMBS GLA TRIM32 EDA SDHC TNFRSF11A LDLRAP1 MMP2 XPNPEP3 PKD1 KIF1B ABCC6 TRIM28 SDHB SDCCAG8 ALMS1 MAFB FN1 PTPN22 ACP5 ERCC4 LEMD3 CYP11B1 BBS7 SDHB LDLR SCNN1A NPHP4 KRT18 HSD11B2 CDKN1B CCN2 CUL3 GANAB PDE3A VANGL1 TSC2 ACTA2 PCSK9 CEP19 CFB SMAD4 MTTP COL4A5 LYZ FOXE3 IDS PRKG1 SLC37A4 PHF21A GUCY1A1 B2M RET INVS KCNJ5 PPARG WRN PLIN1 BMPR2 CDKN2C MMP14 VHL POU6F2 ELN COL4A3 CPOX ABCB6 CDH23 LMX1B THBD KIF1B SLC2A10 PDE11A JMJD1C CYP17A1 TRNK TBX1 IL12B COQ7 TBL2 TBX1 WDR19 LRP6 FMR1 SDHD CORIN RFC2 CACNA1H CYP11B1 MKKS ADA2 LIMK1 NOTCH3 MKS1 FLT1 BBS1 CACNA1D YY1AP1 CDKN2B ND6 LMNA MLX VAC14 PKHD1 TRIP13 PDE11A MEF2A IDS TRIM28 NDUFAF6 NOS3 TRNQ SDHB SDHC STOX1 SMAD3 ALX4 APRT LOX OFD1 IDUA TMEM127 COL3A1 AIP FBN1 LMNA CFH WT1 VHL NR3C1 CYP17A1 TSC1 ALMS1 SMAD4 POU3F4 FGA HMBS TP53 HBB ARMC5 BRCA2 SDHA CACNA1D ABCG5 RET UFD1 TREX1 NOTCH2 ABCC6 G6PC1 ARMC5 SCNN1B CCDC28B GTF2I JAK2 KLHL3 BBS5 MYH7 ERCC6 APOA1 TRNV TMEM127 TGFBR1 GNAS FBN1 ARL6 GCH1 COX2 MDH2 NFIX OFD1 AIP COL4A3 WDR35 ENG MAX CFHR3 TMEM70 NSMCE2 LARS2 LEMD3 ND5 CYP21A2 NR3C1 DZIP1L BNC2 VHL BICC1 ERCC6 PRKACA MC4R PRKACA ADA2 CYP11B1 INF2 HLA-DRB1 MYLK TGFB3 MTRR MYMK POR COL4A4 JAK2 SDHD SCN2B CEP290 ITGA8 FH DYRK1B TRPC6 HLA-B PRKAR1A MLXIPL BBS12 MDM2 MPL TMEM237 VHL BBS2 PDE3A NR3C2 KRT8 GPC3 PRKAR1A BAZ1B ERCC4 VHL TGFBR3 CDKN1A COMT WT1 SLC25A11 RET COX3 AIP ABCG8 HSD11B2 GANAB TMEM67 CD46 ADAMTSL4 TNFRSF11B ANGPTL6 INVS TRNL1
HP:0001873: Thrombocytopenia
Genes 451
PSMB4 GFI1B FANCG KMT2D RPS7 TREX1 ARHGAP31 MS4A1 SLFN14 GATA1 NPM1 ZBTB16 ERCC6L2 TINF2 GATA1 TERT HOXA11 VWF PLAU MTOR ARVCF FANCM IKZF1 RPS15A NBEAL2 RREB1 PSAP GATA1 SPATA5 TERT RAD51C CD81 PRDX1 WAS ANKRD11 FANCD2 RAG1 PRKACG HIRA SPATA5 FLI1 GP1BB RARA BRIP1 STT3B CD81 SEC24C UROS MECOM SLC19A2 HLCS ATRX FANCG TET2 TERT MPL NOTCH1 TERC CFHR1 FOXP3 RPL27 AP3B1 PKHD1 GFI1B CASP10 NIPBL CA2 LMBRD1 RPL11 PDGFRB STAT5B MYH9 STXBP2 ANKRD26 VPS45 SLC35A1 TET2 PHGDH PRKCD SLC7A7 PCCA DOCK6 LIG4 CD46 SF3B1 RPL15 TINF2 ADA2 TERT FANCD2 PTPN22 CFI USB1 SMARCAL1 STAT2 CR2 GBA G6PC3 GALC STX11 LIG4 DNAJC21 SH2D1A MADD PDGFB RPL35 SBDS FANCL FAS CTC1 GBA CALR PNP SP110 VPS33A MPL NHP2 NBN GP1BB FCGR2B ACD PTPN11 CTLA4 TREX1 TINF2 ZAP70 MAGT1 GATA2 C3 IFIH1 SLC7A7 TFRC NFKB1 ITGA2B FANCF APOE ITGB3 VWF ABCA1 SLC19A2 RPS19 FLI1 CASP10 STAT1 DLL4 DGKE TNFRSF13C UQCRFS1 RPL18 SALL4 MECOM SBDS TNFSF11 BTK KIF15 RNASEH2B SLC20A2 PSMB9 STIM1 TNFAIP3 CDC42 PRF1 ITGB3 FANCC ACAD9 GBA NUMA1 JAK2 TNFRSF11A CD40LG MMACHC GP1BB FANCI FAS SCARB2 SLC35A1 GBA MPIG6B SPP1 ITGA2 MMAA FOXP3 STIM1 FARS2 TPP2 RAG1 SBDS RFXAP FLNA HOXA11 ACP5 UROS RNASEH2A RASGRP1 FANCA ABCD4 COG4 DIAPH1 PRKCD GP1BA RPS19 RPL26 COG1 CYCS DHFR GP9 NHEJ1 ACTN1 NPM1 LBR CD36 IFNG CTLA4 MMUT TNFSF12 CFB POMP RPS28 MYSM1 CD109 HPS5 COL4A5 ERBB3 NSUN2 ACP5 NABP1 CFI DNAJC21 GUCY1A1 SRP54 HLCS WIPF1 LYST RBM8A FYB1 WFS1 ADAMTS13 RPS26 GATA1 RPS17 SCARB2 GBA APOE FANCF THBD SLC46A1 MMUT JMJD1C FANCE PALB2 HYOU1 TBX1 PNP SRC OCLN MYSM1 TNFSF12 JAK2 TBX1 FASLG FANCE RFXANK WIPF1 RUNX1 TINF2 GBA CORIN PARN BCOR NBEAL2 RAG2 TMEM165 RNASEH2C SAMD9L GNA14 MADD FANCC SALL4 MAD2L2 WAS PEPD NOP10 FLT1 CD19 SMPD1 SMARCD2 BRCA1 MPL PSMB8 MYH9 CDC42 RNASEH2A RPS10 STAT4 TUBB1 SAMHD1 KRAS BRCA2 MMACHC BRAF ALG8 FASLG NOP10 NOS3 COG6 ETV6 STOX1 SC5D CFH TALDO1 STAT3 TERC PRKAR1A SNX10 RTEL1 ESCO2 AGK RASGRP1 ACAD9 TREX1 XPR1 NBN STT3B NRAS MAD2L2 CLCN7 GATA1 ADA CFH FANCB EOGT STAT3 SLC46A1 ICOS HLA-B SLX4 RFX5 RPL31 BCR TNFRSF13B IRF2BP2 WAS SAMD9 RPL5 USP18 RPS27 RPS24 WRAP53 RPL35A FAS SAMHD1 UFD1 TET2 ASAH1 UBE2T SRP54 GBA WARS2 DKC1 DGUOK ITGA2B MMAB NHP2 NFKB1 SMARCAL1 IRAK1 IFIH1 TERT RNASEH2C CIITA TALDO1 GP1BB NFKB2 EFL1 LAT TBXAS1 RBM8A NLRC4 MAP2K1 CFHR3 PCCB GP1BA ERCC4 ARHGEF1 LARS2 RAD51 OCRL PRF1 DZIP1L MMUT JAM2 ARPC1B XRCC2 DKC1 GATA1 ITK GATA1 WDR1 CTC1 RBPJ TSR2 TET2 LYST PML GBA ADAR SARS2 TCN2 FIP1L1 ELANE RFWD3 TBL1XR1 EFL1 TERC DNASE1 RRAS2 HLA-DRB1 PARN NFKB2 ATP7B DKC1 RPS29 DCLRE1C HELLPAR ABL1 LRBA FANCA GP9 NHP2 BLOC1S6 RUNX1 FANCB COMT PRKCD MYORG FCGR2C UBE2T GP1BA OSTM1 IL7R RTEL1 RAG2 CD46 FCGR2A GP1BA VPS33A IVD KDM6A BTNL2 XIAP MVK
Protein Mutations 2
G20210A V617F
SNP 0
HP:0000708: Behavioral abnormality
Genes 2590
MERTK MBD5 SH2B1 ALDH18A1 MAGEL2 TIMM8A NDUFS4 RPE65 TOR1A GRIA2 CACNA1G PRODH KAT6B PHF21A BRAF CNKSR2 NTRK1 PSAT1 ST3GAL3 APP ARVCF NR4A2 ANTXR1 GABRA1 RREB1 GJC2 TOPORS OCA2 GNA11 ITM2B FBXO11 ATXN10 KCNJ13 ATXN8OS AP4B1 RPS6KA3 GJB6 AARS1 LRRK2 DMD GBA NDUFA6 FOXH1 ANKRD11 TARS1 KNL1 CEP290 SPATA5 BRSK2 VAPB ABCC8 CNNM4 ABCA7 ADNP SEC24C CDK8 TUBB2B TYROBP GABBR2 RLBP1 EXT2 PRKAR1B TBX1 PIK3CA TULP1 HCN1 TWNK GCH1 MBOAT7 CACNA2D4 NDUFV2 WAC MAB21L1 GNS VPS53 ITPR1 GRIN2B FGFR3 GPT2 DLST CUX1 DNMT3A PC SIN3A NOD2 SLC12A6 TRIO FOXC2 ECE1 MAPT KMT2A TMEM106B CNNM4 TTC19 PTCH1 TRRAP MYT1L KMT2E JRK SCN1A GK EEF1A2 VAMP2 ARL3 GUCY2D INTS1 SCN1B IGF2 GRN ASPM PRPH ZMYND11 CNGB3 SPOP AMACR HNF4A SDHA ADA2 CNOT1 ACTL6B SNORD115-1 PRDM8 SNCA MADD TTLL5 ERCC8 SOX3 NDUFB11 MAN1B1 KCNB1 EMC1 SHH MKRN3-AS1 PRPH2 GRIN2B PSAP SLC18A2 RBBP8 ABCA7 FAN1 COX10 TKT VPS33A HMGCL ERF HRAS XK TBC1D24 APC2 NGLY1 GLI2 ATXN1 RDH11 ANK3 PCSK1 NEFH SMG9 CSF1R FMR1 TREM2 ATXN8 AGPAT2 PRPH2 PNKP PREPL SH2B1 NKX2-1 IYD PUF60 CLCN4 ATXN3 CCBE1 ELP1 AGA TAF1 PWRN1 POU3F3 TDGF1 PPP3CA PAX8 ND4 PNKP CHRNA7 PEX1 KAT6A FLI1 ZIC2 AIRE IMPDH1 MBTPS2 POLG DISP1 DHDDS EIF2S3 GNAI3 CACNA2D4 DOCK6 KRAS BAP1 SIX3 AP1S2 APP NPHP4 RPE65 COASY OVOL2 SMARCB1 SLC19A3 DLAT TSPYL1 MSH6 USH1C SLC5A2 PEX13 BSCL2 SLC39A4 NDUFB11 HNRNPA2B1 VCP ZIC2 WDFY3 KYNU CDC42 JAM2 GABRA2 SACS KCNJ2 HMBS ACY1 OPN1LW MED23 CAMTA1 FGF8 NTRK1 PCDH19 EIF2B3 SHH SLC22A5 SYNGAP1 CREBBP OCA2 NODAL ERLIN2 AIPL1 SLC26A4 UBE2A GALNT2 CDH23 SLC9A6 RAD21 EZH2 MED25 VCP SYT1 SMARCA2 ADAT3 ECHS1 TBR1 USH2A DLL1 SLC35A3 RERE CST6 CASK SLC6A8 DGCR6 FGF12 SQSTM1 EPM2A TRNS2 NLRP1 TIMMDC1 DUOX2 TREM2 DEAF1 CACNA1A PLA2G6 COG4 SPRED1 EPM2A SIK1 CDKN1C TBC1D23 IL12A-AS1 ARSG CHCHD10 TSHR CDKN1B SLC13A5 CYP2R1 FOXG1 SLC24A5 HLA-DRB1 UBE3A NDUFS4 UGP2 PER3 WAC PPP2R5D GLI2 TACO1 EYS ATXN10 FDFT1 TAF15 TSHB HCN1 JPH3 AASS SLC2A1 GNAT2 IRF6 C19ORF12 CNKSR2 RPGRIP1 CARS1 SLC18A3 USP9X CUX2 DLL1 NSUN2 RPGR FLT4 TCF20 TYR TECR GALC GRHL2 NLRP3 ALDH3A2 DHX38 PSAP SORL1 GNB5 CUL4B AUTS2 MEIS2 PRODH WFS1 VHL SHANK3 CSGALNACT1 PMM2 AIFM1 PRCD IDUA CRY1 PRPH2 TP63 SIGMAR1 ATP5F1A RPIA CNTNAP2 NDN MAPT GBA NTNG1 SPOP CHRNA7 MBD5 FANCE C12ORF4 SHANK3 SLC6A17 NDUFS6 PNP TSHR PTS ZEB2 XPA CNGA3 MAN1B1 SIM1 WWOX ATRX SYNJ1 DGCR2 PLEC FMR1 PARK7 HCCS GBA MTPAP SYNGAP1 SATB2 CLIP1 PSMD12 TSEN54 DCTN1 SLC9A6 PRPH2 LEPR SNCA PYGL MED12 PIGL OPN1MW USP9X MCCC1 CRBN TWNK ATP7B ABCA4 GLI2 MGAT2 PRRT2 ZFPM2 EIF2B4 TASP1 KIZ TIMM50 PMS1 GABRA2 TBC1D24 HCN1 AVP KRT86 IMPA1 MCTP2 PDE11A CNGA3 C9ORF72 FARS2 FGFR1 MAGEL2 SYP ATN1 NSD1 DPAGT1 NDST1 FBLN1 SEPTIN9 PEX16 KRT12 IQSEC2 NR2E3 AP4M1 SDHB DDX11 LNPK C9ORF72 LRRC32 TMEM216 CISD2 GSS TRNS1 MED12 NDUFA1 CLCN4 GJB6 CRX KCTD17 DNMT3A NEU1 BSCL2 SLC6A8 FOXH1 KCNJ10 CPS1 NDUFA2 PRKAR1A FGD1 PARK7 GRIN1 EDN1 COX3 GLRB HNRNPA1 MECP2 NDUFV2 LSS LRRK2 FBP1 USF3 GNPTAB TREX1 NBN LARP7 OTX2 BCL11B PRKCG NDST1 PLXND1 WAC NDUFAF2 B4GALNT1 HLA-DQB1 PEX2 PEX10 PUS7 PSEN1 ERCC6 STX16 CLCNKB IBA57 SMAD4 HMGA2 TRAPPC9 TCN2 PMP22 AHI1 MC4R SUOX IQSEC1 SLC45A2 DOCK8 AQP2 RPL10 HNF1A WDR26 HMBS PIK3CA TP53 CHST6 GAS1 NDUFAF2 DMPK PIGH PSAP ERCC5 SLC33A1 ZFYVE26 SLC1A4 TREX1 DRAM2 RORB VCP ARMC5 PLAG1 STAG2 POLR3A POMK KDM3B PI4KA GJB2 TMEM126B IRAK1 TRAK1 ANXA11 MDH2 MSL3 HADHA NMNAT1 UBE2A FUS HNRNPK HIBCH PIGY TGIF1 IDS UBQLN2 AVPR2 SETD2 CTSF SOX2 ATAD3A TELO2 DZIP1L SHROOM4 CEP152 POU2AF1 HIVEP2 GLRA1 TDGF1 ADNP CA4 NFASC PEX5 CDC73 C9ORF72 TTC8 ADA2 SCN1B PGAP1 TRNN CTNS CACNA1F SIX3 PML RGR SNCAIP BMP2 SASS6 COL1A1 TMEM106B ZNF462 TCF4 SYN1 GPC4 FH CLCN2 ABCA2 FOXC2 AP1S2 FOS CC2D2A MAP1B PPARGC1A KRT3 GUCA1A NAT8L SQSTM1 FXR1 PINK1 GATAD2B VHL MED12L TPO PEX11B LIAS MOG SDHD PPARG NAXD C9ORF72 WFS1 HAX1 GNAS NRL DCTN1 AFG3L2 ALS2 GAMT CFAP410 PRPS1 MAPT CYP27B1 DRD4 FUS NTNG1 MYO7A FOXP1 PRPH2 SMPD1 GATM JPH3 CNGB3 HLA-A OCA2 NODAL TMEM231 SLC6A1 GPR143 AFG3L2 NONO NALCN ATXN8OS PCNA WDR45 TCF4 ND6 PEX6 NODAL GNE MEN1 AIFM1 CUL4B POLA1 VPS35 DHCR7 DHX30 ZNF711 GUCA1A WARS2 PITPNM3 SLC20A2 WNT10A SLC7A14 NECAP1 RPGR RP1 KCNJ5 CAVIN1 TACR3 CYP11B2 ARX CNGB1 MBOAT7 NDUFAF3 RLIM KCNJ5 SLITRK1 SETD5 ZNF408 ITPA EIF2S3 DCAF17 ATP13A2 GJB2 GCSH DNM1 VSX1 STUB1 UROC1 SNX14 NODAL ARX HUWE1 SAG RAC1 ERCC6 UBE3A BCOR EPB41L1 FUZ GJA8 PSAP FGF8 RPGR GAS1 RPGRIP1 PODXL BMP4 SEMA4A ELN FANCD2 SMARCA2 CAMTA1 PLCB4 NUS1 MYT1L CC2D1A GP1BB PDGFRB ADAMTS2 SQSTM1 CYP27A1 NFU1 GABRD DLL1 GABRG2 PAH GNAS NPHP1 CLTC PSEN1 NDUFAF5 TLK2 PMS2 DUOXA2 SLC6A4 P4HTM TTI2 SEC23B AP4M1 CDON C9ORF72 DLG4 PPOX CHD1 GDI1 SOX5 BRAT1 HESX1 PSEN1 PTCHD1 SDHAF1 AP2S1 STAT5B CREBBP NPAP1 ADCY5 RGS9 PITPNM3 SLC2A1 SLC7A7 BCS1L IFT88 CC2D1A ZC4H2 KRAS SLC25A12 PHOX2B CDK19 KMT2E SLC5A7 RPGR CERT1 PTPN22 USP7 NAGA CHMP2B PUS3 NKX2-1 COQ5 MEG3 ZIC2 EEF1A2 GUCY2D NDUFB10 DNAJC21 AIFM1 ZMYND11 DISP1 SLC35A3 ESR1 FGD1 DNA2 MED25 FOXH1 AP4E1 YWHAG SEMA3E IKBKG PNP DHTKD1 ADH1C NAGA MED13 RNF216 HPSE2 FRA16E CEP78 RSPRY1 TRNS1 FCGR2B GNB3 ABCD1 AP4S1 HCN1 TTC8 YWHAG NADK2 TREX1 RIMS1 GRIA4 ZNF81 ND2 SMARCC2 IFIH1 KIF1A NRXN1 USP8 USP8 FBXO7 C8ORF37 ATF6 DAOA ALS2 DYNC1H1 WDR62 CAMK2A IL6 PANK2 SLITRK1 OTC TYR C4A TRNQ DNAJC21 TOMM40 RAI1 SH2B1 DRAM2 KPTN MECP2 MECP2 SNRPN KDM6B FIG4 PSEN1 HNMT VCP NKAP SLC25A15 DMXL2 SPATA7 DNMT1 HDAC8 NHS KCNQ3 ASPA PRMT7 JRK PRF1 KIF14 CHMP2B ARHGEF18 TREM2 OPN1SW GM2A MSH2 DHCR7 MMACHC KDM5C HLA-DQB1 SDHB CAMK2B USH2A SNCB SPP1 DYM CACNA1A NOP56 ELOVL5 FGFR3 PTPN22 CEP57 PPT1 AKT1 TRNF GJB6 THOC2 NUS1 SOX5 PCNA BCKDHB SARS1 CDC73 KANSL1 CFAP410 HMGCL SATB2 CA4 GLRX5 DNM1 CRX CYP11B1 KAT8 TUSC3 SDHB CLDN10 ALG13 ERCC1 PCNT PRPF8 TET3 CLTC CDON CHCHD10 TYROBP ACTG1 TMEM240 OTUD6B VCP WDR26 DBT CDHR1 SLC45A1 DEAF1 PSMD12 STXBP1 CACNA1A SLC35C1 MAGEL2 ANAPC1 ASXL3 PWAR1 SLC1A4 TRIP12 TCF4 OPN1LW AGRN CTCF ALAD ERCC4 SCN8A CNGB3 COL8A2 HTR2A GLUD1 OPTN POLG CLRN1 NIPBL KCNV2 SMAD4 LIPT1 LAMB1 FGFR1 HECW2 SETD2 PRODH PCDH15 TBR1 CDH15 NPHP4 TAF6 COQ2 B3GALNT2 ARSA SRP54 LINGO1 MID2 SQSTM1 SPRY4 CACNA1G FA2H INSR CDKN2C COL1A2 NDUFA10 MED12 CCDC47 NHLRC1 ADAT3 SNCA UNC13A CPOX APC2 FGF14 PFN1 POLH PRNP PDE10A VEGFC RPGRIP1 TACSTD2 SYT1 MAPT TBX1 NSD1 ARG1 REEP6 CREBBP TMEM237 NDUFS7 PDGFB EML1 APOL4 TMEM231 ABCA4 TBX1 SLC19A3 ATRX EPCAM MECP2 PGAP3 IL10 PDGFRB GABRB3 NDUFS8 DEPDC5 REV3L MAPT TARDBP EHMT1 DNAJC12 CTNS SDHD STRADA WASF1 NDUFAF5 TBK1 FOXP1 BCOR TMCO1 SDHB NDUFS1 RNASEH2C LHX3 NLGN3 ARFGEF2 KISS1 NOTCH3 SYN1 XPR1 FIG4 SMARCE1 MAPT PTCHD1 GPR143 LTBP3 CRBN RGS9BP ATP6V1A ARV1 EP300 SYN2 COL17A1 HTRA2 SPAST ASL GNAT2 IMPG2 SLC25A19 ATP13A2 AVPR2 PPP2R2B SLC18A2 NEUROD2 TMEM240 GNAI3 TBX1 IDS KPTN ZNF41 PIGP DDX3X HPS6 ALS2 FTL STEEP1 GABBR2 TUB CIC RNF13 EIF2B2 ATAD1 AFF4 GPR101 MTHFR SUCLA2 GBA IL23R COX2 FBXW11 SRPX2 ENTPD1 TSC2 RAI1 CHAMP1 PEX12 TFAP2B PHIP PON1 CHD2 FGF8 ITPR3 GRIK2 SNRPN NDP TCF4 TANC2 ATP1A1 NLGN1 RTN4R DPYD POGZ ATXN2 NFIB POMGNT1 KDM5C CDON PDE6G GLI3 SREBF1 SDHD SLC19A3 MANBA TAT SLC25A13 TDGF1 ALMS1 GIGYF2 LRPPRC LHX4 IREB2 TERT SOBP FOXH1 ARMC5 KCTD17 SDHA GLUD2 PPP3CA CNGA1 CASR PEX26 WDR45 EHMT1 NF2 POU1F1 DYRK1A GABRB3 HEXA NDUFS1 SAMHD1 TBC1D24 TGIF1 CLP1 GTF2I TNFRSF1A ABCC8 SCN2A FMR1 TWNK HGSNAT GNAQ GUCA1B MYO9A CYFIP2 KCNA2 LMAN2L FRMPD4 IFIH1 TMEM127 COL13A1 GNAS TWNK AMER1 SETD5 ZSWIM6 CCR1 UQCC2 EIF2B1 NFIX MED12L AIP DYRK1A SCN8A FAS RNF135 UPF3B CDH2 KIRREL3 SKI UPF3B DHDDS TSHR OTUD6B POMC EFHC1 NDUFA9 HCFC1 SYNE1 ESPN CLN6 PDE6C PDE10A FSCN2 GPHN ERAP1 ERCC6 ZDHHC9 SLC1A2 MC4R PACS1 PRKACA GRN ST3GAL3 GDAP2 SLC3A1 SLC5A5 PNPLA6 FTSJ1 LYST GBA AHR SLC25A22 TKT STX1B TBX4 CLN8 NEUROD2 HERC2 CORO1A XPA MBTPS2 TBP GNAS KLRC4 ERCC8 DNASE1 SCAPER MMP1 MLXIPL PRNP FMN2 PRPF31 IQSEC2 HLA-DRB1 NLGN4X ALG12 TMEM237 TOR1A NKX2-1 DLK1 GM2A ACSL4 HCRT GNAO1 BCORL1 NTNG2 GTF2E2 SGSH GPR35 KCNT1 BAZ1B TRAPPC4 MED12 CDKN1A CLCC1 CRADD GRIA3 MID1 GRIN1 MEIS2 XPC PEX1 GABRG2 ARHGEF6 CDHR1 PDE6C ERCC3 DYNC1I2 ACOX1 ERCC2 HLA-DRB1 KCNAB2 FGF17 CTNS TRIO SPR PAH POLH CTSH TGFBI DISP1 NAA10 EZR NTRK2 CDKL5 ACSF3 ABCA12 SLC6A5 NOTCH2NLC EEF1A2 SLC16A2 PET100 PROK2 KCNA1 CLTC PEX3 COL7A1 HSPG2 MAGEL2 SLC2A1 NDUFAF4 AMT GTF2IRD1 DRD3 SLC9A7 CHD7 PIGY RAB39B HNRNPA2B1 ATP2A2 FRMPD4 FGFR3 NHLRC2 TSHR NGLY1 PGAP2 PUF60 LARP7 PIKFYVE STAG1 UCP2 CEP85L CTNNB1 PACS1 MYORG NAA10 GNB5 PIK3C2A MTPAP STXBP1 CTCF STEEP1 ATP1A3 ARSA FMO3 ASS1 ATXN3 TCF4 POLG CACNA1F PRPH2 ZIC1 ATP10A SVBP PIEZO2 NDN GJA5 ATP6 DCX PURA CYP27A1 DCTN1 COMT PROKR2 EBP RTL1 SIM1 GJB2 SCN1A VPS13C TP63 NACC1 SDHA NF1 LAMB2 TBK1 PHGDH RARA ACTL6B TREX1 GFM2 OFD1 HARS1 MEF2C NKX2-5 TRAF3 CNGA3 COL3A1 TH MTHFR ZNF408 HLCS CD96 SATB2 ERCC8 POC1B VCP DLD FOXH1 CLCN4 GABRA5 SURF1 AFF2 KMT2C SLC25A20 SERAC1 TSC1 TNPO3 NIPBL COX7B SLC1A2 MBD5 KMT2A GAS1 PDE4D SHOC2 HDC MAPT TRNW DGCR8 FBP1 EPAS1 TUBB3 PDE4D ERCC3 DNM1 CBS SNCA KDM5B FGFR2 CDON CLN3 FKTN KCNJ1 VPS51 DISP1 ATP6AP2 LSS MFSD8 HARS1 NDUFAF6 SPECC1L GABRA2 STS CHD2 ZNF365 CYP27B1 LIG4 NF1 SIL1 ZNF365 FOXE3 NF1 SH3BP2 SRY SDHAF2 CNOT3 RLBP1 NAGS PAK3 EEF1A2 CDH15 DPYS GNRHR TDGF1 ALS2 KDM5B PSEN2 CACNA2D2 CACNG2 NFIX FTSJ1 COX15 SDHD ROM1 FGF8 CDKL5 SRP54 CSNK1D STXBP1 CTLA4 MAPK8IP3 PPM1D DPYD ATXN2 ARSA ERCC2 DCAF17 KIF1B BEST1 TRNS2 KMT2A STXBP1 IPW RP2 TBC1D7 ASCL1 ATXN7 SLC52A2 HOXA2 ARNT2 AP2M1 CHD8 AUH ELP1 SNRPN SLC45A1 STAG2 LMX1B GPR101 RBM12 KCNA2 ADSL PRNP SIX3 HNF1A MAX DDB2 LRIG2 ZC3H14 ZBTB20 DCPS CISD2 HTT KCNJ10 UNC80 PGAP3 MEFV SUCLA2 RNASEH2B GABRG2 NLGN4X NDUFAF8 MSX1 NOTCH3 ZBTB11 TICAM1 AHCY ATPAF2 HERC2 TERT TRPM3 ALG3 ABCC8 NPC1 FTL POMC NDUFS2 ALG6 SDHC USP27X NDUFS1 HBB SPART UBA5 AP2M1 TFAP2B ZFYVE26 DAO HTT ZIC2 KLHL7 NPC2 TTI2 PIGV ALMS1 CP DOK7 HTT LINS1 SBDS COG6 RIMS2 CERKL NMNAT1 KDM6A TRHR PEX14 PTEN ATCAY MAGEL2 SYNGAP1 PQBP1 HNF4A COG5 MMEL1 MYO7A PSEN1 NSDHL FLT4 KLLN PINK1 IARS1 EPHA4 RDH5 PPP1R12A FBXW11 MAN2B1 PTCH1 EPG5 FGF8 GLI2 PDE6H SLC6A3 PLCB4 ADGRV1 IDUA CWC27 IL12A GLS PRKN CLDN16 IQSEC2 POLG2 IRF5 ALG11 KIAA1109 APP SET CLP1 XPC ELP2 MKRN3 NFIX PDCD1 CHI3L1 SGCE NDP DKK1 ECM1 EIF2B5 GLE1 IFT172 TACO1 FMR1 VAMP1 PAH RTL1 ESS2 NDUFB9 HAL DLK1 TWNK SLC39A4 DGUOK ARL2BP CDH23 FGFR3 ODC1 ASH1L HPRT1 TARDBP VAC14 PIGL CACNA1A SLC2A1 SLC46A1 DHPS CLRN1 RAI1 JMJD1C RSRC1 AGBL5 PROM1 TMEM106B CILK1 SHROOM4 NRXN1 PON2 TNIK LEPR TBX1 PIGT ATP13A2 TMLHE KLF13 FKRP DISC2 CORIN IFT140 PNKP MPLKIP STXBP1 PRPS1 GLDC TBP TIMM50 PTPN22 MADD FGF14 LIMK1 AP3D1 MYT1L APOL2 DSG4 IDH3A EP300 SPART GNAO1 HLA-DQB1 NDUFA6 OPN1MW EP300 CDKL5 TANGO2 PDE6C SNX14 NDUFS2 PIGO STAT4 SOD1 ND3 SPG21 CRYGC BPTF SIN3A SLC6A19 SNRPN DNMT1 ZMIZ1 LMNB1 RNF113A HNRNPK PRSS12 NDE1 TGIF1 MUSK TAF1 ATRX KRT83 DOCK7 POLG EYS ERCC2 DEAF1 NSDHL SCN1A PLA2G6 PSAT1 LEP ADGRG1 PSMD12 SCN8A TK2 PCDH19 MLH1 FOXE1 DISP1 POGZ VCP STAT3 GABRA1 ADAM9 FOXP2 IQSEC2 BPTF LAS1L PPP2CA RNF168 GRIN2D ARCN1 PIGV IDUA CDHR1 BCOR MCOLN1 POLG ARSA SLC12A3 SIM1 GYS2 GABRA1 TGIF1 MAPT DUSP6 UBE3A RRM2B ZMIZ1 WFS1 HLA-B HDAC4 TSC1 ATP1A3 CHRNA2 OPN1MW ATR SETD1B ATP1A3 RPL10 CACNA1A CNTNAP2 GABRD TSHR SEMA4A HTT IRF2BP2 SCN2A EHMT1 ASXL1 TRIM8 RAB11B FIG4 SETD5 DOCK3 SETBP1 PRNP RET UFD1 PCYT1A COQ2 GLT8D1 PSEN1 ZDHHC9 HNF1B ASAH1 HNRNPH2 DNAJC6 GBA MECP2 SHANK3 ATRX PRPF3 TYR KMT5B RUSC2 MED13L RUNX2 NHS KANSL1 GRIN2A PTCH1 SCN1A NR2F1 ANG SLC1A3 TDGF1 ATP13A2 SEPSECS GCH1 DNMT1 FGFR1 CUX2 CHD2 MYOD1 RAI1 HFE BCKDHA NR2E3 PCARE CDKL5 MAK STXBP1 CPT1A ZEB2 SMC1A PCCB NDUFAF4 NEFH INPP5E NALCN OCRL GPHN METTL23 HSD17B10 SMC3 YME1L1 PEX19 CTNS TRNL2 MC1R IQSEC1 TLR3 PRNP RAPSN RAB11A DLL1 HIVEP2 HNRNPA1 SHH DPH1 MSTO1 PIGG PRPF4 TBCK ADAR MTRR MOG HDAC8 MLH3 ITGB6 SRPX2 STAG2 NEK1 LRAT TBL1XR1 WHRN GFM1 ALG13 TREM2 EFL1 ALDH5A1 AQP2 CRX NSD1 MAPT KIAA1549 SLC6A17 ATF6 C12ORF4 GABRD MEG3 TINF2 PSEN1 ADH1C TCF12 APOE TREM2 KMT2C DDX3X ADGRV1 PRPF6 ATP7B TREM2 BCR SOD1 RSRC1 RAB28 SPG7 RNF125 SCN3A AHDC1 SNAP25 PRKAR1A CTNS DLL1 LAS1L EDNRA VHL EXTL3 ARL6 PLA2G6 MAN2B1 COMT KRT81 SEMA4A GCLC AIP CEP250 AGTPBP1 L2HGDH PRPH LARGE1 FCGR2A HTR2A RPS6KA3 PRKAR1A AUTS2 UCHL1 ABCD1 IL1RAPL1 IGF1 GRIA3 OCA2 LHX1 TGIF1 DEAF1 GNE APP TBL1X FAT4 ALG13 ACADS NPM1 ZBTB16 NSUN2 AGTR2 PNPLA6 EPG5 GJB1 ERCC6 PRPS1 COL7A1 DDB2 SATB2 CNNM2 KIF11 SHH ARID1B GABRG2 PDE6A TBX2 IKZF1 PPOX MED13 RORA GRN YY1 ARX SLC1A3 AARS2 TRAPPC14 KCNJ11 RBP3 CTNNB1 UNC119 AIMP1 C9ORF72 PTEN MFN2 CASR NKX2-5 NDN AP3B2 NKX2-1 RAB39B SDHB KCNQ5 TGFBR2 PRPS1 MECP2 CLIP2 LINS1 GRIN2A MAOA PDE6H IGF1R HIRA GNAS SVBP BAP1 MEN1 COX1 SIX3 FOXG1 TIMM8A ELN MCCC2 POLG GNRH1 THOC2 MEF2C DCTN1 ACTB SCN11A SNRNP200 CKAP2L AP3B1 GABRG2 POLG PDGFB PTS CBL POLA1 SCN9A PKHD1 COLQ SON MIR17HG HESX1 GABRB2 TARDBP NOTCH2NLC MATR3 SPG11 PROM1 HPDL DNAJC5 TRNL1 RP9 MRPS22 FRRS1L OPHN1 PCCA RHO NTRK2 C8ORF37 PACS2 GLA PDGFRB HSD17B10 RAX2 SLC25A19 MED13L RARS1 SHH PDE6B TM4SF20 DDC TANC2 SYNGAP1 NEXMIF NFIX SLC12A3 TMEM67 ZNF513 GALC IL12RB1 RNF13 OCRL FGFR2 SLC25A4 ARG1 NDUFA11 NDUFS3 GBA GSN TSPAN7 NAA15 SLC35C1 C12ORF65 ALDH18A1 VPS13A FAM161A AHSG NDUFA12 NBN GRIN2A SLC25A20 TRNH GAS1 GABRA5 ATP13A2 SNRPN COASY SCN2A DEAF1 CNKSR2 FGFR1 IGF1 FTL IDH3B RBPJ SLC7A7 DNM1L PDE4D FGFR1 EGF TAOK1 SIN3A ADH1B GRIN2A ND1 CBS DLG3 WDR73 SUFU NPHP3 FOXRED1 MICOS13 ACAT1 DCHS1 PAK3 HTR2A LTBP2 APP DALRD3 SPR ZEB2 TRIO CCNF ARID2 COMT QDPR GLE1 EBP COL1A1 AP1B1 ITM2B PGK1 HSD17B10 MED12 GUCY2D SLC2A3 CAT RAC1 KIF15 P2RY11 NUP88 MFRP MAOA MECP2 TNF TYR CACNA1H NUMA1 MSTO1 PDHA1 C9ORF72 TNFRSF11A POLR3B MBTPS2 KCNT1 PER2 PSEN2 USH1G RIC1 DRD2 AP3B2 NLGN3 ERBB4 DDX6 TNFSF15 PTCH1 NHLRC1 NLRP3 SEMA4A TRPV4 NDUFV1 WASHC4 TRAF7 MCOLN1 ST3GAL5 RNASEH2A CIZ1 CIC TNFSF4 ODC1 FGFR1 GPT2 AGPAT2 TWIST1 NDUFA13 GABBR2 BCORL1 PIGW NDUFA4 HCRT ACSL4 ND1 STS COG4 MID2 LRMDA CHMP2B PDE10A STAG2 PTCH1 ANOS1 PDZD7 NDUFAF3 POLR3A ABAT ALDH5A1 SNCA PYCR2 GATAD2B SNRPN C19ORF12 DNAJC6 NACC1 TP63 SNCA HLA-DQB1 ASH1L THRB FGF8 VANGL1 TSC2 KANSL1 NOVA2 MAPK1 IFNG DBH NDUFS3 HNF1B NDN TCF20 WDR11 IDS PANK2 SPG21 PPP2R2B RAI1 NABP1 BSCL2 OPHN1 NAGS OCA2 PCGF2 FLCN DNAJC13 ALG11 CAV1 BCAP31 DYRK1A RPS20 HLCS ZEB1 LYST SMO NONO SNRPN MAPT SCN9A LEP CHMP2B SLC25A1 MAN1B1 CPOX IL1RAPL1 TBK1 NEK2 TNIK APC2 ZNF423 SPIB PIGL FGFR1 NDUFS8 CACNA1C NECTIN1 POMT1 FBXO31 CFAP43 GUCA1A VPS13A TBL2 BBS2 CSNK2B HERC1 TAC3 METTL5 PANK2 PRNP GRIN1 TUBB2B NEXMIF CSNK2A1 MTOR RFC2 ATXN3 SARS1 GATA4 TRAPPC9 SNORD116-1 MN1 LRAT POLR2A GRIN1 RRM2B RAX2 ST14 MPLKIP IL12A POLA1 NPHP1 SMARCB1 WDR4 FLT1 PPP2R1A SIX3 UNC93B1 SMPD1 BSCL2 CRKL CACNA1D CDKN2B SZT2 PROP1 GNAT2 HS6ST1 SLC2A1 SAMHD1 DNA2 MST1 RPS6KA3 MRPL12 WFS1 CDON GBE1 SRPX2 SRSF2 SLC18A3 SMC1A FOXRED1 AVPR2 CABP4 OPA1 CACNA1B SDHC GABRB3 PRDM16 EDC3 UBE3A STOX1 ASAH1 RPS23 LAMB2 ACTL6A NDUFS7 TK2 ZIC2 OVOL2 VLDLR UBE3A PRRT2 NUBPL ERCC2 RTN4IP1 CFAP410 EXT2 USP27X UBTF KCNK9 GRN NDUFB3 SYNJ1 EIF4G1 HBB RERE DMPK MAPT ZC4H2 TRNE SKI PIK3CA PRDM8 NR3C1 HFE SMC1A POMT2 SLC46A1 MTFMT PRNP RTTN CHAT SDHC KRAS TLR4 DLAT COX7B SLC25A1 PTCH1 VRK1 PRNP MYT1L GLI2 PDHA1 RP1L1 GAS1 PCDH19 CSF1R TET2 TBP CRB1 NDUFA13 AP4E1 ANK3 PDGFB CIB2 NDUFV1 ATP7A HGSNAT SH3KBP1 DPP6 SLC6A19 MAGEL2 WARS2 STAT4 KISS1R TG GTF2H5 HESX1 AFF2 RUNX1 ALDH3A2 PIGC HPRT1 NSMF ALG1 MAPK10 OPN1LW PIGP UBA5 SGCE UBAC2 CHST6 SCN1B CARS2 PARS2 TMEM138 BMPR1A CHD7 MMADHC ARF1 TGFBI ALKBH8 MTHFR NDN TMEM70 PLCD1 HK1 POMT1 TDP2 PON3 CHMP2B BCKDK CACNB4 CREBBP ALPL SYT14 NAGLU TRNL1 RET TRMT1 ENTPD1 SNRPN ATF6 AKT1 RERE RSPRY1 FIP1L1 TBK1 C2CD3 ND5 SDHD SYT2 HSD17B10 DLG3 GFM2 NAA10 DRD5 SARDH FGFR3 EP300 MAGEL2 NDUFS4 FXR1 AHDC1 MRE11 MFF PAX8 DLL1 SLC24A5 HCRT HLA-DRB1 SETBP1 MECP2 CEP78 LHCGR NODAL GRM7 VDR ERCC4 ALS2 RDH12 ELOVL1 NDUFAF1 FUS HDAC8 PROKR2 USP7 TREM2 SLC25A11 GNAS RHO RET FLII HSD11B2 COA8 CLTCL1 C8ORF37 AP1S2 RLIM DPF2 ASAH1 PIGQ CLN8 HLA-B SREBF1 SDHA MVK
Protein Mutations 1
V617F
SNP 0
HP:0008069: Neoplasm of the skin
Genes 287
FERMT1 TYR BAP1 TNFRSF4 MSH2 COL7A1 CDK4 RPS20 MC1R TINF2 WRN KRAS SMO COL7A1 DDB2 CDKN2A KRT16 PSENEN IL7 APC LAMA3 POLH VEGFC LMNA KRT17 FCN3 GJC2 MSH3 HPGD RECQL4 CREBBP COL7A1 KIT PDGFB PTEN KRT16 SDHC EPCAM PTEN XPA TMC6 GJB6 MLH1 HRAS SUFU TGFBR2 PTCH1 CTNNB1 TNFRSF1B WNT10A MPLKIP CDKN2A IL6 GJB2 TP53 LAMC2 TARS1 NF1 FH GNA14 DCLRE1C NF1 WRAP53 NTHL1 KRAS SMARCE1 FH BAP1 ERCC3 EP300 FDPS ERCC4 MVK PIK3CA PERP PMS1 CTSC PORCN ALX3 NUTM1 ING1 PMS2 KIT SLX4 IGLL1 SEC23B RASA1 CD28 HRAS TRPV3 KLLN AKT1 TSC1 PTCH1 KRT17 TCF3 RNF113A MBTPS2 IGHM PDGFRB MEN1 CD79A PIK3R1 FASLG KDSR NRAS IL7 CYLD TMC8 CD79B WNT10A KRT17 COL1A1 IVNS1ABP DOCK8 PRKCD PTCH1 NRAS ERCC3 KRT14 CXCR4 KRT5 ERCC2 MLH1 BLM MITF NRAS KRAS KIT APC TERC NF1 FLCN TERT TNFRSF1B CDKN2A DCC ERCC2 TSC2 SLC17A9 USF3 NF1 NTHL1 FAS PRKAR1A KIT SNAI2 PIK3CA LMNA HRAS IKBKG FAN1 BRD4 RSPO1 TP53 SDHC GJA1 BLM RNF6 FH MSH2 SLC45A2 TERT CIB1 GJB3 TNFRSF10B PIK3CA ECM1 ERCC2 SEMA4A KRT6B DMPK SEC23B PMVK ERCC5 GJB4 TGFBR2 SMO NF2 NF2 RMRP FAS MLH1 CARMIL2 MVD PDGFB SUFU NF2 DKC1 ERCC3 NRAS CASP10 STAT1 PTEN LAMB3 GJB2 BAP1 GTF2H5 RECQL4 DDB2 SMARCB1 CYLD FGFR1 MSH6 NOTCH3 CXCR4 BMPR1A TYR PLCD1 PTCH2 CTLA4 OCRL KRT1 MSH3 MSH2 KRT17 NRAS SDHB KRT6A MC1R CD28 CREBBP CIB1 PIK3CA SDHB STIM1 AKT1 TMC6 KEAP1 AKT1 CTLA4 NLRP1 MLH3 PTCH2 APC KRT6B MLH1 LZTS1 GJB2 CDKN1B KIT TRAF7 DICER1 PTEN MMP1 PRKAR1A KRT9 BMPR1A NF1 MMP1 CTNNB1 RASGRP1 NF1 SPRED1 FLT4 SDHD LRRC8A KLLN GTF2E2 PTEN SASH1 BLNK ANAPC1 PIK3CA GNAS XPC BRAF ERCC4 ERCC3 MSH6 ERCC2 OCA2 KIT ERCC4 IFNG APC GPR143 CYLD FLT4 STK4 POLH ERCC5 WWOX HRAS SLCO2A1 XPC TMC8
SNP 0
HP:0002104: Apnea
Genes 425
TGIF1 TNFSF11 TRNK MAGEL2 PET100 GLRA1 GNE CSPP1 HSPG2 NODAL GNE MAGEL2 TECPR2 BRAF D2HGDH FGFR3 SHH ARL3 NGLY1 LARP7 ND1 BCHE CTNNB1 SLC5A7 PTF1A SCN5A OCA2 NDUFA2 NDUFAF2 CEP120 NEB RPS6KA3 NDN TSEN54 BUB1B FGF8 GAS1 PRPS1 SIM1 FOXH1 CPLANE1 RET SDHA PLCB4 LAMB2 CEP290 TCIRG1 DST ARMC9 CEP41 DLL1 CSPP1 SIX3 MYO9A GABRG2 COL3A1 PEX13 MTHFR DCTN1 PIBF1 FOXH1 SURF1 P4HTM ND4 MECP2 FGFR3 SLC25A20 NDUFS8 CDON COLQ KIAA0586 BRAT1 CC2D2A PLPBP GAS1 PCK1 CREBBP FBP1 NPAP1 SOX9 PCCA FGFR2 AHI1 CDON PHOX2B SLC5A7 INPP5E VPS51 SHH USP7 DISP1 TRNV NDUFAF6 STAT2 ZIC2 SNORD115-1 SH3BP2 DISP1 CHRNE TOE1 FGFR2 DNA2 MKRN3-AS1 GSN FOXH1 LIFR TDGF1 TMEM216 COX15 NDUFA12 HRAS NGLY1 GLI2 FGF8 CDKL5 INPP5E KATNIP SNRPN NADK2 GPHN KIAA0753 SCO2 FGFR1 MKS1 ND5 BTD PWRN1 IPW ASCL1 AP3D1 HTRA2 TMEM216 SCN4A DISP1 GNAI3 STAG2 GPR101 SIX3 KIAA0586 SNRPN SLC19A3 SCO1 TSPYL1 UNC80 ACADSB SCN2A KCNQ2 ZIC2 MECP2 PRMT7 KCNQ3 ND3 PDHA1 SNX10 TERT FGF8 KIAA0586 SHH NDUFS2 NDUFS1 AMER1 CREBBP KIF7 OCA2 HSPD1 NODAL SKI KIF5A CEP57 CEP57 PTCH1 ZIC2 SYT1 ECHS1 CEP120 TRPV4 PURA DLL1 NDUFV1 HMGCL SATB2 RERE TWIST1 NDUFA13 GABBR2 MAGEL2 NDUFA4 PLAA OFD1 CDON SLC6A9 ECHS1 HYLS1 PTCH1 STXBP1 NACC1 GLI2 PWAR1 PLCB4 TCF4 TACO1 AGRN IDUA TCTN2 NDUFS3 PRRT2 LIPT1 SLC18A3 NDN MKRN3 TRNL1 IDS FGFR1 RAI1 TBR1 OCA2 PCGF2 FLCN COQ2 DKK1 LIFR VAMP1 NDUFA11 NONO NDUFA10 CCDC47 ND2 IDUA FGFR3 RPGRIP1L SFTPB ATP5F1A ASCL1 FBN1 ZNF423 NDN SLC2A1 SYT1 CLCN7 KCNQ2 NTNG1 SPOP NDUFB8 CREBBP TMEM237 BUB1 NDUFS7 PDE6D TMEM231 ACY1 TMEM237 NEK1 PIGT TSPYL1 NDUFS8 NDUFAF5 SNORD116-1 PLAA CEP104 PEX5 MCCC1 SLC6A5 CTSD SIX3 LTBP3 EP300 GLI2 ABCA3 RPGRIP1L FAM149B1 SOD1 KCNQ3 FARS2 DNA2 MAGEL2 BRAT1 ATN1 DPAGT1 TMEM107 TCTN1 CDON SRPX2 GNAI3 IDS NDUFV1 SLC39A8 FOXRED1 GABBR2 LRRC32 TMEM216 CISD2 ZIC2 AFF4 GPR101 ADGRG1 EDN3 FOXH1 NDUFA2 EDN1 RARS2 NDUFV2 ARCN1 SCN8A FBP1 GNPTAB FGF8 SNRPN TCF4 ZC4H2 TGIF1 TMEM237 POGZ NDUFAF3 NDUFAF2 CPLANE1 TCTN3 TRNW SMC1A MTFMT SCN4A CHAT TDGF1 SCN2A SLC25A1 PTCH1 RPGRIP1L PRNP GLI2 PDHA1 GAS1 GAS1 DMPK MKS1 SURF1 NDUFS1 PSAP COQ2 ARL13B TGIF1 GLUL AHI1 MAGEL2 GBA KAT6B PI4KA MYO9A ARMC9 RUNX2 GRIN2A PTCH1 COL13A1 SLC18A3 OPA1 TDGF1 AHI1 CSPP1 NFIX AIP NDUFS2 TMEM138 TGIF1 IDS NDN PIBF1 PCCB KCNQ2 NEFH SKI INPP5E NDUFA9 NPHP1 TECPR2 ALPL TDGF1 RET DLL1 SNRPN SHH PHOX2B CPT2 DPH1 CEP290 SIX3 GBA TMEM67 BMP2 CEP41 HERC2 C2CD3 SRPX2 STAG2 SYT2 B9D1 BUB3 ND6 RBM10 FGFR3 EP300 CRYAB MAGEL2 TRIP13 NDUFS4 CC2D2A FXR1 AHDC1 FXR1 INPP5E RNF125 LIAS AHDC1 MECP2 WFS1 NODAL SNAP25 GDNF DLL1 USP7 ATP6 NODAL PRPH TMEM67 CHAT NALCN DISP1 BTD
HP:0001392: Abnormality of the liver
Genes 1400
TNFSF11 UBR1 TRNK B3GLCT PEX3 NDUFS4 SCYL1 TREX1 CASP8 IARS1 SLC25A13 TRAPPC11 ABCC2 ALG9 GTF2IRD1 CAVIN1 EPB41 CD247 RASA2 APC NHLRC2 PEX3 TSHR NGLY1 ARVCF FANCM UCP2 ND1 ANTXR1 SDHD NELFA RREB1 NLRP3 HPGD CD70 LETM1 KIF3B IFT172 NPHP3 ARSA ASS1 TCF4 WDR35 SHPK RFX6 PSAP PEX11B PEX6 ERCC4 PAX4 SETBP1 HBB APOB RIT1 CEP164 ZAP70 ZIC3 STK11 STN1 GPC1 CYP27A1 GNPTAB DYNC2H1 PEX11B PDGFRL PEX1 PKLR GALK1 AP1S1 TTC7A BRIP1 TREX1 HSD3B7 PLIN1 FDX2 CD81 TNFRSF13B SEC24C POLG2 UROS KLF11 IL36RN PIK3CA CLDN1 SLC37A4 PIGA CD96 CYBA ERCC8 AKT2 FANCG FOXF1 TET2 NDUFV2 GLIS3 DLD PEX2 GNS AKT2 SLC25A20 RRAS2 CASP10 TNPO3 XRCC4 PC NEUROD1 WDR19 NOD2 CEP290 PTRH2 CCDC115 C8ORF37 CPOX SLC13A5 NSMCE2 HAMP VPS45 FBP1 SPTB PRKCD SPECC1L CBS DNAJB11 COG8 HOXD13 RNU4ATAC KMT2E PKD2 TTC21B PKD2 PDX1 NPHP1 AKR1D1 IFT27 CBL PHKG2 PEX19 USB1 NLRP3 SPTB TMEM70 PEX26 CR2 PEX12 SEC63 SPOP ACVRL1 FAH STX11 HNF4A SDHA NEK1 MADD ERCC8 PDGFB FANCL CPLX1 FAS ALDOB PSAP TCIRG1 CALR PEX16 ACADVL RINT1 FAN1 TET2 TKT RFX5 SLC2A1 VPS33A HMGCL MYRF RFT1 SLC4A1 XK NGLY1 DLL4 PCSK1 MSH2 C11ORF95 MVK MCM4 FLI1 AGPAT2 TINF2 ARSA IYD CFTR CR2 CASK ESCO2 LRP5 AGA TRIM37 MET NLRP3 SMPD1 KRT18 FANCF IGF2R NCKAP1L WDPCP GATA6 BBS9 LACC1 ACADVL APPL1 IFT80 CPT1A PEX1 IGF2 KIF20A STAT1 DLL4 PLEKHM1 RMRP KRAS IFT140 UQCRFS1 PEX12 HNF1A PRKCSH TRNN SCO1 BTK SLC25A15 MSH6 PEX13 ERCC8 BSCL2 SLC39A4 NDUFB11 RBCK1 HNRNPA2B1 PALLD RNASEH2B UGT1A1 NDUFAF8 SLC44A1 PSMB9 CCND1 AHCY ATPAF2 SMAD4 SKIV2L SNX10 HMBS TERT ALG8 ABCC8 SC5D TMEM216 NPC1 POMC FANCI FAS SLC22A5 SCARB2 HBB HFE LDLRAP1 HADH MMAA MYBPC3 PEX6 MET NOTCH2 PEX10 CTLA4 RPGRIP1L TRIM28 NPC2 SCYL1 ALMS1 CP VCP TUFM IDUA SBDS COG6 RFXAP GPC3 B9D1 TRHR DHDDS TTC7A PEX14 CYP19A1 INTU SLCO1B3 PTEN NLRP1 TIMMDC1 BBS7 DUOX2 HNF4A COG5 LDLR MMEL1 DNASE1L3 RASGRP1 FANCA DLD COG4 MARS1 PCK2 SOS1 KRT18 IARS1 ENG SCNN1B TYMP HNF1A DHFR GPI LPIN2 TGFB1 MAN2B1 KCNQ1OT1 TTC21B NPM1 NDUFS4 SLC2A1 HNF1A TSHB IL18BP ANK1 CTLA4 MMUT PCSK9 CEP19 KLF1 POLG2 IL21R APC IRF5 IL17RC SAR1B TERT PIGM PEX1 ERBB3 LYZ DYNC2H1 ATAD3A DNAJC21 CTNNB1 MPI PEX14 CFTR PSAP IFT80 RHBDF2 PPARG RTL1 TGFB1 MKS1 DDOST HBA2 TRNE TSFM NDUFB9 NPHP3 EWSR1 GCGR POU6F2 PLPBP PMM2 IDUA SFTPA2 IRAK4 APC HBG2 SLC29A3 RAG2 PEX10 JAK1 GBA MMUT JMJD1C SLC30A10 CPT2 NDUFS6 PALB2 GALT OCLN ETFDH TBX1 WDR19 FLNC NCF4 FASLG COX4I2 IFT172 RFXANK PEX12 PIEZO1 EPB41 BCS1L GBA CORIN ENG SPTA1 PTPN3 PHKB AGA RAG2 TPI1 FECH ALAS2 IL17F MADD MKKS FANCC PYGL LIMK1 PEPD BLK AMACR MCCC1 TWNK MKS1 CNOT1 APC ATP7B NCF1 CD3D NDUFAF1 IL2RB RNU4ATAC CDKN2A NDUFA6 SAA1 FARSA PMS1 IL7R RNASEH2A FAH GAA ABCB11 BRCA2 NDUFS2 TTC37 LMNA SPTA1 PKHD1 ND3 IL17RA KRAS TMEM216 KLF1 IGLL1 BRCA2 DPAGT1 SPTB IGHM PEX16 FASLG PEX10 SOX10 SLC39A8 FAM111B DNAJC19 GDF2 INSR HLA-DRB1 MRPL44 PEX13 NDUFA1 CYBB NEU1 CD3E BSCL2 ATP6AP1 MLH1 PTPRC BCHE TNNI3 GPIHBP1 SNX10 KRT8 PTPN11 CC2D2A FBP1 ACAD9 GNPTAB IDUA CTSK XPR1 ACVRL1 TFAM CYBB TFR2 POLG HADHB MTTP NRAS ARSA LPIN2 CC2D2A CLCN7 DOLK NEU1 ADA SETBP1 FANCB STAT3 ABCB4 PEX6 PEX2 PEX10 ETFB SFTPC SLX4 TSC1 SLC25A13 PGM1 A2ML1 RPGRIP1L PHKG2 HMBS MEFV GABRD ITCH BRCA2 SEMA4A PLAGL1 TRMT5 PALB2 NDUFAF2 ASXL1 ABCG5 DMPK USP18 VPS33B TMEM67 UFD1 HYMAI C1QBP AXIN1 TREX1 HNF1B HNF4A ASAH1 SLC29A3 NOTCH2 UBE2T SRP54 GBA DKC1 JAK2 TSHR TCIRG1 BBS5 POLG2 ERCC6 MMAB HBB NFKB1 IL1RN KCNQ1 TMEM126B ACADM EIF2AK3 ABCB4 DNAJC19 TALDO1 ARL6 PEX12 AP1S1 STEAP3 UNC13D PEX5 HADHA HFE SP110 NFKB2 TRAPPC11 PHKA2 ANK1 IDS CPT1A RNF43 PCCB NDUFAF4 SETD2 KCNN4 ERCC4 CTLA4 INPP5E HMGCS2 DZIP1L NEUROG3 PEX16 JAM2 COG1 POU2AF1 PEX19 DIS3L2 CD28 POLG PEX5 RHAG ADA2 BPGM UROD BCS1L RBPJ WDR19 MRPS7 HNRNPA1 BMPER CPT2 H19-ICR SLC25A13 ADAR TMEM67 MTRR GYPC MLH3 HBA2 GFM1 EFL1 TERC DDRGK1 FOS BOLA3 TF GLB1 MEG3 BBS12 DPM1 AIRE LIG4 PARN HSD3B7 ATP7B PIGS TPO BBS2 PEX11B TRIM37 GLB1 PPARG DCLRE1C SCNN1A UQCRB GPC3 CYP7B1 ALG9 NHP2 IGF2 EXTL3 MAN2B1 COMT PRKCD BLNK MYORG IL2RG OSTM1 IL7R SLC17A5 GCLC ABCG8 SMPD1 APC ETFA RHAG WT1 SPRTN LIPA RAB27A RAG2 SDHC IER3IP1 NR1H4 SMAD4 CYTB BTNL2 ADAMTSL2 INVS GDF2 PSMB4 CLCN7 FGFR2 GNE PEX6 ARHGAP31 JAK2 MS4A1 GNE G6PD BBIP1 DHCR7 MPI TINF2 INSR ERCC6 CAVIN1 ATP6AP2 LBR BBS1 IFNG KIT RRM2B LIPE HNF4A LMNA JAK3 BMP2 ABCG8 PIK3C2A LMBRD1 IFT172 PEX3 NBAS IFT140 BTK AMACR HBG1 CTBP1 LZTFL1 BTNL2 PEPD KCNJ11 GALT GAA SNX14 MFN2 SEC63 MYC ERCC6 DYNC2I1 TP53 CASR NKX2-5 BBS10 RAD51C NAB2 MPV17 TMEM67 GALE PSAP PEX13 REST TGFBR2 PRPS1 PLEKHM1 TTC8 CLIP2 ABCC8 H19 CYBC1 ELN RAG1 PKD1 NPHP1 EPB42 CLEC7A HIRA GP1BB DYNC2LI1 TCIRG1 CYP27A1 SLC26A4 PMM2 FERMT3 HSD17B4 PEX3 ELN FUCA1 EXTL3 HJV TMEM67 MYD88 AGGF1 ARSB MOGS RIPK1 KCNN4 NDUFAF5 HFE NOTCH1 PMS2 DUOXA2 FOXP3 WDR19 USP9X TRMU ND4 SDCCAG8 AP3B1 CBL APOC2 LPL CD28 PKHD1 SON LIPE PPOX TCF3 SUMF1 CA2 HESX1 CC2D2A PDGFRB CEP83 STXBP2 TARS2 GLRX5 HNF1B PCK1 IFT122 TET2 SLC40A1 BBS4 SLC7A7 ARL6 ABHD5 BCS1L STK11 PEX2 PCCA TTC37 DOCK6 DAXX INPPL1 DIS3L2 KRAS TNFRSF13C PRSS1 AP1B1 HSD17B10 SF3B1 SLC25A19 TERT DYNC2I2 TNFRSF1B FANCD2 SLC30A10 IL7R LMNA AGL GPC4 FECH H19-ICR TRNV NAGA RMND1 CIITA KIT GBA G6PC3 CEP290 PEX26 GUCY2D NDUFB10 TRMU TJP2 TMEM67 DNAJC21 PEX26 IL12RB1 SH2D1A XRCC4 SLC25A4 IDUA IL2RA ARG1 PEX19 NDUFA11 NDUFS3 MED25 GBA SLC35C1 HJV IQCB1 MRPL3 SP110 EPB42 VPS13A NAGA SERPINA1 NHP2 SLC4A1 ATP8B1 LIG4 ADK SLC25A20 RAG1 CEP55 RRAS SLC22A5 SKIV2L CLDN1 PSAP TREX1 ZAP70 ALDOB LMNA GATA2 ND2 ND5 IFIH1 IFNGR1 BRCA1 SLC7A7 NDUFS7 FGFRL1 APOE GATA6 JAM3 GCDH UGT1A1 CBS AP3D1 SOS2 ABCA1 NPHP3 TKFC FOXRED1 LIPA PEX3 CSPP1 ACAT1 PCCB CASP10 ALDH7A1 TNFRSF13C FADD BLVRA PPARG GCK KPTN MECP2 LBR AP1B1 PCCA SBDS KCNH1 SLCO1B3 MRAS MRPS28 TNFSF11 CYP7B1 DCDC2 PDGFRA PEX1 SLC25A15 NPHP3 ADA SLC20A2 LIPA PRF1 ND3 TRAF3IP1 ACAD9 GBA SLC4A1 GBA JAK2 TNFRSF11A SUMF1 GUSB CD40LG MSH2 DHCR7 LARS1 MMACHC F5 MIF GUSB ABCC2 NSD2 TRIM32 GBA LBR NCF2 MAN2B1 CEP290 FOXP3 RAC2 PKD1 TNFSF15 RELA SDHA TPP2 SDCCAG8 CIDEC RAG1 STAT6 CDKN1C IFT43 HAVCR2 HMGCL HBB SLC4A1 ACP5 XIAP RNASEH2A IL2RG ATP7A SPTB POLR3A AGPAT2 BTK CARS2 ALG13 ERCC1 ATRX TMEM231 ND1 COG7 IDUA MUC5B COG4 PRKCD NPHP4 LRRC8A RMRP SPINK1 PIEZO1 MPC1 EARS2 ABHD5 NDUFAF3 LCAT PSAP ABCA1 ABCD3 C1S CPA1 KCNJ11 LONP1 CTCF GANAB MSH6 TSC2 PEX14 DGUOK TNFSF12 TMEM107 PEX16 SLCO2A1 COG2 SDHB TRNL1 IDS CHD7 SLC37A4 BSCL2 DPM2 NAGS B2M ARSA CTNNB1 TNNT2 SRP54 CAV1 RPS20 SLCO1B1 DYNC2LI1 LYST PLIN1 CD19 HMOX1 APOA1 ADAMTS13 CCDC47 CYP7A1 ND2 SLC25A1 EIF2AK3 CPOX CPOX CIDEC ITCH APC2 SERPINA1 GPD1 PTRH2 LYRM4 GBA UGT1A1 APOE PFKM POLG TNFRSF1A SPIB CLCN7 YARS2 NSD1 NDUFS8 F5 KCNN3 LMNB2 DYNC2I1 RHAG GNMT HYOU1 TBX1 TNFSF12 EPCAM JAK2 PEX14 ATP8B1 TBL2 MLH1 AKR1D1 TBX19 ATP11C FANCE PDGFRA TGFB1 CTNS NCF2 PNPLA2 TNFRSF1B CEP120 DDRGK1 RFC2 FUCA1 SLCO1B1 PSTPIP1 NPHP3 SLC40A1 CTRC UGT1A1 NDUFS1 TMEM165 RNASEH2C NSD2 TRNW LHX3 FH RRM2B NOP10 PEX5 PEX19 IL12A IL6 FLT1 CD19 SURF1 LTBP3 SMPD1 BBS1 MPV17 B9D2 BRCA1 BSCL2 MPL PSMB8 DCTN4 KRIT1 CLCA4 CTSC LRP5 PROP1 ASL CLCN7 TRIP13 SLC25A19 FCGR2A MST1 ANKS6 ALDOA TRAF3IP2 TBX1 IDS SRSF2 TRIM28 WDPCP ALG8 CD79A PIK3R1 NOP10 TRNS1 TRAF3IP1 ALG2 RAF1 SCNN1G COG6 CD79B HEXB CTSA CPT2 PRDM16 STOX1 ASAH1 SC5D NDUFS7 HK1 TALDO1 NUBPL RPGRIP1 COX15 MAGT1 PAX8 ABCA1 STEAP3 HADHA TERC PHKA2 RTEL1 INS CYBA NDUFB3 PEX12 GPC3 HADH CASR SMAD4 RASGRP1 HBB CASR GBE1 RERE DMPK ICOS FADD MAD2L2 DCDC2 PNPLA6 SKI LMNA ABCB11 EOGT WT1 SEC23B TRNW ICOS RFX5 SLC25A13 ABCB4 GLB1 DCLRE1C ALMS1 NCF1 HBG2 CYBC1 CDAN1 FGA PARS2 LRPPRC RPGRIP1L IL2RG LHX4 KCNH1 TBX19 CDIN1 ACOX1 HBB TMPRSS6 TNFRSF13B LMNA TET2 HAMP NRAS PEX26 TP53 PNPLA2 POU1F1 WRAP53 FAS ABCG8 SAMHD1 WDR35 NDUFV1 ATP7A RFXAP TMEM199 G6PC1 PEX6 CCDC28B KRAS GTF2I DGUOK HGSNAT APOA1 NHP2 TG NEK8 IFIH1 TERT RUNX1 CLPB RNASEH2C ALG1 CIITA HADHA COX14 SLC11A2 RNU4ATAC OFD1 XYLT1 WDR35 EFL1 CD27 BMPR1A PEX2 RBM8A ATP8B1 MKS1 POLD1 NSMCE2 RAD51 POMC MMUT PRKCSH HBA1 CAV1 XRCC2 ITK VHL BICC1 RECQL4 AUH ERCC6 PKLR FARSB RAB27A NAGLU CTC1 PRSS2 PEX5 SLC5A5 LYST GBA JAG1 MYPN C4B LETM1 STX1A RFWD3 APC CFTR CEP290 WHCR GPC4 ICOS RFXANK CDKN1B ERCC8 HPD CA2 ND6 ACADM PRKAR1A MLXIPL VIPAS39 LZTR1 HLA-DRB1 MPL INPP5E PAX8 CD55 HLA-DRB1 MVK DKC1 DLK1 DYNC2I2 APOE KRT8 UGT1A1 POU1F1 SGSH GPR35 BAZ1B ERCC4 NDUFAF1 FBN1 RFT1 HBA1 WT1 TERC PIK3CA GNAS ATP6V1B2 PEX1 CPT2 ATP6 COA8 ACOX1 TCTN2 GANAB TMEM67 KCNAB2 VPS33A GALNS CEL PYGL NEU1 XIAP GALM BTD PRKAR1A FGFR2 MVK
HP:0001903: Anemia
Genes 774
LCAT KMT2D RPS7 TNFSF11 GSS PET100 COL7A1 GATA1 EPB41 TERT NHLRC2 NTRK1 FANCM RPS15A PTF1A NLRP3 MALT1 HPGD FMO3 SHPK PSAP TERT HBB RPL15 STK11 AK1 WAS SDHA TARS1 PKLR TTC7A HBA1 PHGDH RARA ALAS2 BRIP1 RPL26 FDX2 CD81 PNPO UROS SLC19A2 ATRX ERCC8 FANCG TET2 GP1BA TERC RPL35 CFHR1 SURF1 ALAD CASP10 EPHB4 ACTN4 LMBRD1 ABCB7 NOD2 CPOX TRNW VPS45 SPTB PHGDH PRKCD KCNE1 EPO FOXP1 TINF2 ADA2 PHKG2 CFI USB1 AMN NLRP3 SPTB NDUFAF6 STAT2 CR2 ACVRL1 AMMECR1 STX11 MEFV LIG4 THRA TSR2 RPL35 SBDS FANCL FAS TCIRG1 CALR SLC25A10 COX10 HBA1 SLC2A1 VPS33A HMGCL COX15 MDM4 SLC4A1 CTLA4 FLI1 MMADHC HBA2 TINF2 SCO2 CASK TFRC HBA2 EXT2 NLRP3 FANCF MTRR ND4 RPS19 STAT1 PLEKHM1 DGKE RPS28 RMRP IFT140 UQCRFS1 NPHP4 BMPR1A TRNN SLC19A3 BTK PSMB9 STIM1 UMPS SMAD4 ITGB3 FANCC SMAD4 ISCU STAT1 SNX10 TERT FANCI FAS NDUFS2 SCARB2 HBB MMAA GPX1 FARS2 GALNT2 CP ECHS1 SBDS RFXAP TTC7A RAG1 UROS TRNS2 NLRP1 RASGRP1 ATRX FANCA ABCD4 MARS1 RPS19 HBB ENG TYMP DHFR GPI LPIN2 KIF23 RPS24 NPM1 SLC2A1 TACO1 IFNG ANK1 AASS CTLA4 MMUT RPS29 KLF1 CFB UMPS MYSM1 ERBB3 NSUN2 FERMT1 DNAJC21 UROD HBA2 LYRM7 RPS10 ELANE WFS1 RPS26 EWSR1 PIGA ABCB6 HPRT1 FANCF HBG2 SLC29A3 THBD RAG2 SLC46A1 PGM3 MMUT FANCE COL7A1 PALB2 PNP IL12B MYSM1 SPTA1 ATRX FASLG COX4I2 RFXANK PIEZO1 EPB41 GBA ENG SPTA1 MPLKIP PARN LAMC2 RAG2 TPI1 FECH ALAS2 GNA14 FANCC CD59 PEPD RPL5 ZBTB24 IDH1 ATP7B CLCN7 GCLC IL2RB FARSA RPS10 STAT4 SPTA1 MLX KRAS KLF1 HBB TBCE BRCA2 SPTB RNF113A FASLG DNAJC19 GATB PNPO BRCA1 CISD2 GSS GDF2 HAVCR2 CFH STAT3 SRD5A3 NDUFA2 PRKAR1A IDH2 SNX10 COX3 CD3G NDUFV2 CTSK TREX1 ACVRL1 TFR2 MTTP NBN NRAS LPIN2 CLCN7 SLC12A3 ADA NDUFAF3 NDUFAF2 CFH CRIPT FANCB STAT3 HLA-B SLX4 CLCNKB SLC25A13 DNMT3B TCN2 RPL31 YARS2 RPS26 ORAI1 IRF2BP2 ASXL1 SAMD9 RPL5 RPS27 CD247 SURF1 RPS24 RPL35A FTCD TREX1 ASAH1 UBE2T SRP54 GBA DKC1 TCIRG1 ITGA2B LAMB3 MMAB HBB NFKB1 IRAK1 RECQL4 RPL27 DNAJC19 TALDO1 STEAP3 UNC13D LAMB3 NDUFS2 NFKB2 PHKA2 ANK1 HBD LAT HELLS PCCB MTHFD1 KCNN4 ERCC4 LARS2 OCRL DKC1 GATA1 POLG RHAG ADA2 BPGM TSR2 TET2 PML SARS2 MTRR BMPR1A GYPC HBA2 CP COL4A1 TBL1XR1 EFL1 TERC ATRX TF BMPR1A LIG4 PARN ATP7B PFKM REN DCLRE1C WFS1 FANCA ACAD8 NHP2 FANCB PRKCD PLA2G4A IL2RG OSTM1 PTH1R GCLC SMPD1 SLC4A1 RHAG WT1 LIPA RAG2 CLPX SDHC FCGR2A SMAD4 KDM6A BTNL2 IRX5 PSMB4 FANCG UBR1 ND6 MS4A1 G6PD GATA1 NPM1 ZBTB16 ERCC6L2 TINF2 COL7A1 BMPR1A RPS27 PUS1 IFNG KIT RRM2B LAMA3 IKZF1 ABCG8 LMBRD1 TF HBB HBG1 GALT GATA1 CASR RAD51C PRDX1 MUC1 PLEKHM1 MTR IGH CYBC1 ITGB4 FANCD2 RAG1 PRKACG EPB42 TCIRG1 COX1 FERMT3 MYD88 AGGF1 NPHP1 RPL11 NT5C3A RIPK1 KCNN4 MPL SLC40A1 SLX4 FOXP3 RPL27 CBL PPOX CA2 RPL11 GREM1 STAT5B STXBP2 GLRX5 TET2 SLC7A7 STK11 PCCA CD46 SMAD4 DAXX ABCB7 PACS2 RPS15A GLA HBA2 SF3B1 RPL15 TERT FANCD2 PTPN22 IL7R FECH SMARCAL1 HBB KIT G6PC3 TMEM67 DNAJC21 IL2RA CTC1 GSR SLC35C1 PNP SP110 EPB42 SLC4A1 NDUFA12 NBN TRNS1 FCGR2B TRNH RAG1 AGXT ACD TGFB1 ZAP70 C3 IFNGR1 SLC7A7 DNM1L NFKB1 LAMA3 RMRP HBB ND1 ABCA1 SLC19A2 TKFC STING1 RPS14 CASP10 TNFRSF13C RPS17 TBXAS1 RPL18 TRNQ MECOM PGK1 SBDS TNFSF11 PDGFRA CAT KIF15 ADA XRCC4 BCL10 TNFAIP3 PRF1 GBA SLC4A1 NUMA1 PDHA1 JAK2 TNFRSF11A GLA FANCL CD40LG LARS1 MMACHC SLC25A38 CUBN TMPRSS6 GBA MPIG6B SPP1 ELMO2 FOXP3 STIM1 RPL35A KIF1B SDHA TRNF TPP2 RAG1 NDUFV1 HMGCL HBB RPL18 SLC4A1 HBB-LCR ACP5 SPTB NDUFA13 MMP1 NDUFA4 ATRX PCNT PRKCD RPS7 RPL26 COG1 RMRP PIEZO1 PLEC ABCA1 NHEJ1 ABCD3 ANAPC1 SPTA1 FAM111A TNFSF12 DBH NDUFS3 LIPT1 RPS28 RAC2 SLCO2A1 SLC25A21 SDHB CHD7 NABP1 TNFRSF4 CFI PHF21A NPHP4 TRNT1 SRP54 HBB LYST HMOX1 APOA1 ADAMTS13 NDUFA10 GATA1 HSPA9 RPS17 GBA ENG PFKM FAM111A DDX41 CLCN7 YARS2 COL7A1 NDUFB8 RHAG NDUFS7 HYOU1 TNFSF12 TOR1A ZBTB20 SLC4A1 NDUFS8 ATP11C FANCE WIPF1 TGFB1 NDUFAF5 PSTPIP1 BCOR CAD SAMD9L TRNW MAD2L2 NPHP1 CD19 SURF1 TP53 LAMC2 SMARCD2 BRCA1 MPL PSMB8 GATC CCND1 CLCN7 MMACHC KRT14 ALDOA SRSF2 ALG8 NOP10 TRNS1 FOXRED1 OPA1 ETV6 HK1 TALDO1 ERCC2 COX2 COQ2 TEK STEAP3 TERC ALX4 RPS14 RTEL1 RASGRP1 HBB MAD2L2 GATA1 PGM3 CDCA7 PUS1 SEC23B SAMD9L HBA1 SLC46A1 MTFMT ICOS COL17A1 PIGT RFX5 DCLRE1C HBG2 CDAN1 IREB2 CDIN1 HBB TNFRSF13B F8 TET2 HAMP WAS F2 WRAP53 HBG1 NDUFS1 FAS TET2 KCNQ1 STIM1 ADAR PTEN SMARCAL1 SRD5A3 GTF2H5 TERT RUNX1 HPRT1 CIITA SLC11A2 PLEC BIRC3 SPTA1 EFL1 TBXAS1 RBM8A NLRC4 CFHR3 RAD51 PRF1 TRNT1 QRSL1 NDUFA9 HBA1 ALPL XRCC2 CBLIF GATA1 ITK ERCC6 PKLR FARSB TRNL1 CTC1 ANK1 LYST GBA ACVR1 PGK1 FIP1L1 ALAS2 RFWD3 ND5 APC DNASE1 CA2 HLA-B MMP1 NDUFS4 HLA-DRB1 AK2 CD55 DKC1 RPS29 SFXN4 HELLPAR LRBA GTF2E2 ERCC4 HBA1 UBE2T SEC61A1 ERCC3 RTEL1 COA8 CD46 VPS33A ITGB4 MVK
Protein Mutations 4
C282Y C677T H63D V617F
HP:0001744: Splenomegaly
Genes 494
PSMB4 GFI1B CLCN7 TNFSF11 GNE IGH PIEZO1 TREX1 MS4A1 USB1 G6PD CAVIN1 CASP8 ERCC6 EPB41 LBR IFNG NGLY1 ARVCF SH2B3 BMP2 ABCG8 NBEAL2 PIK3C2A RREB1 AKT1 HPGD SH2B3 HBG1 ATM IFT172 BTNL2 PEPD FMO3 TCF4 PTEN CASR ZAP70 GPC1 GALE GNPTAB PLEKHM1 CYBC1 RAG1 PKLR EPB42 HIRA GP1BB DYNC2LI1 SH2B3 ALAS2 TCIRG1 HSD3B7 BRAF CD81 TNFRSF13B FERMT3 SEC24C UROS PTEN FUCA1 HJV MYD88 ARSB ATRX CYBA TET2 RIPK1 KCNN4 GP1BA NLRP12 HFE GLIS3 PEX2 GNS FOXP3 MPL AP3B1 CBL APOC2 LPL CD28 PKHD1 CASP10 SUMF1 CA2 THPO CC2D2A NOD2 CCDC115 CPOX STXBP2 GLRX5 VPS45 TET2 SPTB ADAMTS3 PRKCD SLC7A7 TTC37 BCL2 INPPL1 TNFRSF13C SF3B1 AKR1D1 TNFRSF1B PHKG2 IL7R GPC4 USB1 NLRP3 CR2 FAH GBA G6PC3 STX11 BACH2 SH2D1A ERCC8 FAS IDUA GBA TCIRG1 CALR PIK3R1 RINT1 PNP COX10 TET2 SLC2A1 EPB42 VPS13A SLC4A1 SLC4A1 RAG1 MVK MCM4 CLDN1 PSAP TINF2 MAGT1 LMNA GATA2 MPL IFNGR1 CR2 CASK AGA NLRP3 SMPD1 APOE AP3D1 LACC1 LIPA CASP10 RMRP OTC TNFRSF13C TBXAS1 IRF8 PPARG C4A CALR CCND1 KCNH1 CYP7B1 DCDC2 ERCC8 SLC39A4 MEFV CCBE1 ADA LIPA PSMB9 PRF1 BCL6 SKIV2L GBA SLC4A1 GBA SNX10 JAK2 TNFRSF11A SUMF1 GUSB CD40LG F5 MIF GUSB NPC1 FAS SCARB2 HBB GBA MPIG6B NCF2 MAN2B1 HLA-DRB1 NOTCH2 CTLA4 TPP2 NPC2 SCYL1 ALMS1 IDUA HBB GPC3 XIAP RAG1 UROS SPTB PTEN NLRP1 AGPAT2 DNASE1L3 RASGRP1 COG7 IDUA COG4 PRKCD IL12A-AS1 PIEZO1 PEX7 GPI LCAT PSAP ABCA1 NPM1 ABCD3 THPO ANK1 CTLA4 IL12A DGUOK MMUT TNFSF12 KLF1 UMPS PHYH PIGM SLCO2A1 ERBB3 LYZ IDS CHD7 TNFRSF4 B2M HBB ALPK1 LYST MKS1 HBA2 CD19 APOA1 CCDC47 GATA1 CPOX IDUA GPD1 GBA APOE HBG2 RAG2 CLCN7 KCNN3 GBA JMJD1C MPL SLC30A10 TBX1 OCLN AKT1 TNFSF12 JAK2 ATP8B1 JAK2 IL10 TBX1 AKR1D1 SLC4A1 NCF4 FASLG COX4I2 PIEZO1 EPB41 PDGFRA TGFB1 CTNS GBA NOTCH1 NCF2 TNFRSF1B SPTA1 DDRGK1 NBEAL2 TPI1 PEPD IL6 CD19 NCF1 IL2RB SMPD1 NEU1 MPL PSMB8 IL7R RNASEH2A FAH GAA CCND1 SPTA1 PKHD1 KRAS KLF1 MST1 ALDOA IDS SRSF2 SPTB FASLG NOP10 SOX10 COG6 ASAH1 HAVCR2 HLA-DRB1 CALR HK1 CYBB BSCL2 ATP6AP1 PTPRC IL23R ABCA1 GPIHBP1 SNX10 RTEL1 CYBA GPC3 RASGRP1 GNPTAB IDUA CTSK HBB CASR IGH CYBB JAK2 NRAS ICOS LPIN2 DCDC2 CLCN7 DOLK GATA1 NEU1 ADA ABCB11 PIK3CA SEC23B SAMD9L ICOS CARD11 GLB1 DCLRE1C TLR4 JAK2 NCF1 CYBC1 CDAN1 FGA RPGRIP1L PHKG2 KCNH1 MEFV CDIN1 MVK ITCH HBB BCR TNFRSF13B LMNA TET2 HAMP ASXL1 WRAP53 FAS UFD1 TP53 SLC29A3 TNFRSF1A GBA MEFV JAK2 DGUOK STAT4 HGSNAT ERCC6 APOA1 HBB NFKB1 IL1RN IFIH1 TERT RUNX1 FAT4 ALG1 ABCB4 TALDO1 STEAP3 CCR1 UBAC2 RNU4ATAC HFE NFKB2 PIK3CD WDR35 PHKA2 CD27 ANK1 LAT IDS FAS NLRC4 KCNN4 CTLA4 TRNT1 DZIP1L HBA1 CAV1 GATA1 ITK CALR ERAP1 PKLR RAB27A WDR1 NAGLU CD28 RHAG CTC1 ADA2 BPGM ANK1 JAK2 LYST GBA TMEM67 GYPC HBA2 JAK2 GPC4 ICOS KLRC4 TERC DDRGK1 CFAP410 DPM1 LIG4 PARN MPL INPP5E HSD3B7 ATP7B HLA-DRB1 DKC1 DCLRE1C ABL1 LRBA CYP7B1 NHP2 SGSH GPR35 RUNX1 COMT PRKCD HBA1 ATP6V1B2 IL2RG OSTM1 SLC17A5 SMPD1 SH2B3 DHCR24 RHAG LIPA TMEM67 RAG2 VPS33A XIAP HLA-B TET2 BTD MVK
SNP 0
HP:0001369: Arthritis
Genes 273
NLRP3 PSMB4 ACP5 SLC37A4 PTPN22 MIR140 LMNA HGD COL1A1 MMP13 FRZB MMP14 COL9A3 NTRK1 ARVCF PTPN22 LMX1B HPRT1 GBA HLA-C PFKM ABCG8 TNFRSF1A IL2RB RREB1 NLRP3 HPGD TF BTK JMJD1C COPA COL2A1 PIK3CD EXT1 COMP TBX1 IL12B STAT4 TNFRSF11B IL10 TBX1 GJB6 LRP6 IL2RA TRPV4 MUC1 WIPF1 COMP MMP13 GJB2 PSTPIP1 RNASEH2C HPRT1 DCLRE1C HIRA GP1BB TRAPPC2 IRF5 IL6 ATP7B EPCAM CLCN7 SEC24C HJV IL36RN COL3A1 KIF7 SLC37A4 GHR NLRP12 STAT4 SPTA1 MLX COL11A1 SLC40A1 HPGD PTPN2 SMAD3 IGLL1 COL9A1 PTPN22 SLC22A4 FGFR3 COL2A1 UMOD CCN6 IDS TCF3 PRPS1 IGHM MYH14 CD79A PIK3R1 FASLG COL1A1 HNF1B CD79B NLRP3 ASAH1 HLA-DRB1 PRKCD ANKRD55 HLA-B COL5A1 CCR6 DNAJB11 COL2A1 MATN3 IL23R KNSTRN GLA F8 PTPN22 RAG1 RNF168 COL5A1 PTPN2 COL11A2 TREX1 TFR2 COL11A2 SLC26A2 UMOD SLC12A3 FAS CD247 EPB42 VPS13A EXT2 NOD2 COL11A2 CLCN7 NOD2 HGD ZNF687 CLCNKB FCGR2B TLR4 IL2RA MVK COMP CTLA4 TREX1 MEFV CAV1 IFIH1 ANKRD55 WAS AGA MATN3 NLRP3 CFI FAS COL9A2 SAMHD1 UFD1 SH3KBP1 HNF1B ASAH1 LACC1 G6PC1 TNFRSF1A MEFV TRAPPC2 CASP10 ANKH STAT4 UFSP2 TRPV4 SMAD3 COL2A1 MYD88 GPR101 IRAK1 C4A HPRT1 ZMPSTE24 ACAN STAT4 CCR1 GCH1 UBAC2 BTK HFE CD247 AIP HPGD MEFV ACAN UFSP2 RNASEH2B FAS PSMB9 MTHFD1 COL2A1 GDF5 PSTPIP1 SLC4A1 RAG2 PADI4 OCRL PHEX COL9A1 COL9A3 MIF ANKH ERAP1 KIF22 SCARB2 SPP1 CANT1 MMP2 ADA2 LBR HLA-DRB1 PTPN22 FOXP3 PRPS1 CCN6 ADAR IL2RB NLRP3 GNAS COMP COL2A1 HPRT1 FBN1 KLRC4 DNASE1 ACP5 PHEX HLA-B RNASEH2A LEMD3 HOXD10 SPTB BTK HNF4A DNASE1L3 RASGRP1 ATP7B IL10 ASPN HLA-DRB1 PRKCD MVK LRRC8A IL12A-AS1 APOE ACAN LRBA AEBP1 CCN2 CIITA COMT BLNK SEC61A1 COL9A2 ANK1 COL5A2 CTLA4 PRG4 MATN3 IL12A CD244 TGFB3 FCGR2A F9 NFKBIL1 SLCO2A1 TRPS1 HLA-B IDS
Protein Mutations 4
A147T N363S R620W V600E